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Abstract 
The emergence of nanotechnology have revolutionized the landscape of cancer therapy, 
offering an effective and universal platform for delivery of various anti-cancer therapeutics 
with improved potency and safety. As a classic family of drug delivery vehicle, mesoporous 
silica based nanomaterials have attracted tremendous attention due to their tuneable size, 
morphology, structure and surface/framework chemistry. Moreover, mesoporous silica 
based nanomaterials have recently been reported as potent immuno-adjuvant to stimulate 
robust immune response, and exhibited promising performance in cancer immunotherapy. 
However, given the complicated in vivo environment and the potential risks of accumulation 
in major organs as well as unwanted toxicity, the design of mesoporous silica based 
nanomaterials with improved biosafety and delivery efficiency is of great importance. This 
thesis aims to develop new generation of mesoporous silica based nanoparticles mediated 
nanosystem for cancer therapy via rationally engineered architecture and molecular 
structure.  
The first section of this thesis reports an innovative anion assisted approach to prepare large 
pore dendritic mesoporous silica nanoparticles. More importantly, this synthetic approach 
can not only be used for prepare inorganic silica materials, but also for hybrid dendritic 
mesoporous organosilica nanoparticles (DMONs). The key innovation of our approach is 
that we selected a water soluble anion, salicylate, as the structure directing agent to match 
the hydrolysis and condensation kinetics of organic and inorganic silica precursors, leading 
to self-assembly of a unique dendritic structure, while conventional methods using nonpolar 
oil molecules would significantly interfere the co-condensation behaviour of two types of 
precursors and results in aggregated and irregular nanoparticles. Furthermore, we found 
that the hybrid DMONs possess a composition gradient with an organosilica rich shell and 
inorganic silica rich core. Selective etching of the inorganic silica part results in the formation 
of dendritic hollow mesoporous organosilica nanoparticles. With negligible cytotoxicity and 
hemolytic activity, these nanoparticles are promising candidates for drug delivery 
applications. This work has been published on Chemistry of Materials.  
Building on the successful development of the anion assisted synthetic approach, in the 
second section of this thesis, we incorporated disulphide bond in the hybrid dendritic silica 
framework and reported the first example of cancer cell-specific degradable dendritic 
mesoporous organosilica nanoparticles (DDMONs). These smart nanoparticles were able 
to recognize and respond to the minor difference of glutathione (GSH) concentration 
between normal cells and cancer cells, causing preferential nanoparticle degradation and 
concomitant drug release in the latter. As a proof of concept, we delivered a cytotoxic protein 
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using DDMONs and observed a dramatically higher inhibition rate in cancer cells (B16F0) 
than normal cells (HEK293). The cancer cell specific degradable nanoparticles significantly 
reduced the side effects of therapeutics, providing new opportunities in designing safe and 
effective drug delivery nanosystems. This work has been published on Chemistry of 
Materials. 
In the third section of the thesis, we extended the findings the previous work to design a 
novel cascade delivery system with tandem functions by integrating a hypoxia-activated 
prodrug (AQ4N) and glucose oxidase (GOx). Yolk–shell organosilica nanoparticles with a 
tetrasulfide bridged composition, a small-pore yolk, and a large-pore shell featuring a shell-
to-yolk stepwise degradability are constructed as a carrier for AQ4N and GOx, one enzyme 
that catalyzes the oxidation of glucose to produce hydrogen peroxide. The glutathione 
(GSH) is depleted by tetrasulfide bond in the framework and induces shell degradation for 
fast release of GOx, which in turn induces starvation (glucose removal), oxidative 
cytotoxicity (H2O2 production and GSH depletion), and hypoxia (oxygen consumption). 
Finally, the hypoxia activates the liberated prodrug AQ4N for chemotherapy. The cascading 
and synergistic functions including GSH depletion, starvation, oxidative cytotoxicity, and 
chemotherapy lead to improved performance in tumour inhibition and antimetastasis. This 
work has been published on Advanced Functional Materials. 
In the fourth section of this thesis, we developed silica based immune-adjuvants for the 
stimulation of robust immune response for cancer immunotherapy. We constructed double-
shelled dendritic mesoporous organosilica hollow spheres with ethyl incorporated 
framework, and demonstrated their excellent adjuvant performance and provide superior 
immunity in cancer immunotherapy, and better than their counterparts either with a pure 
silica composition or a single-walled architecture. This study provides new insights in the 
rational design of effective nanostructured adjuvants for vaccine developments. This work 
has been published on Angewandte Chemie. 
In the last section of this thesis, we report rationally designed hybrid nanoreactors with 
integrated functions as Fenton catalysts and glutathione depletion agents for amplifying the 
immunogenic cell death and activating immune cells. A simple physical mixture of 
nanoreactors and chemodrugs in combination with immune checkpoint blockades show 
synergistically and concurrently enhanced chemo-immunotherapy efficacy, inhibiting the 
growth of both treated primary immuno-suppressive tumours and untreated distant tumours. 
The “off-the-shelf” strategy uses in situ generated tumour antigens and avoids cargo loading, 
- 3 - 
 
representing a substantial advance in personalized nanomedicine for clinical translation. 
This work has been published on Angewandte Chemie. 
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cancer therapy. Step I: RGD-directed tumor vasculature and cell membrane targeting; 
Step II: TAT-mediated nuclear targeting. Reproduced with permission from ref.[176]. 
Figure 3.1 SEM (a, d), TEM (b, e) and ET slice (c, f) of DMONs (a, b, c) and DHMONs (d, 
e, f). 
Figure 3.2 29Si MAS NMR spectra (a, b), N2 adsorption-desorption isotherm (c, d) and 
pore size distribution (inset of c and d) of DMONs (a, c) and DHMONs (b, d). 
Figure 3.3 (a-c) TEM images of DMONs synthesized at (NaSal/CTAB) of (a) 0.5/1, (b) 
0.75/1 and (c) 1/1. Scale bar: 100 nm.  
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Figure S3.1 13C CP/MAS NMR spectra of DMONs. 
Figure S3.2 TEM image of MONs prepared at CTAB/NaSal molar ration of 1/0. 
Figure S3.3 N2 adsorption-desorption isotherm (a) and pore size distribution (b) of 
MONs/DMONs prepared at various CTAB/NaSal molar ratio. 
Figure S3.4 SEM images (a, b), TEM image(c) and ET slice (d) of DMSNs synthesized 
using pure TEOS at CTAB/NaSal molar ratio of 1 to 1. 
Figure S3.5 TEM images of DMSNs synthesized at various CTAB/NaSal molar ratio: (a) 
1/0, (b) 1/0.25, (c) 1/0.5 and (d)1/1. Scale bar: 100 nm. 
Figure S3.6 N2 adsorption-desorption isotherm (a) and pore size distribution (b) of 
MSNs/DMSNs prepared at various CTAB/NaSal molar ratio. 
Figure S3.7 TEM images of DMONs synthesized at organosilica (OSi)/inorganic silica (Si) 
molar ration of (a) 0.1/1 and (b) 0.3/1. 
Figure S3.8 N2 adsorption-desorption isotherm (a) and pore size distribution (b) of 
DMONs prepared at various OSi/Si molar ratio. 
Figure S3.9 TEM image of DMONs synthesized at low stirring speed of ~ 100rpm 
(NaSal/CTAB =1 and OSi/Si= 1). No obvious difference can be observed compared to 
DMONs at ~300 rpm (figure 3.1b, main text), indicating that the penetration process of Sal- 
into micelle is a thermodynamically controlled process. 
Fig S3.10 Time dependant study of DMONs synthesized at CTAB/NaSal ratio of 1/1. 
Fig S3.11 Time dependant study of DMSNs synthesized at CTAB/NaSal ratio of 1/1. The 
temperature was decreased to 65°C to slow down the reaction rate. Scale bar: 100 nm. 
Figure S3.12 BSA release profile of DMONs and DHMONs as a function of time. 
Figure S3.13 Percentage of RBCs hemolysis after co-incubation with DMONs and 
DHMONs at different concentrations ranging from 25 – 2000 μg/mL. Inset: Digital photos 
showing the hemolytic effects after 2 h co-incubation with DMONs and DHMONs. Water 
was used as the positive control and PBS as the negative control. (* p < 0.05 based on t-
test)  
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Scheme 4.1 Pore structure dependent degradability of nanoparticles within normal cells 
and cancer cells. A) The redox reaction of disulfide bond and GSH. B) Schematic 
illustration for (I) the organic–inorganic hybrid composition of DDMONs, (II) small pore 
MONs, (III) large pore DDMONs, (IV) normal cells, (V) MONs and (VI) DDMONs 
degradation in normal cells, (VII) cancer cells, (VIII) MONs and (IX) DDMONs degradation 
in cancer cells. 
Figure 4.1 TEM (a) and SEM images (b) of DDMONs synthesized at NaSal/CTAB molar 
ratio of 0.5/1. (c) EDS mapping of DDMONs. (d, e) Solid state 29Si NMR (d) and 13C NMR 
(e) spectra of DDMONs. 
Figure 4.2 Degradation test of DDMONs (a1-a4) and MONs (b1-b4) tested at 1 mM (a1-a2, 
b1-b2) and (a3-a4, b3-b4)10 mM GSH solution for 24 h (a1, a3, b1, b3), and 48 h (a2, a4, b2. 
b4) in the presence of serum. GSH oxidation percentage (black columns) and relative 
quantity of –SH groups (OD 412 nm, red columns) after incubation of DDMONs or MONs 
in 1 mM (c) and 10 mM (d) GSH solution for 48 h in the presence of serum. 
Figure 4.3 In vitro degradability of DDMONs-PEI after incubation with B16F0 cancer cell 
for 4 h (a1), 24 h (a2) and 48 h (a3) and HEK293t normal cells for 24h (b1) and 48h (b2). In 
vitro degradability of MONs-PEI after incubation with B16F0 cancer cell for 4 h (c1), 24 h 
(c2) and 48 h (c3) and HEK293t normal cells for 24h (d1) and 48h (d2). 
Figure 4.4 a) Schematic illustration of the role of serum protein in the pore structure-
dependent degradability. TEM images of MONs (b-c) and DDMONs (d-e) incubated in 10 
mM GSH solution for 24 h (b, d) and 48 h (c, e) in the absence of serum. 
Figure 4.5 (a-b) Cumulative release of RNase A-Aco from DDMONs-PEI (a) and DMONs-
PEI (b) in various concentration of GSH solution for 48 h. (c) Confocal images of cell 
uptake of DDMONs-PEI/RNase A-Aco-FITC complex by B16F0 cells at 10 h. (d) Confocal 
images of DDMONs-PEI/RNase A-Aco-FITC complex incubated with B16F0 cells for 24 h. 
The endo/lysosome was stained with Lysotracker Red. While arrow indicates separated 
red dots from green florescence, suggesting proteins were escaped from endo/lysosomal 
entrapment with assistance of nanoparticles. (e-f) Cell viability test of DDMONs-PEI 
delivery systems by delivering cytotoxic RNase A-Aco against B16F0 cancer cell (e) and 
Hek293t normal cell (f) 48 h (** P < 0.01). 
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Figure S4.1 Hydrodynamic diameter of DDMONs in PBS buffer solution (a) and PBS 
solution supplemented with 10 mM GSH and 10% FBS (b) measure by DLS. 
Figure S4.2 Solid state 13C NMR spectra of as-synthesized DDMONs. 
Figure S4.3 The total ion current (TIC) chromatograms of a) blank, b) 0.2 mg/mL CTAB 
standard, c) wash solution 1, d) wash solution 2 and e) wash solution 3. The insets in b) 
and c) are the mass signal of the peaks in the two TIC, while f) is the enlarged version of 
the inset.  
Figure S4.4 Raman spectrum of DDMONs. 
Figure S4.5 Digital image of as-synthesised DDMONs. The yellowish colour indicates the 
presence of sulfur content. 
Figure S4.6 N2 sorption isotherm and pore size distribution (inset) of DDMONs. 
Figure S4.7 TEM (a-b, d-e) and SEM (c, f) images of disulfide incorporated dendritic 
mesoporous organosilica nanoparticles synthesized at various NaSal/CTAB concentration 
and molar ratio: (a-c) NaSal/CTAB = 2.09 mmol L-1/4.17 mmol L-1 ; (d-f) NaSal/CTAB = 
4.17 mmol L-1/4.17 mmol L-1. 
Figure S4.8 N2 sorption isotherms and pore size distributions of disulfide incorporated 
dendritic mesoporous organosilica nanoparticles synthesized at NaSal/CTAB = 2.09 mmol 
L-1/4.17 mmol L-1 (a) and NaSal/CTAB = 4.17 mmol L-1/4.17 mmol L-1 (b).  
Figure S4.9 TEM image (a), nitrogen adsorption-desorption isotherm (b) and pore size 
distribution (c) of small pore disulfide bridged MONs. 
Figure S4.10 TEM image (a) and N2 sorption results (b) of ethyl incorporated non-
degradable DMONs.  
Figure S4.11 DLS results of DDMONs incubated with serum-containing 10 mM GSH 
solution for 48 h. 
Figure S4.12 TEM images of DDMONs incubated with 10 µM GSH for 48 h. 
Figure S4.13 TEM images of DMONs incubated at 10 mM GSH for 48 h. 
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Figure S4.14 Solid state 13C NMR spectrum of DDMONs-Epoxy and DDMONs-PEI. The 
peaks of C1 (12 ppm), C2 (22 ppm) and C6 (44 ppm) are overlapped with the carbon 
signals from organosilane. 
Figure S4.15 TGA curves of DDMONs, DDMONs-epoxy and DDMONs-PEI under oxygen 
flow. The weight loss from 200 to 900 °C were 2.1 and 7.6% for DDMONs-epoxy and 
DDMONs-PEI, respectively, compared to the unmodified DDMONs. The surface 
conjugated quantity of epoxy group and PEI is calculated to be 0.18 and 0.08 mmol/g, 
respectively.   
Figure S4.16 N2 sorption isotherm (a) and pore size distributions (b) of DDMON-PEI and 
DMONs-PEI.  
Figure S4.17 TEM images of DDMONs-epoxy (a) and DDMONs-PEI (b).  
Figure S4.18 Cytotoxicity of DDMONs-PEI and DMONs-PEI for B16F0 cancer cell (a, b) 
and HEK293t normal cell (c, d) at 24 h (a, c) and 48 h (b, d).    
Figure S4.19 TEM images of DMONs-PEI incubated with (a) B16F0 cancer cells and (b) 
HEK293t normal cells for 48 h.  
Figure S4.20 Intracellular degradability of DDMONs-PEI after incubation with MCF-7 
breast cancer cells, CHO normal cells and RAW264.7 macrophage cells for 24 h and 48 h. 
Scale bar: 500 nm. 
Figure S4.21 DLS analysis of MONs incubated with serum-free (a) and serum-containing 
(b) PBS buffer solution at 10 mM GSH for 0, 24 and 48 h. 
Figure S4.22 a) A semi-preparative RP-HPLC trace of the final products obtained from 
RNase A-Aco labelling reaction. LC method: 1%/min linear gradient of 10-60 % solvent B 
at a flow rate of 7 mL/min. b) MALDI-MS result of the purified RNase A-Aco-FITC. 
Figure S4.23 Confocal image of B16F0 cells incubated with RNase A-Aco-FITC for 10h. 
No green florescence can be observed, indicating the negligible cellular uptake of proteins.  
Figure S4.24 Cell viability test of DDMONs-PEI delivery systems by delivering cytotoxic 
RNase A-Aco against B16F0 cancer cell (a) and Hek293t normal cell (b) at 24 h. 
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Table S4.1. Structural properties of DDMONs after stepwise surface functionalization. 
Scheme 5.1. A schematic illustration of the cascade delivery system. YS-DMONs were 
firstly fabricated to form a small-pore yolk and large-pore shell together with a tetrasulfide 
incorporated framework (a). A small molecule prodrug AQ4N and an enzyme GOx were 
encapsulated in the YS-DMONs with cascading functions (b). Intracellular GSH causes the 
cleavage of tetrasulfide bond through the redox chemistry, leading to the fast degradation 
of the large pore shell and concomitant GSH depletion as well as release of the GOx (i). 
The released GOx oxidizes glucose, which (1) reduce the energy supply of tumor, (2) 
induce oxidative damage through generated cytotoxic H2O2 and depleted antioxidant 
(GSH), and (3) consume molecular oxygen to create a hypoxic microenvironment (ii). The 
hypoxia activates the prodrug AQ4N, which is liberated with the inner yolk degradation, 
creating AQ4 and eliciting potent cytotoxicity for tumor inhibition (iii). 
Figure 5.1. Characterization and intracellular stepwise degradability of YS-DMONs. (a) 
Schematic illustration of the synthesis process of YS-DMONs. TEM images of MONs (b), 
CS-DMONs (c) and YS-DMONs (d). SEM image of YS-DMONs (e). Dark-field STEM 
image (f) and corresponding EDS mapping (g) of YS-DMONs. Solid state 29Si NMR (h) 
and 13C NMR (i) spectra of YS-DMONs. Nitrogen adsorption-desorption isotherm (j) and 
pore size distribution (k) of MONs and YS-DMONs. (l) Bio-TEM images of YS-DMONs 
after incubation with 4T1 cells for different days, illustrating a shell-to-yolk stepwise 
degradability of the nanoparticles. Scale bar: 200 nm 
Figure 5.2. YS-DMONs-GOx mediated generation of H2O2 and hypoxic environment in 
4T1 cells. a) CLSM images of 4T1 cells with oxidative stress/hypoxia detection probes in 
different treatments. Quantitative analysis of fluorescent intensity of H2O2 production (b) 
and hypoxia environment (c) in 4T1 cells with different treatments (n = 3, mean ± SD).  (d) 
CLSM images of 4T1 cells exposed to YS-DMONs mediated intracellular delivery of AQ4N 
and GOx for 4 h. GOx-FITC was used for generating green fluorescence.   
Figure 5.3. Effect of the cascade delivery system on the cell viability and apoptosis in 4T1 
cells. a-b) Cell viability of 4T1 cells subject to different treatment at normoxic (a) and 
hypoxic (b) conditions for 48 h (n = 3, mean ± SD). The corresponding concentration of 
YS-DMONs from low to high concentration is 0.781, 3.125, 12.5, 50 µg/ml. (c) Comparison 
of the inhibition of cell viability by YS-DMONs-AQ4N-GOx at normoxic and hypoxic 
conditions obtained from (a) and (b). d) IC50 values YS-DMONs-AQ4N-GOx against 4T1 
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cells in normoxic and hypoxic conditions. (e) Analysis of the glucose-responsive cell 
viability inhibition activities of different formulations after 48 h incubation (n = 3, mean ± 
SD) The corresponding concentration of YS-DMONs is 6.25 µg/ml. (f) Flow cytometry 
analysis of 4T1 cell apoptosis induced by various formulations for 4 h using the Annexin V-
FITC/PI staining. 
Figure 5.4. YS-DMONs mediated sequential delivery system inhibits 4T1 tumors and 
reduces lung metastasis. (a) Tumor volume over 12 days (n = 5, mean ± SD). (b) Tumor 
weights at the end point (day 12) (n = 5, mean ± SD). (c) H&E staining images of tumor 
sections at the end point. 1: Control; 2: YS-DMONs-AQ4N; 3: YS-DMONs-GOx; 4:AQ4N + 
GOx; 5: YS-DMONs-AQ4N-GOx. Scale bar: 100 µm (d) Representative digital images 
showing the formation of tumor nodules in the lungs. (e) The numbers of tumor nodules 
present in the lungs (n = 5, mean ± SD). 
Figure S5.1 29Si solid-state NMR spectra of CS-DMONs. 
Figure S5.2 Nitrogen adsorption-desorption isotherm (a) and pore size distribution (b) of 
CS-DMONs. 
Figure S5.3 DLS results of YS-DMONs in PBS.          
Figure S5.4 Concentration dependent cytotoxicity of YS-DMONs against 4T1 cells after 
48h incubation (n = 3, mean ± SD).  
Figure S5.5 TEM (a), 29Si solid state NMR (b), N2 adsorption-desorption isotherm (c) and 
pore size distribution of YS-DMSNs.  
Figure S5.6 GSH-depleting capability of YS-DMONs and YS-DMSNs in 4T1 cells (n = 3, 
mean ± SD). The cellular GSH level was measured using Cellular Glutathione Detection 
Assay Kit.  
Figure S5.7 DLS results of GOx in PBS.  
Figure S5.8 AQ4N (a) and GOx (b) loading capacities on different nanoparticles (n = 3, 
mean ± SD). The loading of GOx was conducted after AQ4N adsorption and washing, 
leading to a reduced GOx loading capacity. This is explained by the inevitable adsorption 
of a certain amount of AQ4N even in the outer dendritic shell, which hinders the interaction 
between GOx molecules and the organosilica pore surface.   
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Figure S5.9 fluorescence spectrum of YS-DMONs-AQ4N-GOx in water. 
Figure S5.10 AQ4N and GOx-FITC release profile of YS-DMONs-AQ4N-GOx-FITC in 
PBS containing different concentrations of GSH. The released amount in the supernatant 
was measured based on fluorescent intensity using microplate reader (n = 3, mean ± SD). 
Figure S5.11 TEM image of YS-DMONs after incubation with 2 µM GSH for 5 days. 
Figure S5.12 DLS results in YS-DMONs after incubation with 5 mM GSH for a) 1 day, b) 3 
days and c) 5 days. 
Figure S5.13 TEM images showing the stepwise degradation of the AQ4N and GOx co-
loaded YS-DMONs after incubation with 5 mM GSH for a) 1 day, b) 3 days and c) 5 days. 
Scale bar: 100 nm. 
Figure S5.14 AQ4N release profile of YS-DMONs-AQ4N in PBS containing 5 mM of GSH. 
Figure S5.15 AQ4N release profile of CS-DMONs-AQ4N in PBS containing different 
concentrations of GSH (n = 3, mean ± SD). 
Figure S5.16 CLSM image of 4T1 cells incubated with YS-DMONs-AQ4N-GOx-FITC for 
12h. AQ4N (red colour) showed several individual red dots, suggesting that the drug are 
still entrapped in nanoparticles. The green fluorescence generated from GOx-FITC 
exhibited partially overlapped dots with AQ4N as well as green colour that spread around 
cell nuclei and separated from red ones, confirming that GOx-FITC molecules had started 
to release. These results clearly demonstrate a sequential intracellular release pattern of 
GOx-FITC and AQ4N.  Scale bar: 10 µm  
Figure S5.17 4T1 cell proliferation in RPMI1640 medium containing different 
concentrations of glucose. The results confirm the important role of glucose in providing 
nutrient and energy for cell growth (n = 3, mean ± SD).   
Figure S5.18 Biodistribution of YS-DMONs-AQ4N-GOx based on the silicon content in 
various organs and tissues of 4T1 tumour-bearing mice at 24 h post injection as 
determined by the ICP-OES. 
Figure S5.19 The conversion rate of AQ4N in vitro (a) and in vivo (b). 
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Figure S5.20  In vivo tumour microenvironment altered by administration of YS-DMONs-
AQ4N-GOx. (a) GSH level, (b) ROS level and (c) hypoxia environment in tumour tissues. 
Figure S5.21 H&E staining of heart, liver, spleen, lung and kidney (Scale bar: 200 μm).    
Table S5.1 Physical parameters of MONs, CS-DMONs and YS-DMONs. 
Scheme 6.1 Schematic illustration of synthesis procedure of DMOHS-nS and DMSHS-2S.  
Figure 6.1 TEM (a-b) and SEM images (c-d) of DMOHS-2S. Dark-field STEM image (e) 
and corresponding EDS mapping of DMOHS-2S (f-h). Solid state 29Si NMR (i) and 13C 
NMR (j) spectra of DMOHS-2S.  
Figure 6.2 OVA (a) and TF (b) release profile from various nanoparticles in PBS solution. 
c) Confocal images of OVA-FITC, DMSHS-2S/OVA-FITC and DMOHS-2S/OVA-FITC 
incubated with RAW264.7 for 10 h at OVA concentration of 10 μg/ml. White arrows 
indicates the presence of green fluorescence outside the red region, suggesting 
successful endo-lysosomal escape. OVA-FITC positive cell population (d) and MFI (e) in 
different groups in triplicates measured by flow cytometry. **p < 0.01, ***p < 0.001. 
Figure 6.3 The secretion level of IFN-γ (a), IL-12 (b), TNF-α (c) and IL-4 (d) by 
splenocytes obtained from immunized mice and restimulated with OVA. * p<0.05, ** p< 
0.01, *** p< 0.001. 
Figure 6.4 Antitumor performance of various vaccine formulations. a) Experimental 
procedure for the therapeutic immunization model. The tumor volume (b), survival rate (c), 
tumour free percentage (d) and body weight (e) of mice after immunization. * p<0.05, ** p< 
0.01. 
Figure S6.1 TEM images of ethane bridged DMONs (a), DMONs coated with a hybrid 
dendritic layer (b), DMONs coated with two hybrid dendritic layers (c), and the 
corresponding DMOHS-1S (d), DMOHS-2S (e) and DMOHS-3S (f) obtained via HF 
etching.  
Figure S6.2 (a) N2 adsorption-desorption isotherm of DMOHS-1S, DMOHS-2S and 
DMOHS-3S and (b) their corresponding pore size distribution calculated from adsorption 
branch.  
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Figure S6.3 TEM image of DMSHS-2S obtained from calcination of DMOHS-2S. 
Figure S6.4 FTIR spectrums of DMOHS-2S and DMSHS-2S.  
Figure S6.5 a) OVA adsorption capacity of different nanoparticles. The initial OVA 
concentration is 500 μg/mL, which is almost completely adsorbed by 2.5 mg/mL of 
nanoparticles. b) TF adsorption capacity of different nanoparticles. The initial TF is derived 
from 1×106/mL of B16F10 cells, equivalent to a protein concentration of 237 μg/mL as 
determined by BCA assay. More than 80% TF was absorbed by 6 mg/mL of nanoparticles. 
Release profile of OVA (c) and TF (d) from nanoparticles over 10 and 7 days, respectively. 
Figure S6.6 Dose dependent cell viability of RAW264.7 cells after incubation with 
DMOHS-2S or DMSHS-2S for 48 h. 
Figure S6.7 FACS plots of the effector-memory T cells population in the splenocytes of 
mice immunized by various vaccine formulations. 
Figure S6.8 FACS plots of the populations of CD4+ and CD8+ T cells in splenocytes of 
mice immunized by various vaccine formulations.  
Table S6.1 Structural parameters of nanoparticles measured by N2 adsorption-desorption. 
Scheme 7.1 (a) The nanostructure and composition of mesoporous organosilica 
nanoparticles. (b) After mixing with DOX for local administration, the nanoreactors are able 
to (i) amplify ICD, (ii) acting as immune-adjuvants to stimulate the maturation of immune 
cells, accomplishing synergistic effects with ICB (PD-L1 antibody) for effective inhibition of 
both treated primary tumours and non-treated distant tumours. 
Figure 7.1 (a) SEM, (b) TEM, (c) dark-field scanning TEM and (d) EDS elemental mapping 
images of Cu-DMONs. (e) EPR spectra of DMONs and Cu-DMONs. (f) Time-dependant 
cellular uptake of silicon and copper by RAW264.7 macrophages and 4T1 cancer cells 
measured by inductively coupled plasma optical emission spectrometry (ICP-OES). 
Figure 7.2 (a) CLSM images for analysing the intracellular ROS level. The green 
fluorescence is generated by the oxidized ROS probe. (b) CLSM images for visualizing the 
CRT exposure on the surface of membrane upon treatment of different formulations for 6 
h. (c) Quantitative measurement of intracellular ROS level using micro-plate reader. (d, e) 
Quantitative analysis of CRT exposure level using flow cytometry. (f) 4T1 cell viability after 
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24 h treatment of different formulations. The weight ratio of DOX/nanoparticles is 1/10. (g) 
4T1 cell viability after 24 h treatment of nanoparticles with various concentration. The DOX 
concentration is fixed at 2 µg/ml.   
Figure 7.3 Flow cytometry analysis of CD80 and CD86 expression on splenocytes treated 
with PBS or different nanoparticles. Macrophages were marked by F4/80 antibody (a, b) 
and DCs by CD11C antibody (c, d). (e-g) Secretion of cytokines from RAW264.7 
macrophages treated with different nanoparticles. 
Figure 7.4 a) Tumour-growth curves of mice treated with chemo-therapy in a unilateral 
tumour model and b) the IFN-γ level in the serum. c-d) Tumour-growth curves of mice 
treated with chemo-immuno-therapy in a bilateral tumour model. The primary tumours 
were treated with different formulations while the distant tumours received no treatment. e) 
The infiltration of CTLs (defined as CD3+ CD8+) in the distant tumour tissue. f) The TNF-α 
level in the serum (n = 5). The black arrows indicate the injection of PBS, DOX or 
nanoparticle/DOX, while red ones indicate the injection of PD-L1 antibody.  
Figure S7.1 Digital image of Cu-DMONs post surfactants extraction. 
Figure S7.2 The N2 adsorption-desorption isotherm and pore size distribution of DMONs 
and Cu-DMONs. 
Figure S7.3 29Si solid-state NMR spectrum of DMONs and Cu-DMONs 
Figure S7.4 Cu2+ leaching profile of Cu-DMONs at simulated extracellular (pH 7.4 + 2 µM 
GSH) and intracellular conditions (pH 5.0 + 2 mM GSH).  
Figure S7.5 Cell viability of RAW264.7 and 4T1 after incubation with various 
concentrations of Cu-DMONs for 48 h.  
Figure S7.6 Intracellular GSH level of RAW264.7 (a) and 4T1 (b) cells after incubation 
with 100 µg/ml of DMONs or Cu-DMONs for 12 h. 
Figure S7.7 Bio-TEM of Cu-DMONs after incubation with 4T1 cell for 1 day (a), 2 days (b), 
and 5 days (c). Scale bar: 200 nm. 
Figure S7.8 Flow cytometry analysis of 4T1 cell apoptosis induced by various formulations 
for 4 h using the Annexin V-FITC/PI staining. 
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Figure S7.9 The intratumoral Si (a) and Cu (b) content 12 days post injections.  
Figure S7.10 Tumour-growth curves of mice treated with chemo-immuno-therapy in a 
bilateral tumour model. The primary tumours were treated with different formulations while 
the distant tumours received no treatment. 
 
List of Abbreviations used in the thesis 
 
MONs             Mesoporus organosilica nanoparticles 
DMONs          Dendritic mesoporus organosilica nanoparticles  
TEOS             tetraethyl orthosilicate 
TEM              transmission electron microscopy 
PEG              polyethylene glycol 
CTAB           cetyltrimethylammonium bromide 
CTAC           cetyltrimethylammonium chloride 
TEA              triethanolamine 
PEI                polyethylenimine 
ROS              reactive oxygen species 
RBCs            red blood cells 
MTT              3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MSN             mesoporous silica nanoparticles 
DMSN          dendritic mesoporous silica nanoparticles 
MCF-7          human breast cancer cells 
CHO-K1       Chinese hamster ovary K1 
HEK-293T    human embryonic kidney cells 293T 
GOx             glucose oxidase 
FDA             US Food and Drug Administration 
THPMP        3-(trihydroxysilyl) propylmethylphosphonate 
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DLS             dynamic light scattering 
ET                electron tomography 
BET             Brunauer-Emmett-Teller 
BJH             Barrett–Joyner–Halenda 
EA               elemental analysis 
AFM           atomic force microscopy 
OD              optical density 
ICP-OES     inductively coupled plasma optical emission spectrometry 
RITC           rhodamine b 
FITC           fluorescein isothiocyanate 
BSA            albumin from bovine serum 
DMEM       dulbecco's modified eagle medium 
DMSO       dimethyl sulfoxide 
EPR           electron paramagnetic resonance; enhanced permeability and retention 
DCFH-DA   dichlorofluorescin diacetate 
CLSM        confocal laser scanning microscopy 
DAPI        4',6-diamidino-2-phenylindole 
MFI          median fluorescent intensity 
RES        reticuloendothelial system 
MRI         magnetic resonance imaging  
DPD        dissipative particle dynamics  
AR           aspect ratios  
QD          quantum dot  
FA            folic acid  
MTX        methotrexate  
HA           hyaluronic acid  
VEGF      vascular endothelial growth factor  
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RGD        arginine−glycine−aspartic acid  
DHMONs   dendritic hollow mesoporous organosilica nanoparticles  
BTEE       1,2-bis(triethoxysilyl)ethane  
NaSal      sodium salicylate 
DDMONs   degradable dendritic mesoporous organosilica nanoparticles  
BTES       1,4-bis(triethoxysilyl)-propane tetrasulfide 
EDX         Energy-dispersive X-ray  
HPLC       high performance liquid chromatography 
TGA          thermogravimetric analysis 
GSH          glutathione 
PDT          photodynamic therapy  
YS-DMONs    yolk-shell tetrasulfide bond bridged dendritic mesoporous organosilica 
nanoparticles 
CS-DMONs    core-shell tetrasulfide bond bridged dendritic mesoporous organosilica 
nanoparticles 
ICP-OES      inductively coupled plasma optical emission spectrometry 
H&E        Hematoxylin and eosin 
NMR       nuclear magnetic resonance  
FTIR       fourier transform infrared 
TF           tumour cell fragments  
MHC       major histocompatibility complex  
APCs      antigen presenting cells  
ICD        immunogenic cell death  
ICB        immune checkpoint blockades  
CRT       Calreticulin  
PI           Propidium iodide  
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Chapter 1 
 
Introduction 
 
1.1 Background 
The application of nanomaterials in biomedical field have offered vast advantages, including 
reducing the off-target drug accumulation, enhancing the therapeutic potency and acting as 
adjuvants to stimulate immune response.[1] Mesoporous silica based nanoparticles are 
generally considered biocompatible, and possess high payload due to their high surface 
areas and pore volume, enabling them as a highly promising family of nanosystems for drug 
delivery.[2] However, the biosafety risks and the limited delivery efficiency are the major 
obstacles that hinders their clinical translation. In particular, the inert silica framework is a 
double-edged sword. It ensures a high mechanical stability at in vivo condition, but also 
leads to the potential risks of accumulation in major organs and limited functionalities.[3] In 
this sense, developing safe, degradable and effective mesoporous silica based 
nanoparticles mediated nanosystem is of great interest. 
Organosilica is a very classic family of hybrid silica based materials discovered in 1999,[4] 
showing enormous promise in adsorption, separation and catalysis due to their functional 
organic-inorganic hybrid framework.[5] The promise of organosilica nanoparticles in drug 
delivery was firstly demonstrated by Shi and co-workers, who showed the high drug loading, 
superior cellular uptake and sustained release profile compared to conventional silica 
materials, and therefore excellent in vivo performance.[6] Depending on the type of organic 
groups incorporated in the framework, the hybrid silica nanoparticles could exhibit colourful 
properties, which in conjunction with their porous nature can yield advanced drug delivery 
nanosystems. However, the key challenges exist in rational design and engineering of the 
composition, pore structure and architecture of organosilica nanoparticles to establishing 
safe and efficient nano-delivery platform.     
1.2 Research objective and scope 
This PhD project aims to fabricate mesoporous silica based nanoparticles with controllable 
compositions, large pore structures and complex architectures for construction of safe and 
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efficient therapeutic delivery systems. To this goal, this project contains the following 
objectives:  
1. Developing a general anion assisted synthetic approach for fabrication of mesoporous 
silica based nanoparticles with tuneable composition, pore size and architecture;  
2. Developing disulfide bond incorporated mesoporous organosilica nanoparticles with GSH 
responsive and cancer specific degradability;  
3. Developing disulfide bond incorporated mesoporous organosilica nanoparticles with yolk-
shell structure for co-delivery of multiple therapeutics for synergistic cancer therapy; 
4. Developing mesoporous organosilica based immuno-adjuvants with rationally designed 
composition and architecture for potent anti-cancer vaccine;  
5. Developing organic/metal ion co-incorporated hybrid silica nanoparticles for concurrently 
enhanced cancer chemo/immuno-therapy. 
1.3 Thesis Outline 
Chapter 1. Introduction 
This chapter introduces the background and motivation of this PhD project, and outlines the 
research scope and aims. 
Chapter 2. Literature Review 
This chapter summarizes the current progress of silica based nanoparticles for cancer 
therapy and provides a critical perspective on the challenges, lessons and opportunities in 
this field. This chapter has been published on Nanomedicine: Nanotechnology, Biology, 
and Medicine, 2016, 12, 317. 
Chapter 3. Anion Assisted Synthesis of Large Pore Hollow Dendritic Mesoporous 
Organosilica Nanoparticles: Understanding the Composition Gradient 
This chapter report a general and facile anion assisted synthetic approach to fabricate 
silica based nanoparticles with tuneable composition (organic group incorporation), pore 
size (dendritic large pore structure) and architecture (hollow structure). This chapter has 
been published on Chemistry of Materials, 2016, 28, 704. 
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Chapter 4. Structure-Dependent and Glutathione-Responsive Biodegradable 
Dendritic Mesoporous Organosilica Nanoparticles for Safe Protein Delivery 
This chapter report the synthesis of a disulfide bond incorporated dendritic organosilica 
nanoparticles and demonstrated superior cytotoxic protein delivery performance as a result 
of their unique cancer cell specific degradability. This chapter has been published on 
Chemistry of Materials, 2016, 28, 9008 
Chapter 5. Stepwise Degradable Nanocarriers Enabled Cascade Delivery for 
Synergistic Cancer Therapy  
This chapter report the synthesis of a disulfide bond incorporated yolk-shell mesoporous 
organosilica nanoparticles with a unique shell-to-yolk stepwise degradability in response to 
GSH, which enables a cascade delivery system for hypoxia-activated prodrug and glucose 
oxidase with tandem functions for synergistic cancer therapy. This chapter has been 
published on Advanced Functional Materials, 2018, 1800706.  
Chapter 6. Multi-shelled Dendritic Mesoporous Organosilica Hollow Spheres: Roles 
of Composition and Architecture in Cancer Immunotherapy 
This chapter report the synthesis of multi-shelled organosilica nanoparticles and explored 
their immune-adjuvant activity for cancer immunotherapy. Our results indicate that double 
shelled architecture and the ethyl incorporated composition of nanoparticles play important 
roles in triggering the systemic antitumor immunity. This chapter has been published on 
Angewandte Chemie International Edition, 2017, 56, 8446.       
Chapter 7. Hybrid Nanoreactors: Enabling an Off-the-shelf Strategy for Concurrently 
Enhanced Chemo-immunotherapy 
This chapter report a hybrid nanoreactor constructed by co-incorporation of copper ions and 
disulfide bond into the silica framework, which greatly amplified the immunogenic cell death 
of chemo-drug treated tumour cells and activated the immune system. These dual functions 
collectively potentiate the chemo-immunotherapy of breast cancer. This chapter has been 
published on Angewandte Chemie International Edition, 2018, doi:10.1002/anie.201807595. 
Chapter 8. Conclusions and Outlook 
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This chapter summarize the key findings of this PhD project and provides a personal 
perspective on possible future directions in developing silica based drug delivery 
nanosystems for cancer therapy. 
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Chapter 2 
 
Literature Review 
 
Advances in silica based nanoparticles for 
targeted cancer therapy 
This chapter has been published on Nanomedicine: Nanotechnology, Biology, and 
Medicine, 2016, 12, 317. 
Abstract: Targeted delivery of anticancer drug specifically to tumour site without damaging normal 
tissues has been the dream of all scientists fighting against cancer for decades. Recent breakthrough 
on nanotechnology based medicines has provided a possible tool to solve this puzzle. Among diverse 
nanomaterials that are under development and extensive study, silica based nanoparticles with vast 
advantages have attracted great attention. In this review, we concentrate on the recent progress using 
silica based nanoparticles, particularly mesoporous silica nanoparticles (MSNs), for targeted drug 
delivery applications. Firstly, we discuss the passive targeting capability of silica based nanoparticles 
in relation to their physiochemical properties. Then, we focus on the recent advances of active 
targeting strategies involving tumour cell targeting, vascular targeting, nuclear targeting and 
multistage targeting, followed by an introduction to magnetic field directed targeting approach. We 
conclude with our personal perspectives on the remaining challenges and the possible future 
directions. 
Keywords: silica nanoparticles; active targeting; passive targeting; magnetic field directed targeting; 
cancer therapy 
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2.1 Introduction 
Cancer has been among the leading cause of death worldwide. Current cancer treatments are mostly 
relying on radiation and chemotherapeutic agents, which suffer from severe side effects due to non-
specific damage towards normal tissue and cells. Therefore, targeted drug delivery and release to 
tumour sites is of great importance for minimised side effects and enhanced therapeutic efficiency. In 
recent decades, the development of nanotechnology based medicine (nanomedicine) has made 
great breakthrough in the pharmaceutical and biotechnology fields[7] since the discovery of the first 
drug delivery system using liposomes in the 1960s.[8] Later on, a wide range of nanomaterials have 
been developed for drug delivery, including polymers, liposomes, silica, metal oxides and 
semiconductor nanocrystals.[9] Liposomes are extensively used nanocarriers in biomedical field since 
their discovery by Bangham and coworkers approximately 40 years ago.[10] However, liposomes 
suffer from relatively low stability and rapid clearance from circulation by the reticuloendothelial system 
(RES) unless they are protected by hydrophilic polymers such as polyethylene glycol (PEG).[10] 
Polymeric nanoparticles, such as polyglutamic acid, polylactic acid and poly-d,l-lactide-co-glycolide 
nanoparticles have been widely used for drug delivery.[11] The particle sizes of polymers are 
controllable in the range of 10 – 100 nm, which is beneficial for tumour tissue penetration and cell 
uptake. However, their drug loading capacity and controlled release behaviour should be further 
improved. Gold and iron oxide are extensively studied metallic nanoparticles in the fight against 
cancer due to their interesting intrinsic property. Gold nanoparticles are well known for their application 
in photothermal therapy. This is based on their surface-plasmon resonance property, which enables 
the conversion of photon into thermal energy. Upon the release of heat to surroundings, the 
temperature can rapidly increase, leading to inhibition of cancer cells. In the case of iron oxide, 
particularly Fe3O4 nanoparticles, their superparamagnetic property allows in vivo tracking using 
magnetic resonance imaging (MRI) and magnetic field directed tumour targeting, which will be 
discussed in later section. However, due to the solid nature of gold and iron oxide nanoparticles, the 
payload and release profile of cargo is unsatisfactory. Moreover, their biodegradability has been 
another concern for clinical use.[12] The readers are referred to recent review articles where different 
types of nanomaterials for cancer therapy are comprehensively reviewed and compared in details.[9, 
13] 
Among the different types of nanocarriers, silica based nanoparticles, particularly mesoporous silica 
nanoparticles (MSNs) have been highlighted as promising candidates for tumour targeted drug 
delivery due to their vast advantages, which was firstly introduced by Vallet-Regi and co-workers in 
the early 2000s.[14] Tremendous efforts have been devoted to developing synthetic systems of MSNs. 
Their pore size and particle size can be finely tuned in a very wide range from 2 to 50 nm and from 
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10 nm to micron range, respectively. This allows the precise control on accommodating guest 
molecules with different sizes within the mesopores and their release profile. Moreover, the high 
specific pore volume and surface area (typical values ranging from 0.5–2 cm3 g-1 and 200–1000 m2 
g-1, respectively) enable a high payload. It should be noted that these advantages refer mainly to 
MSNs thanks to their pore rich structure, rather than other types of silica based nanoparticles with 
solid nature. Importantly, the surface of MSNs are rich with reactive silanol groups that are capable of 
conjugating with almost all types of functional groups, such as metal/metal oxide, targeting ligands, 
polymers and fluorescent agents. These functional groups can provide MSNs with various interesting 
properties, including tumour targeting, stimuli responsive release, bio-imaging, etc. In addition, the 
well-developed sol-gel chemistry allows constructing MSNs with various morphologies and 
structures. For instance, besides traditional spherical and rod like morphology, hollow spheres, yolk 
shell nanorattles, dendritic nanoparticles, Janus MSNs and hemi-spheres are reported recently. The 
synthesis approaches of MSNs have been extensively reviewed elsewhere,[15] thus will not fall into 
the scope of this review. Last, silica nanoparticles have good biocompatibility. A large number of 
reports have confirmed the low cytotoxicity of MSNs, although it also depends on the synthetic 
approach. Colloidal silica has been approved by the Food and Drug Administration (FDA) for oral 
administration for decades.  
In general, targeted drug delivery systems encompass three targeting strategies, which are passive 
targeting, active targeting and magnetic field directed targeting. Passive targeting refers to the 
preferential accumulation of nanoparticles at tumour site in the absence of targeting ligands. The 
accumulation efficiency is purely determined by the physiochemical properties of nanoparticle, such 
as size, shape, surface charge, etc. Active targeting is an approach that can enhance the preferential 
accumulation of nanoparticles at tumour site through surface modification with ligands that have 
selectivity and affinity towards tumour related tissue, cell or sub-organs. Magnetic field directed 
targeting involves functionalized nanoparticles with magnetic compositions, such as magnetite, to 
guide their flowing direction towards tumour site by applying an external magnetic field. Although it 
has been more than 30 years since the first proposed concept on targeted nanoparticles and 10 years 
since the first report on silica based delivery systems for active targeting, unfortunately none of them 
has reached clinical application. One of the main reasons is the lack of comprehensive information 
on the biobehaviours of silica based nanoparticles in the complicated in vivo conditions. To date, 
highly encouraging tumour elimination results are rather handful. This review will mainly focus on the 
recent progress on constructing silica based nanostructures for tumour targeted delivery, stemming 
from conventional passive targeting systems, where the current understanding on the importance of 
physiochemical properties of silica based nanoparticles will be critically discussed. Then active 
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targeting systems will be outlined and analysed based on different targeting sites at tumour region. 
Next, magnetic based targeting approach will be briefly discussed. Finally, we will provide an outlook 
on the challenges and future directions in this filed. 
2.2 Passive targeting  
Passive targeting is primarily relying on the enhanced permeability and retention (EPR) effect, which 
is firstly reported by Maeda in 1986.[16] The origin of EPR effect is due to the rapid growth of tumours, 
resulting in the formation of new blood vessels (also known as angiogenesis) to supply sufficient 
oxygen and nutrient for further proliferation. These rapidly formed imperfect and aberrant blood 
vessels possess leaky epithelium and discontinuous microvasculatures with fenestrations ranging 
from 200 - 2000 nm depending on the tumour type and location.[17] The fenestrations enhance the 
permeability of vessels surrounding tumours and enable nanoparticles moving in the blood stream to 
extravasate and accumulate into tumour matrix. On the other hand, it is well known that in normal 
tissues, the fluid in blood stream is constantly subjected to lymphatic drainage. However, the efficiency 
of the drainage system is significantly suppressed in tumours, leading to enhanced retention of 
nanoparticles in tumour tissues.[18]  
Since EPR effect has been very widely utilized for in vivo tumour targeted drug delivery,[19] great efforts 
have been devoted to improve the cancer cell accumulation/uptake performance of silica based 
nanoparticles. This primarily replies on prolonged circulation time, which can be achieved through 
overcoming two primary extracellular barriers: avoiding renal clearance and escaping the RES. 
Recent progress in understanding the relationship between chemophysical properties of silica 
nanoparticles, including particle size, morphology, porosity and structure and their bio-behaviours has 
provided useful guidance to design nanomaterials rationally. Despite those remarkable 
achievements, solid evidence based conclusions have not been made at this stage regarding the role 
of a certain textual parameter and some conflicting reports do exist. One possible explanation could 
be the fact that isolating one structural parameter of nanoparticle while keeping all the other 
parameters exactly the same to study the biobehaviour is fairly challenging. In this section, we mainly 
focus on the recent progress about the influence of particle size, morphology, surface property and 
topography on passive targeting capacity. 
2.2.1 Size 
Particle size plays a vital role in blood circulation, biodistribution, tissue penetration and cellular uptake. 
The elimination of injected MSNs is primarily through two pathways: RES and renal clearance. The 
former deals with large particles and latter takes place in the presence of small particles. Several 
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studies showed that the MSNs accumulated mainly in RES-related organs such as the liver and 
spleen, and cleared from the body within a period of a few months.[20] This severe accumulations in 
organs may result in compromised tumour targeting specificities and raise concerns of long-term 
toxicity of these nanoparticles and organ diseases, such as silicosis.[21] Although extensive in vitro 
evaluations of silica nanoparticles have reported their low cytotoxicity against different cell lines, their 
in vivo safety, unfortunately, is still unclear. For example, Tang et al demonstrated that non-toxic 
MSNs are able to facilitate the growth of human malignant melanoma.[22] However, an opposite 
observation was reported by Tamanoi et al, who found that MSNs did not affect tumour growth in 
mice.[23] The biosafety of MSNs, including cytotoxicity, hemolytic activity, etc., is also heavily 
dependent on the synthesis procedure, physiochemical property and surface functionalization (e.g. 
PEGylation, see section 2.3). Readers are referred to excellent reviews for more details.[24] 
At the systemic level, to ensure a prolonged blood circulation time, nanoparticles must be at least 10 
nm to avoid renal clearance.[25] Furthermore, several reports have revealed that particle size ranging 
from 100-200 nm is favoured for escaping RES and effective accumulation and retention in the tumor 
matrix through EPR effect.[16, 26] Shi and co-workers investigated the in vivo biodistribution and urinary 
excretion of spherical MSNs with different particle sizes (80–360 nm).[27] They mainly distributed in 
the liver and spleen, a minority of them in the lungs, and a few in the kidney and heart. Importantly, 
their results showed that particles with relatively small size of 80 nm possessed the longest mean 
residence time of ~2 h and were more slowly biodegraded as indicated by a lower excreted amount 
of degradation product. At the tissue level, the upper size limit for nanoparticles is ~ 400 nm, exceeding 
this size may cause suppressed diffusion through the tumour interstitium with insufficient amount to 
achieve clinical or therapeutic effect.[18, 28] At the cellular level, Mou and co-workers studied the size 
effect of silica nanoparticle on the cellular uptake in Hela cells,[29] where a size-dependent manner 
was observed in the order of 50 > 30 > 110 > 280 > 170 nm. This result suggests that relatively small 
particle size is favoured for efficient cellular uptake, which is consistent with the trend of other 
nanoparticles that 50 nm is the optimal particle size.[30] Nanoparticles with size less than 50 nm are 
difficult for fabricate and tend to aggregate, thus their cellular uptake amount is reduced.[29]   
2.2.2 Shape 
Recently, several literatures have reported the significant role of nanoparticles shape on EPR based 
tumour passive targeting.[31] The first attempt to study shape effect on cellular accumulation of 
particles was conducted by Freund and co-workers in 2005, where a theoretical model was 
proposed.[32] In their simulation, the cell membrane was assumed containing diffusive mobile 
receptors capable of wrapping around a ligand-coated cylindrical or spherical particle. The “wrapping 
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time” was suggested as the key to explain the faster endocytosis of spherical particles than the 
cylindrical particles. The importance of shape asymmetry and the initial orientation of particles for their 
interaction with the lipid bilayer of cellular membrane was also suggested by Yang and Ma using 
dissipative particle dynamics (DPD).[33] These simulation results have provided an excellent starting 
point in understanding the shape effect, although more conclusive results still rely on in vitro and in 
vivo experiments due to the complexity of physiological conditions and the diversity of cell types and 
corresponding cell internalization pathway.  
 
Figure 2.1 (A) Transmission electron microscope images of MSNP exhibiting different AR values; (B) 
HeLa cells were treated with 20 μg/mL FITC-labeled particles for 6 h in complete RPMI. The fold 
increase in mean fluorescence intensity (MFI) compared to spherical FITC-labeled MSNP (MSNP0) 
was used for comparison. RITC-labeled nanosphere uptake was used as another internal control for 
comparing each FITC-labeled spheres and rods to an alternatively labeled sphere. (C) HeLa cells 
were seeded into 8-well chamber slides before addition of the FITC-labeled particles at 20 μg/mL for 
6 h in complete RPMI. After fixation and permeabilization, cells were stained with 5 μg/mL wheat germ 
agglutinin 633 and Hoechst 33342 dye, followed by visualization under a confocal 1P/FCS inverted 
microscope. *, p < 0.05 compared with spherical FITC-labeled particle (MSNP0); #, p < 0.05 
compared with FITC-labeled MSNP1; $, p < 0.05 compared with FITC-labeled MSNP3. Reproduced 
with permission from ref. [49]. 
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The first in vitro investigation on the shape effect of silica nanoparticles on cellular uptake efficiency 
and kinetics was reported by Lin and co-workers.[34] They synthesized spherical MSNs with size of 
80–150 nm and tube like MSNs with a width of 80–150 nm and 400–1000 nm in length. The results 
revealed that the endocytosis efficiencies are both morphology and cell line dependent. For Chinese 
hamster ovarian (CHO) cells, the endocytosis rates for both MSNs were similar and rapid, whereas it 
was significantly faster in the case of spherical MSNs than that of tube-like MSNs in fibroblast cells. 
However, the polydispersity of the two types of MSNs may act as another variable besides the particle 
shape. It is expected that a more suitable system is desired for comparison. Tang and co-workers 
designed three types of monodispersed silica nanoparticles with different aspect ratios (ARs, 1, 2, 4) 
while the particle diameter, chemical composition and surface charge remain similar.[35] Interestingly, 
despite that all types of particles were readily internalized in A375 human melanoma cells, AR values 
exhibited positive correlation with the cellular uptake amount and internalization rates. The authors 
attributed the different cell/nanoparticle interaction to the differences in the curvature. Rod-like 
nanoparticles with longer longitudinal axis may provide larger contact area with the cell membrane 
than spherical nanoparticles do, resulting in enhanced nanoparticle/cell membrane interaction. In 
another work, Nel and co-workers investigated the cellular uptake efficiencies of three different rod 
like MSNs with dimensions of 110-130/60-80 nm (AR=1.5-1.7), 160-190/60-90 nm (AR=2.1-2.5), and 
260-300/50-70 nm (AR=4-4.5) in HeLa and A549 cancer cell line (Figure 2.1).[36] They reported that 
the cellular uptake quantity and rate is associated with the AR of rod like particles and the intermediary 
length MSNs with an AR of 2.1-2.5 were taken up faster and in larger quantities compared to shorter 
or longer length rods, thus more efficient delivery of hydrophobic chemotherapeutic agents to HeLa 
cells was observed. The rod-shaped nanoparticles not only exhibit higher cellular uptake efficiency 
then spherical nanoparticles, but also possess enhanced tissue penetration capability as reported by 
Chauhan et al., who found that rod like silica coated CdSe/CdS quantum dot (QD) of 15 nm diameter 
and 54 nm length  penetrated tumors 4.1 times faster than 35-nm diameter spheres (CdSe QD).[37] 
Besides rod-shaped nanoparticles, the biobehaviour of silica nanoparticles with other shapes were 
also studied. For example, Ferrari and co-workers compared the biodistribution of intravascularly 
injected silica beads with different morphologies, including spherical, quasi-hemispherical, cylindrical 
and discoidal.[38] Discoidal particles exhibited enhanced accumulation compared with the others in 
most of the organs but the liver, where cylindrical particles were deposited at a larger extent. To gain 
comprehensive insight on the effect of particle shape on in vivo behaviour, Tang and co-workers 
prepared two different shaped MSNs with aspect ratios of 1.5 and 5.[39] They found that the 
administrated MSNs were mainly present in the liver, spleen and lung (>80%) and there was an 
obvious particle shape related in vivo behaviour. Short-rod MSNs tended to accumulated in the liver 
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with a rapid clearance rate, while long-rod MSNs distributed in the spleen and the clearance rate is 
relatively slow.  
Currently, the significant shape effect of nanoparticles on the cell internalization and in vivo particle 
biohaviour has been clearly shown. However, it is still difficult to conclude that asymmetrical shaped 
silica nanoparticles, e.g rod-shaped silica nanoparticles, are more suitable candidates than traditional 
spherical nanoparticles for passive targeting since the conclusions obtained in silica based 
nanosystems are inconsistent with other nanoparticles with different composition. For example, it is 
reported that spherical gold particles with diameters of 14 or 75 nm showed 375–500% greater uptake 
in HeLa cells than 74× 14 nm rod-shaped particles.[40] Crespy et al. observed a cell type independent 
correlation between increase of aspect ratio of polymer nanoparticles and decrease of uptake.[41] 
Another study reported that the cellular uptake of polystyrene nanoparticles was reduced upon 
changing from a three-dimensional spherical particle to a two-dimensional disk.[42] The existence of 
these conflicting reports on the shape effects might be attributed to two possible underlying reasons: 
1) Taking the shape as a single variable is quite difficult as highly uniformly shaped nanoparticles can 
hardly be obtained and a certain degree of particle aggregation in physiological conditions is 
inevitable. 2) The difference in particle composition, the surface charge and hydrophobicity may alter 
the nanoparticle-cell interaction outcome. This implies that in silica nanosystems, the surface 
properties may completely change their biobehaviour.  
2.2.3 Surface property 
MSNs generally possess very high surface area and large surface-to-volume ratio. This is important 
because the interaction between nanoparticles and the environment is occurred on their surface. 
Therefore the surface properties of MSNs, including functional groups, hydrophilicity/hydrophobicity 
and charges, dramatically influence their biodistribution, circulation half life, extravasation, cell binding 
and internalization.[43] Bare silica nanoparticles containing exposed silanol groups on their surface are 
negatively charged in physiological conditions (pH ~7.4), thus interact strongly with red blood cell 
membrane, eventually causing hemolysis.[44] This hemolytic activity of silica nanoparticles cause 
reduced biocompatibility and impede their application for passive targeting of tumour tissues. Despite 
that the underlying reason of hemolysis is still not fully understood, it has been confirmed that the 
hemolytic activity can be significantly reduced by incorporating organic components in the silica 
framework, suggesting that organosilica nanoparticles are of great potential for drug delivery 
applications.[6, 45] 
Another barrier that hinders the passive targeting of nanoparticles in tumour tissue is opsonisation, 
that is, plasma proteins called opsonins tend to coat on the particle surface and form protein corona, 
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which can be recognized by RES system and rapidly eliminated.[46] To minimise opsonisation, the 
most commonly used strategy is to functionalize silica nanoparticles with hydrophilic polymers, such 
as PEGs and their derivatives.[47] PEGs act as a shell that mask the surface exposed silanol groups 
to reduce their interaction with environment and form a hydrophilic layer around nanoparticles,[48] 
which reduce the non-specific protein binding through steric hindrance and electrostatic repulsion 
effects, thus the opsonisation can be inhibited and biocompatibility and the colloidal stability of 
particles can be ameliorated.[49] Meng and co-workers demonstrated that the EPR effect based 
sufficient nanocarrier accumulation at tumor site (∼12%) can be achieved through surface decoration 
with polyethyleneimine (PEI)-PEG copolymer, which also minimized the chemotherapeutic side 
effects.[47a] The influence of molecular weights and chain densities of PEG on the nonspecific binding 
of PEGylated MSNs to protein was investigated by He et al.[47d] Their results revealed that the optimal 
molecular weights of PEG is 10-20 k, and the corresponding optimal chain densities for PEG10k–
MSNs and PEG20k–MSNs were 0.75 wt% and 0.075 wt%, respectively. The phagocytosis and 
hemolysis percentage of PEGylated MSNs was also significantly lower than bare MSNs. PEGs also 
alter the biodistribution of MSNs, as several studies reported that compared with non-PEGylated 
MSNs, PEGylated MSNs showed decreased accumulation in liver, spleen and lung tissues after 
intravenous administration, and the blood-circulation lifetime was prolonged and excretion rate was 
decreased.[27, 39, 47b, 47d] 
Despite the vast investigations on the excellent performance of PEGylated MSNs on passive 
targeting, some limitations still remain.[50] It was reported that PEGs tended to decompose in most 
physiological conditions due to the presence of oxygen and transition metal ions.[51] Another study 
revealed that the protein resistance property of PEGs was dramatically reduced at temperature above 
35 °C.[52] Although PEGs are generally accepted non-toxic and non-immunogenic, several reports 
showed that unexpected changes in the pharmacokinetic behavior of PEGylated nanoparticles occur 
when nanoparticles were injected repeatedly in the same animal.[53] Ishida et al suggested that 
repeated injection of PEGylated nanoparticles would induce production of specific anti-PEG IgM and 
consequently result in accelerated blood clearance (ABC) of nanoparticles.[54] Therefore, alternative 
functional groups other than PEG have been developed. Jiang group reported the strong protein 
resistance property of zwitterionic polymers which possess balanced charge and minimized dipole 
due to their strong hydration capacity via electrostatic interactions.[55] Later on, zwitterionic copolymer 
functionalized silica nanoparticles were confirmed with excellent protein repulsive property and long 
term stability in biochemically relevant solutions.[56] A recent study showed that zwitterionic copolymer 
coated MSNs displayed negligible cytotoxicity and significantly reduced macrophage cell uptake ratio, 
suggesting their great potential as nanocarriers for drug delivery or diagnostics.[57] Another alternative 
14 
 
strategy to improve the blood circulation lifetime and prevent RES clearance is through lipid coating,[58] 
by which the half life of modified silica nanoparticles can be increased more than 10 times than bare 
silica nanoparticles, and a decreased capture by RES-related organ was also observed.[58c]   
The surface charge of nanoparticles also plays a central role in their passive targeting performance.[59] 
Since the cell membrane is negatively charged, cationic modified nanoparticles show higher cell 
internalization than their negative or neutral counterparts due to the electrostatic interaction.[60]   
However, positively nanoparticles are commonly more cytotoxic and immunogenic than their neutral 
and anionic counterparts because of platelet aggregation, as well as more active in opsonisation, thus 
quickly cleared by the RES effect.[61] Neutral charged nanoparticles show lower interaction with 
plasma proteins, which result in a smaller hydrodynamic size compared to both positively or 
negatively charged particles, thus displaying favourably long circulation lifetime and interstitial 
transport in tumors.[43a, 62] In all of the cases, the surface charge of nanoparticle eventually tend to be 
negative due to the plasma protein coating, regardless of the initial surface charge. The coating of 
plasma protein is dependent on the surface charge density, surface topology, composition and porous 
structure of nanoparticles. This complex nature and various tumor models used for studies might be 
the underlying reasons for some contradictory results in literatures. In addition, detailed and 
systematic studies on the effect of surface properties on the passive targeting property are still highly 
desired. 
2.2.4 Surface roughness 
It has been discovered for a long time that viral vectors with rough surface have very high delivery 
efficiency,[63] but only very recently have the effect of surface roughness of silica nanoparticles on 
cellular uptake and drug delivery efficiency been reported.[64] Niu et al recently synthesized rough silica 
nanoparticles mimicking the virus surface topography by attaching small shell particles on relatively 
large sized core particles through electrostatic interaction (Figure 2.2).[64a] The obtained rough silica 
nanoparticles showed enhanced binding capacity and sustained released for biomolecules as well 
as improved cellular uptake efficacy compared to silica nanoparticles with smooth surface, thus 
cellular delivery efficiency is significantly increased. This concept of surface roughness induced 
enhanced cellular delivery was further extended to MSNs systems, where a 37% higher cellular 
uptake and improved therapeutic efficiency can be obtained.[64b] These results are consistent with 
previous reports, where an enhanced bioadhesive capacity of nanoparticles with rough surface 
towards mucosa was observed compared to smooth ones.[65] Nel et al. suggested that the positive 
influence of surface roughness on the particle-membrane interaction is due to nonspecific binding 
forces.[43a] Results based on simulations indicate that the nanoscale surface roughness can lead to 
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greatly minimized repulsive interactions, including electrostatic and hydrophilic, thereby promoting 
adhesion and internalization.[66] Although current reports have provided a proof of concept of the 
positive correlation between surface roughness and particle-membrane interaction, detailed 
investigation on the role of surface roughness is very rare. For instance, whether and to what extent 
the size, density and composition of the nanoscale spikes influence the particle-membrane interaction 
is unknown. The picture will be further complicated by considering the combination of other effects, 
such as the surface hydrophobicity. In vivo studies are also highly desired to understand the 
biobehaviour of spiked nanoparticles.   
 
Figure 2.2 (A) Illustration of: a) the synthesis procedure, and, b) the comparison of cellular delivery 
performance between two nanocarriers. a) Sample 1 represents silica nanoparticles, which can be 
further modified with positively charged amine groups or PEI. Sample 2 comprises the negatively 
charged silica nanoparticles with small diameters. Sample 3 was prepared by using amino-modified 
1 as the core and 2 as the shell particles after calcination, which is modified with amine groups or PEI. 
b) Compared to smooth nanocarriers, rough ones exhibit both higher binding ability towards 
biomolecules (e.g., proteins and genetic molecules) and increased cellular uptake efficiency, 
independent of surface functionality. (B) Surface characteristics of 3. a,b) SEM images show the virus 
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mimicking rough surface. Scale bar: 100 nm. (C) Virus-mimicking nanoparticles enhance cellular 
delivery performance in HeLa cells. a,b) Confocal microscopy images of Cy3-oligoDNA (red color) 
delivered by (left) 1-NH 2 and (right) 3-NH 2 . The nuclei are stained in blue (DAPI) and the cell 
membranes in green (FITC). Scale bar: 20 μm. Reproduced with permission from ref. [101]. 
Despite the chemophysical parameters of silica based nanomaterials discussed in above sections, 
other parameters, such as elastic modulus, is also hypothesized governing the biodistribution and 
circulation period of nanoparticles in vivo.[67] For instance, Merkel and co-workers reported the 
fabrication of hydrogel material with a low Young’s modulus, which enable them with increased 
circulation times through bypassing several organs, such as the lung, that tend to capture materials 
with high Young’s modulus.[68] Their following work further demonstrated that the highly deformable 
particles tend to escape from clearance tissues and  those resembled red blood cells in size showed 
the highest circulation time and slowest clearance.[69] These reports have clearly evidenced the 
importance of the elastic modulus of materials on their biobehaviour. Unfortunately, to our knowledge, 
there has been no report on the influence of elastic modulus on the biobehaviour of silica based 
nanoparticles so far, presumably due to the difficulty in precisely tunning their modulus. Designing 
silica nanomaterials with enhanced passive targeting performance and reduced organ accumulation 
through various approaches is expected as one of the future directions.  
Although EPR based passive targeting strategy has been of widespread use and great success, it is 
not without limitations.[59b] Since the angiogenesis may not occur homogenously throughout the whole 
solid tumor and the size and density of fenestrations on the vessel wall are dependent on the tumour 
growth stage, tumour type and location, cancer therapy solely relies on passive targeting may result 
in unsatisfactory therapeutic efficiency and severe side effect.[70] These issues can be partially solved 
by active targeting. 
2.3 Active targeting 
Active targeting involves functionalizing the surface of nanoparticles by ligands that have specific 
affinity to the receptors over-expressed on the cancer cells, which is considered as a complementary 
strategy to EPR effect to increase the efficiency of cancer therapy. In 1980, the first active targeting 
drug delivery nanocarriers using antibody modified liposomes was reported.[71] To date, a wide range 
of ligands have been developed for efficient active targeting, including small molecules, peptides, 
antibodies and antibody fragments, and nucleic acids (e.g., aptamers), which have been well 
reviewed elsewhere.[72] In general, the site specific active targeting strategy can be divided into three 
types: tumour cell targeting, vascular targeting and subcellular organelles targeting (Figure 2.3). In 
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this section, recent progress on active targeting ligands modified silica-based drug delivery systems 
for cancer therapy will be reviewed and some current misunderstandings and challenges will be 
discussed. 
 
Figure 2.3 Schematic illustration of active targeting strategies: Tumour cell targeting, vascular 
targeting and nuclear targeting 
2.3.1 Tumour cell targeting 
Tumour cell targeting is the most commonly used strategy in active targeting as it is a straightforward 
approach to enhance the affinity of silica nanoparticles towards cancer cells through ligand-receptor 
interaction, leading to increased cellular uptake and drug delivery efficiency. The first study on tumour 
cell targeting based on MSNs is reported by Slowing et al., who observed that N-folate-3-aminopropyl-
grafted MSNs were internalized into HeLa cells more efficiently than other surface functionalized 
MSNs and the endocytosis mechanism was suggested through a folic acid (FA) receptors-mediated 
process.[73] A following work conducted by Rohsenholm et al. reported that FA modified MSNs 
exhibited fivefold more uptake by folate receptors positive cancer cells compared to folate receptors 
negative cancer cells.[74] Zink and co-workers synthesized multifunctional folate-modified iron oxide 
mesoporous silica nanoparticles that are traceable by both magnetic resonance (MR) imaging and 
fluorescence imaging.[75] The surface conjugation with folate increased the uptake into cancer cells 
compared with normal cells, leading to enhanced drug delivery efficiency. As the chemical structure 
of the chemotherapeutic agent methotrexate (MTX) is similar to folic acid, Rosenholm et al. designed 
a PEI functionalized MSNs drug delivery systems where MTX served as both a targeting ligand and 
a cytotoxic agent.[76] Enhanced cancer cell inhibition relative to free MTX was observed while 
nonspecific MTX-induced cell death is not observed in normal cell line. In vivo studies was conducted 
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by Lu et al, who demonstrated that folic acid modified MSNs after drug loading was able to 
dramatically improve the potency of tumor suppression.[23] A low dose of 0.5 mg of CPT-loaded MSNs 
per mouse was sufficient for achieving complete tumor growth inhibition.  
Besides the widely used FA based targeting ligands, other types of ligands are also under 
investigation and development to target different over-expressed receptors. Yu and co-workers 
synthesised hyaluronic acid (HA) modified MSNs targeting CD44 over-expressed HCT-116 (human 
colon cancer cells).[77] Compared to bare MSNs, HA modified MSNs exhibited a higher cellular uptake 
via HA receptor mediated endocytosis, leading to greater cytotoxicity to HCT-116 cells than free drug 
and drug loaded bare MSNs. In another work, lactobionic acid was used as the targeting ligand 
towards asialoglycoprotein receptor and collagen served as capping agent to develop multifunctional 
MSNs simultaneously possessing cell-specific targeting capability and stimuli-responsive controlled 
drug release property.[78] Aptamers, also called nucleic acid ligands, are single-stranded DNA or RNA 
oligonucleotides that can form three-dimensional conformations and possess high affinity and 
specificity towards various kinds of targets.[79] Since aptamers are generally accepted non-
immunogenic and easy to synthesise, characterise and modify,[18] they have been widely used in 
cancer cell-specific drug delivery systems.[80] Zhu et al. for the first time applied aptamer into MSNs 
based cancer cell targeted drug delivery system, where an improved cell inhibition was observed 
compared with MSNs without conjugating targeting ligands.[81] Similarly, Li group and Lu group also 
constructed MSNs-aptamer bioconjugates for targeting PAR-1 overexpressed Hela and nucleolin 
overexpressed MCF-7 cancer cell line, respectively.[82] Very recently, several systems combining 
aptamer-mediated targeting and intracellular stimuli-triggered drug release have been developed, 
confirming the great targeting performance of aptamer both in vitro and in vivo.[83] Transferrin, a type 
of protein based targeting ligand, has been conjugated on the surface of MSNs. Up to 10-fold increase 
in particle uptake by PANC-1 compared to normal cells with low levels of surface transferrin receptor 
was observed.[84] Another type of commonly used cancer cell targeting ligands is antibody, which 
have also been functionalized onto MSNs and showed high affinity and selectivity.[85]  
Despite the great effort that has been devoted to developing tumour cell specific active targeting 
systems, the actual role of targeting ligands on the surface of nanoparticles is still a controversial 
topic.[86] Because the successful accumulation of nanoparticles at tumour site has to experience blood 
circulation, extravasation and penetration into tumour matrix,[87] the efficiency of nanoparticles 
reaching the target is primarily determined by the chance of particles in blood stream passing by the 
target and being entrapped.[88] This chance purely relies on EPR based passive targeting and can be 
elevated by increasing the blood circulation time through tuning the physicochemical properties of 
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nanoparticles or PEGylation as discussed in Section 2. Unfortunately, the tumour cell specific ligands 
cannot alter the chance as they only enable an enhanced cellular uptake performance for the portion 
of nanoparticles that have reached tumour site after extravasation from the vasculature.[86a] From this 
point of view, tumour cell targeting ligands can facilitate a higher intracellular drug concentration and 
cytotoxicity, while has little to do with the improvement in tumor accumulation.[86b, 86c]  
Lu et al. reported that the FA conjugated MSNs showed a negligible increase in the tumour 
suppressing effect compared to bare MSNs.[20c] The same observation was also reported in an FA 
conjugated polymer nanoparticles based drug delivery system.[89] The inconsistency in results on the 
role of tumor cell active targeting agents can be interpreted with four possibilities. First, not all tumor 
cells over-express receptors all the time and the receptor density on the cell surface at different stages 
varies significantly.[86a] A ligand-receptor mediated improved nanoparticle-membrane interaction 
happens only when receptors are over-expressed on tumour cells with a high density and at the 
meantime nanoparticles pass by. This may cause large variations on experimental results. Second, 
the density of active targeting ligands on the surface of nanoparticles is another critical issue, but only 
little attention has been paid to this point. It has been reported that the ligand/nanoparticle ratio strongly 
affects the cell recognition specificity and higher amount of ligand density showed greater selectivity 
and enhanced targeting efficiency.[85b] Nevertheless, it is argued that targeting ligands modified 
nanoparticles may preferentially interact with tumor cells near the leaky vessels, hindering the deep 
penetration and uniform distribution of nanoparticles in the tumour tissue.[86b] Also, a high density of 
targeting ligands on nanoparticles may cause reduced cellular uptake efficiency due to their steric 
hindrance effect.[90] Hence, the density of the targeting ligands conjugated on the surface of 
nanoparticle may strongly affect the accumulation performance at tumour site, thus needs to be 
carefully manipulated and optimized for maximized targeting efficiency. Third, in a complex biological 
environment, the targeting ligands can be shielded due to the occurrence of opsonisation, resulting in 
loss of their targeting ability.[91] Therefore, utilizing targeting ligands and simultaneously preventing the 
plasma protein coating is another noteworthy issue. The fourth possibility is that the majority of the FA 
modified nanoparticles may accumulate in liver as it is the major storage organ of excess folate,[92] 
resulting in decreased tumour specific targeting efficiency.  
In general, current results have clearly demonstrated that tumour cell specific active targeting strategy 
can improve the cellular uptake efficiency, which is dependent on cell type and properties of targeting 
ligands. However, considering the complexity of in vivo conditions, the contribution of targeting ligands 
to tumour site specific accumulation is still not clear and most likely EPR based passive targeting is 
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the dominant propulsion. Hence, more detailed studies on the role of tumour cell targeting ligands at 
in vivo conditions are desired.    
2.3.2 Vascular targeting 
Vascular targeting has been demonstrated as a promising alternative in treating solid tumours. It 
indirectly destructs tumor tissues by cutting off their supplies of oxygen and nutrients through targeting 
and killing the endothelial cells of the tumor vessels.[93] Due to the fact that extravasation from blood 
vessel and cellular uptake by tumour cells is not required in vascular targeting,[94] it holds great 
advantages over traditional tumour cell targeted therapy. For instance, the problems of poor delivery, 
drug resistance and tumor heterogeneity can be potentially minimized. Moreover, an endothelial cell 
specific targeting ligand developed for vascular targeting could be generally applied to most or all 
types of tumours.[95] In the case of vascular targeting, due to the intimate contact of endothelial cells 
with blood, they are highly accessible targets for nanocarriers within tumour tissue and the tumour 
accumulation efficiency no longer primarily relies on EPR effect, but the binding selectivity and affinity 
of vascular targeting ligands to blood vessels.  
Although the idea of vascular targeting for cancer therapy was emerged as early as 1920s,[96] only 
until 1990s a proof of concept was provided by Burrows and Thorpe, who demonstrated the first 
successful tumour vasculature targeted tumour eradication in vivo.[97] Since then, various 
nanoparticles, such as quantum dots,[98] single-walled carbon nanotubes[99] and nanographene 
oxide,[94a, 94b] have been conjugated with vasculature targeting ligands, including vascular endothelial 
growth factor (VEGF) and arginine−glycine−aspartic acid (RGD) peptides, to develop drug delivery 
systems with enhanced therapeutic efficiency. The first example of in vivo tumor vascular targeted 
drug delivery using MSNs was reported by Chen et al. in 2013.[100] TRC105 antibody was conjugated 
on the surface of MSNs to target CD105 receptors overexpressed in the tumour vasculature in the 
4T1 tumour tissue, leading to ~2 fold enhancement of tumor uptake when compared to that of EPR 
effect based passive targeting. In another study, luminescent MSNs conjugated with RGD were found 
capable of efficiently targeting the tumours through interactions with integrin αvβ3 over-expressed on 
the tumor vasculature.[101] Very recently, based on the idea of vascular targeting, multifunctional hollow 
structured and metal compound incorporated MSNs with in vivo tracking capability for chemotherapy 
or phototherapy have been developed.[102] These encouraging results have clearly demonstrated the 
great potential of vascular targeting strategy for cancer therapy.    
Despite the remarkable progress on the tumor vasculature targeted drug delivery, the current 
targeting efficiency, generally less than 10% id/g (injected dose per gram of animal weight), is still far 
from satisfactory, which represents a bottleneck for the development of future anticancer 
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nanomedicine. Significant accumulation of nanoparticles in major organs, particularly lung, liver and 
kidney, was observed even in those “promising” drug delivery systems.[100, 102b] These observations 
remind us that the success of vascular targeting systems still requires the development of ligands with 
high specificity and nanoparticles with “stealth” property to escape the capture by major organs, in 
order to meet the minimum requirements for clinical applications. Therefore, the combination of proper 
targeting ligands with rationally designed nanoparticles, including size, shape, surface charge and 
functionalization, is of great importance to overcome existing issues.  
2.3.3 Nuclear-targeting 
When most drug delivery systems have focused on delivering therapeutic agents in the cytoplasm, in 
fact, the cytoplasm is not the final destination for certain therapeutics. For instance, therapeutic genes 
have to enter into the cell nucleus to correct disfunctional and/or missing genes. Some anticancer 
drugs, such as doxorubicin, can cause oxidative DNA damage and topoisomerase II inhibition in the 
nucleus and result in apoptosis of tumor cells.[103] However, the activity of free anticancer drugs/DNA 
after arriving at the nucleus can be reduced due to the presence of many biobarriers,[103] leading to 
suppressed therapeutic efficiency. To overcome this issue, several cell nuclear-targeted delivery 
systems have been developed through surface conjugating with nuclear localization signal, including 
silver nanoparticles,[104] quantum dots (QDs),[105] magnetic nanoparticles[106] and gold 
nanoparticles.[107]  
 
Figure 2.4 (A) (i) Schematic diagram of the procedures for preparating amine group- and TAT-C6-
FITC peptide-conjugated MSNs. (ii) Schematic illustration of transport of DOX@MSNs-TAT across 
the nuclear membrane. (iii) TEM images of MSNs with sizes of (a) 25, (b) 50, (c) 67, and (d) 105 nm. 
Scale bars: 100 nm. (B) CLSM images of MSNs-TAT with diameters of (a) 25, (b) 50, (c) 67, and (d) 
105 nm after incubation with Hela cells for (i) 4, (ii) 8, and (iii) 24 h. Scale bars: 5 μm. Reproduced with 
permission from ref.[172]. 
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The first MSNs based cell nuclear-targeted drug delivery system was developed by Pan et al. in 2012 
(Figure 2.4).[108] MSNs with various sizes (25, 50, 67 and 105 nm) were synthesized and conjugated 
with TAT, a type of nuclear localization signal peptide, to study the effects of particle size and TAT 
conjugation on the nuclear membrane penetrability. They found that TAT conjugated MSNs with a 
diameter of 50 nm or smaller are able to penetrate the nucleus membrane and deliver the active 
anticancer drug into the nucleus, leading to significantly enhanced therapeutic efficiencies. This 
nuclear-targeted drug delivery was further applied to overcome the multidrug resistance of cancer 
cells, owning to the direct intranuclear drug accumulation and release.[109] Very recently, the nuclear-
targeted drug delivery system was successfully employed in gene therapy, as reported by Wu et 
al.[110] They synthesized mesoporous organosilica nanoparticles (MONs) with ultra-small particle size 
of ~30 nm and large pore size of ~6.2 nm through a co-templating assembly strategy. After 
conjugating with PEI and TAT, MONs demonstrate a significantly enhanced payload of DNA 
molecules, satisfactory protection of plasmids from nuclease-mediated degradation, and intranuclear 
high plasmid transfection efficiency.  
2.3.4 Multistage targeting 
The majority of reported targeted drug delivery systems are focusing only on targeting single tumour 
related site, such as endothelial cells, tumour cells or cell nuclei, which still suffer from unsatisfactory 
therapeutic effects due to insufficient drug accumulation in tumour site. With progress in the designed 
synthesis of silica nanoparticles with controllable structures, it is possible to conjugate multiple 
targeting ligands on the surface of silica nanoparticles with affinity and specificity towards different 
tumour related sites. Sequentially targeting two or more disease sites results in greater delivery 
efficiency and reduced systemic side effects.  Although very limited number of reports has been 
published in this field, we believe that these multistage targeting nanomedicines will guide the future 
direction in designing advanced drug delivery systems. 
The first breakthrough in developing MSNs based multistage targeting drug delivery system is 
achieved by Qu group.[111] The multifunctional MSNs is constructed with a magnetic Fe3O4 core, 
which is responsible for simultaneous  magnetic resonance imaging and magnetic targeting to direct 
drugs to tumour sites, and a silica layer that capable of drug loading and surface functionalization. 
TAT was firstly conjugated on the magnetic MSNs for nuclear-targeting, followed by decorating with 
charge-conversional polymer comprised of citraconic anhydride and folate-grafted chitosan. Folic acid 
moieties are for the purpose of targeting folate receptors over-expressed tumor cells. This smart 
system can achieve a multistage drug delivery: First, the accumulation of nanoparticles in tumour site 
was enhanced by using magnetic guidance. Second, the cellular uptake was facilitated by the folate 
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receptor mediated endocytosis. Third, cell nuclear targeting could be achieved due to the presence 
of TAT peptides. This multistage targeting strategy exhibited unprecedented advantages over other 
nanoparticle based drug delivery systems and has led to enhanced cell growth inhibition efficiency in 
cancerous cell. This multistage targeting strategy is further applied in vivo as reported by Shi group 
(Figure 2.5).[112] MSNs were covalently conjugated with RGD, which can effectively bind to the tumor 
vasculature and subsequently to the cell membrane, and TAT peptides, which serve as a nuclear 
targeting signal for efficient nuclear uptake. The vasculature-/membrane-to-nucleus sequential drug-
delivery strategy results in a significantly enhanced therapeutic efficacy, as evidenced by the almost 
complete tumour eradication (tumor growth inhibition rate of 98.6%) by the vein-injection of the 
nanomedicine at a reasonable dose.   
 
Figure 2.5 Schematic illustration of vasculature-to-cell membrane-to-nucleus sequential targeted drug 
delivery based on RGD and TAT peptides coconjugated MSNs for effective cancer therapy. Step I: 
RGD-directed tumor vasculature and cell membrane targeting; Step II: TAT-mediated nuclear 
targeting. Reproduced with permission from ref.[176]. 
2.4. Magnetic field directed targeting 
Different from previous active targeting strategies based on internal receptor mediated particle-
membrane interaction, magnetic field based targeting can be achieved through applying an external 
magnetic field that is capable of directing magnetic nanoparticles and thus enhances their 
accumulation at tumour site.  
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Shi group firstly synthesized rattle-type hollow magnetic MSNs with Fe3O4 particles encapsulated in 
the cavity, although no in vitro data was provided.[113] In another work, Wu and co-worker prepared 
rattle-type magnetic MSNs with a magnetic core and a mesoporous silica shell, which show negligible 
hemolytic activity and very low cytotoxicity against MCF-7 and HeLa cells. Importantly, the 
synthesized nanoparticles exhibited a magnetic field directed accumulation at targeted organ.[114] The 
first successful in vivo drug delivery based on magnetic directed tumour targeting is reported by 
Stucky et al in 2011.[115] They constructed nanorattle hollow spheres with rare-earth-doped NaYF4 as 
shells and silica coated Fe3O4 particle as the core in the cavity. This multifunctional mesoporous 
nanostructure with both upconversion luminescent and magnetic properties emits visible 
luminescence upon NIR excitation and can be directed by an external magnetic field to a specific 
target. The drug loaded nanostructures showed excellent tumor growth inhibition and significantly 
enhanced accumulation at tumour site in the presence of an external magnetic field.  
2.5. Conclusion and Outlook 
Nanotechnology based cancer treatment has exhibited remarkable advantages over traditional 
approaches. Among the different nanomaterials that have been developed for this purpose, silica 
based nanoparticles, in particular MSNs, hold a great potential as nanocarriers due to their interesting 
properties such as high payload, ease of surface functionalization and excellent biocompatibility. 
Since the biodegradability of pure silica is relatively slow due to the stable cross-linked framework, the 
accumulation of nanoparticles in organs has been an obstacle that hampers their clinical application. 
In an attempt to enhance the biosafety, bio-responsive degradable silica based nanocarriers that are 
capable of self-destructing into harmless and clearable products at physiological conditions has been 
reported recently. Croissant et al reported degradable periodic mesoporous organosilica 
nanoparticles by incorporating disulfide bond in the framework, which showed excellent redox 
responsive degradation behaviour.[116] Very recently, a pH sensitive degradable 
MSNs/hydroxyapatite (HAP) hybrid nanocarrier is reported by Hao et al. The MSNs/HAP nanocarrier 
showed high drug loading, good biocompatibility and antitumor effect and greatly reduced side effects 
of DOX.[117] The successful development on the biodegradable silica based nanoparticles may open 
the door of designing drug carriers with enhanced biosafety.  
Targeted drug delivery can reduce the systemic side effect that may damage normal tissues and 
organs by facilitating the drug accumulation at tumour site. To this end, a great number of MSNs 
based multifunctional nanocarriers have been rationally designed based on different targeting 
strategies, including passive targeting, active targeting and magnetic field directed targeting as 
mentioned in previous sections. Passive targeting is primarily based on EPR effect, which has been 
25 
 
confirmed rather effective in several targeted drug delivery systems. In order to enhance the EPR 
effect at tumour site and internalization by tumour cells, great efforts have been devoted to establish 
the correlation between the physiochemical properties of nanoparticles and their passive targeting 
performance. Particle size, shape, surface property and topography have been found playing 
important roles. However, few conclusive results have been obtained on the optimal physiochemical 
properties of nanoparticles due to the complexity of passive targeting process. Passive targeting 
involves four steps, including blood circulation, extravasation from blood vessel, penetration within 
tumour tissue and internalization by tumour cells. For each step, the optimal physiochemical 
properties of nanoparticle could be completely different. For instance, Namdee et al. have recently 
reported the effect of the particle size on their margination propensity, that is, the capacity of particles 
to interact with the blood vessel walls, a prerequisite for the extravasation process.[118] Their results 
suggested that microspheres have disproportionately higher margination than nanospheres in all 
hemodynamic conditions due to the fact that the latter tend to interact with red blood cells and localize 
at the mid region of blood stream. However, with respect to tumour interstitium penetration and cellular 
uptake, particle size less than 200 nm is favoured. The different requirement of physiochemical 
property of particles at each step of passive targeting will be further complicated when taking the other 
parameters and various tumour model into consideration. In this regard, new concepts such as 
adjusting the elastic modulus of nanoparticles[68-69] may shed light on future studies to design silica 
based nanoparticles with reduced RES clearance.  
To overcome the low efficiency of tumour accumulation, innovative strategies have been developed 
to conjugate silica nanoparticles with targeting ligands that are capable of interacting with receptors 
over-expressed on tumour related cells. Tumour cell targeting is the most extensively investigated 
active targeting strategy. Although a large number of reports have confirmed its highly promising 
efficiency in vitro, encouraging in vivo performance is still lacking. Only few reports have proven that 
this strategy really improves the in vivo accumulation of nanoparticles at tumour site.[119] This is not 
surprising because it should be kept in mind that the current so called “tumour cell targeting” strategy 
is not really designed to target any particular tumour cells. They merely facilitate the interaction 
between nanoparticles and cell membrane if the receptors happen to be over-expressed at the time 
when nanoparticles pass by. In this sense, tumour cell targeting may improve the uptake of 
nanoparticles by cancer cells, while differentiating the tumour tissues and normal tissues and 
enhancing their accumulation in the former is extremely difficult, especially considering much larger 
amount of normal cells where receptors are also expressed even at a lower level. Therefore, EPR 
based passive targeting is still the primary targeting approach. Tumour vascular targeting could be an 
alternative strategy, by which the targeting process can be significantly simplified because 
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extravasation from blood vessels and tumour penetration is no longer required. Since the exploration 
of MSNs based tumour vascular targeting systems has only recently begun, the margination 
propensity, the interaction between nanoparticles and endothelial cells and the binding affinity of 
targeting ligands towards receptors have not been extensively reported. Similarly, nuclear targeted 
drug delivery systems are another very recently developed strategy for the purpose of enhanced 
therapeutic efficiency. Although a number of reports have demonstrated its great potency both in vitro 
and vivo, unfortunately it has nothing to do with altering the tumour site specific accumulation. 
Therefore, a combination of multiple targeting strategies, including active targeting and magnetic field 
directed targeting, that is able to simultaneously or continuously target several tumour related sites, is 
expected as the future direction in developing targeted drug delivery systems to improve the 
probability and accuracy of their tumor recognition.  
In addition to the fabrication of multifunctional nanoparticles, the development of in vitro evaluation 
platform that can precisely mimic the in vivo condition is of great importance. Currently, most of the in 
vitro experiments are still conducted in two dimensional cell culture plates, where tissue penetration 
is not involved. Such results may not represent the behavior of nanoparticles in the in vivo three 
dimensional (3D) tumour studies. Possibly this is one of the reasons to explain the current situation: 
many drug delivery systems show excellent performance in vitro but only a few successes in vivo.  To 
address this issue, 3D cell culture systems have been developed. For instance, Yu and co-workers 
reported the superior tissue penetration capability of ultra-small hybrid silica spheres (~10 nm) in 3D 
glioma spheroids.[120] This 3D spheroid culture may fill the gap between traditional 2D cell culture and 
live tissue. Other more sophisticated 3D cell culture systems based on porous scaffolds or hydrogels 
are also reported. One typical example is a 3D human-mimicry platform termed “organ-on-a-chip”, 
which contains human tissues/organs made from perfusion cultures, such as liver, lung, heart, kidney, 
and blood vessels.[121] This 3D in vitro platform can provide new opportunities in understanding and 
predicting the biobehaviours of nanocarriers more conveniently and precisely than traditional 
approaches, which is expected to facilitate the progress of targeted drug delivery systems moving 
from bench to clinical trials.  
The accumulation of knowledge based on the findings and understandings within the past decades 
has led to the exponential growth of technological progress in the field of engineering silica based 
nanoparticles in targeted cancer therapy. It is expected that, in the near future, smart nanomedicine 
systems with improved efficacy and enhanced biosafety generated through more advanced and 
sophisticated design will pave the way in cancer diagnostics and treatment and improve both the 
duration and quality of a patient’s life. 
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Chapter 3 
 
 
Anion Assisted Synthesis of Large Pore 
Hollow Dendritic Mesoporous Organosilica 
Nanoparticles: Understanding the 
Composition Gradient 
 
The chapter has been published on Chemistry of Materials, 2016, 28, 704 
ABSTRACT: Dendritic hollow mesoporous organosilica nanoparticles (DHMONs) with a 
unique dendritic shell and hollow cavity, large pore size (29.5 nm) and high pore volume 
(1.88 cm3 g−1) have been synthesized via an anion assisted approach and a new 
understanding of the composition gradient in dendritic organosilica nanoparticles (DMONs). 
The resultant DHMONs possess enhanced protein loading capacity, more sustained release 
profile and improved hemocompatibility compared to DMONs. 
3.1 Introduction 
Mesoporous organosilica nanoparticles (MONs) are a unique class of nanoporous materials 
containing both organic and inorganic moieties in the hybrid silica framework. To date, a 
number of MONs with various structures have been successfully synthesized through 
surfactant directed self-assembly, showing great potential in drug delivery applications.1-4 
Hollow MONs in particular have attracted considerable attention due to the hollow void 
space that can serve as a storage reservoir, capable of encapsulating large number of guest 
agents. In order to deliver large molecular weight biomolecules (e.g. proteins, plasmid DNA), 
recent research interest has been directed towards enlarging the pore size of MONs.5-6 
Unfortunately, only marginal progress has been made with pore size smaller than 8 nm, 
presumably due to the lack of effective synthetic strategy for large pore MONs. 
Simultaneous creation of both a hollow cavity and large pore is even more difficult in MONs 
and has not been reported. 
Currently, the co-condensation of inorganic and organosilica precursors is one of the most 
extensively employed synthetic approach for MONs with well-defined structures and uniform 
morphologies.1, 5, 7-9 Despite that those two precursors are well known with distinctly different 
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hydrolysis and condensation behaviours,10 surprisingly, whether or not silica and 
organosilica are homogeneously distributed in the hybrid framework is not clearly 
demonstrated. Answers to this question are important not only at the fundamental level but 
also to shed light on new synthetic approaches of novel MONs with interesting architectures. 
Dendritic mesoporous silica nanoparticles (DMSNs) with unique central-radial pore 
structures are emerging as a promising platform for biomedical applications owning to their 
large pore size and highly accessible surface areas compared to conventional mesoporous 
silica nanoparticles.11 In general, two synthetic approaches have been developed for 
DMSNs. The first is the oil based biphasic/emulsion/microemulsion approach.12-17 The other 
one is the “weak templating method” using counterions to compete with silicate oligomers 
to form stellate morphology.18 Nevertheless, the preparation of large pore (> 8 nm) dendritic 
organosilica nanoparticles (DMONs) is rarely reported, most likely because the organosilica 
precursors with intrinsic hydrophobicity cannot technically fit into these conventional 
synthetic systems. 
Herein, we report a facile anion assisted approach to prepare dendritic hollow mesoporous 
organosilica nanoparticles (DHMONs) with a large pore size of 29.5 nm. Our success relies 
on the rational choice of specific anions that can penetrate into micelle and induce structural 
transformation,19 thus monodispersed DMONs with a pore size of 17.5 nm were firstly 
obtained. It is found that DMONs possess a composition gradient with a silica dominant core 
and organosilica rich shell. Selective etching of the silica core leads to the formation of 
DHMONs. To the best of our knowledge, this is the first report on the synthesis of ultra-large 
pore organosilica nanoparticles with a unique dendritic shell and a hollow cavity. Taking the 
advantage of the unique architecture and organosilica-rich composition, we show that the 
DHMONs possess enhanced protein loading capacity, sustained release profile and lower 
hemolytic activity compared with DMONs, suggesting their great potential in delivering large 
biomolecules.   
3.2 Results and discussion 
DMONs were prepared in an aqueous solution using tetraethyl orthosilicate (TEOS) and 1,2-
bis(triethoxysilyl)ethane (BTEE) as precursors, triethanolamine as a catalyst, 
cetyltrimethylammonium bromide (CTAB) and sodium salicylate (NaSal) as structure-
directing agents. The scanning electron microscope (SEM) and transmission electron 
microscopy (TEM) images of the DMONs are shown in figure 3.1. DMONs are 
monodispersed with a uniform diameter of ~200 nm (figure 3.1 a,b). The central-radial 
structure can be clearly observed under TEM image (figure 3.1b). Electron tomography (ET) 
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was used to further investigate the structure. An ET slice cutting across the center of one 
DMON particle reveals a central core with a diameter of ~80 nm and radial pore opening of 
~ 16 nm (figure 3.1c). After alkaline etching of DMONs using 0.6 M Na2CO3 at 60 ˚C for 4 h, 
monodispersed DHMONs with similar size to DMONs of ~ 200 nm can be obtained as shown 
by SEM image (figure 3.1d). TEM image reveals that DHMONs possess a shell with radial 
pore channels and an inner hollow cavity (figure 3.1e). The ET slice clearly confirms the 
hollow nature of DHMONs (figure 3.1f). The inner cavity is ~80 nm in diameter, while the 
dendritic shell with breakages has a thickness of ~ 60 nm. 
 
Figure 3.1. SEM (a, d), TEM (b, e) and ET slice (c, f) of DMONs (a, b, c) and DHMONs (d, 
e, f). 
To gain insight on the composition of nanoparticles, nuclear magnetic resonance (NMR) 
techniques were utilized. The presence of ethane moieties in the DMONs is confirmed by 
solid state 13C CP/MAS NMR spectra (figure S3.1). 29Si MAS NMR is useful to differentiate 
the composition from two precursors. For DMONs, the two peaks at –102 and –111 ppm 
correspond to Q3 (Si(OSi)3(OH)) and Q4 (Si(OSi)4) species (from TEOS). The other two at –
57 and –66 ppm are attributed T2 (C–Si(OSi)2(OH)) and T3 (C–Si(OSi)3) species originated 
from BTEE (figure 3.2a).20 In the case of DHMONs, the relative intensity of the Q3 and Q4 
peaks is dramatically reduced (figure 3.2b), indicating that most inorganic silica content has 
been removed after etching treatment due to their lower stability compared to organosilica.21 
The nitrogen adsorption−desorption isotherms of DMONs and DHMONs are shown in 
Figure 3.2c and d, respectively. A steep capillary condensation step occurs in the relative 
pressure (P/P0) of 0.8-0.9 in the case of DMONs, corresponding to a pore size of ~17.5 nm 
(inset of Figure 3.2c) and a small mesopore volume of 0.15 cm3 g-1. For DHMONs, the 
capillary condensation step occurs at a higher P/P0 range (>0.9) with increased mesopore 
volume of 0.76 cm3 g-1. Accordingly, the pore size is calculated to be 29.5 nm (inset of Figure 
3.2d).  The Brunauer-Emmett-Teller (BET) surface area and the total pore volume of DMONs 
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are measured to be ~243 m2 g−1 and ~0.44 cm3 g−1, but significantly increased to ~399 m2 
g−1 and ~1.88 cm3 g−1 in the case of DHMONs. The increased pore size, pore volume and 
surface area (DHMONs vs DMONs) are consistent with the observation of hollow cavity and 
breakage observed in Figure 3.1f. 
 
Figure 3.2. 29Si MAS NMR spectra (a, b), N2 adsorption-desorption isotherm (c, d) and 
pore size distribution (inset of c and d) of DMONs (a, c) and DHMONs (b, d). 
By comparing the SEM, TEM, ET and NMR results together, it is clear that DMONs have a 
composition gradient. This phenomenon may not be simply explained by the faster 
hydrolysis and condensation rate of TEOS than that of BTEE under basic condition,10 since 
selective etching was also utilized in previous inorganic-organic hybrid silica systems while 
no obvious composition difference could be observed.1, 7-8 The formation mechanism was 
attributed to the difference in degree of condensation in the hybrid matrix. In our system, we 
speculate that the composition gradient in the hybrid matrix of DMONs is presumably due 
to the presence of Sal-. When the Sal-/CTA+ complex is formed, the surface charge of the 
CTA+ micelles can be partially neutralized. The Sal-/CTA+ complex with a reduced surface 
charge would preferentially assemble with inorganic silica species due to their higher charge 
density than that of organosilica species.22 In this sense, the difference of hydrolysis and 
condensation rate between TEOS and BTEE can be further magnified by the distinct 
precursor/micelles assembly priority, leading to the formation a silica core first followed by 
the co-condensation of TEOS and BTEE to form an outer shell. Selective etching of silica 
core results in a hollow cavity in the DHMONs. It is unlikely that the outer layer is inorganic 
silica rich, otherwise after etching a particle size reduction would be expected. The co-
condensation of TEOS and BTEE is evidenced by the formation of breakage in the dendritic 
shell and enlarged pore size in DHMONs. The composition gradient has not be observed in 
conventional Sal- free or oil based systems, possibly because the former condition cannot 
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trigger a sufficient difference in condensation rate between inorganic and organic silica 
precursors while the latter may significantly inhibit the hydrolysis and condensation of 
organosilica precursor due to its strong hydrophobicity. 
In order to understand the formation mechanism of the dendritic structure, systematic 
studies have been conducted. When the NaSal/CTAB molar ratio () was increased from 
0/1 to 0.5/1, an increase in particle size from ~50 (figure S3.2) to ~140 nm (figure 3.3a) is 
observed. The porosity is limited as measured by nitrogen sorption analysis (figure S3.3). 
Further increasing (NaSal/CTAB) to 0.75/1 and 1/1 leads to the formation of DMONs with 
central-radial structures (figure 3.3b, c) and enlarged pore sizes from 8.4 (figure S3.3) to 
17.5 nm (figure 3.2c). This gradually enlarged pore sizes with increasing (NaSal/CTAB) 
indicates the micelle penetration capability of Sal-. The particle size is also increased from 
~140 to 200 nm (figure 3.3b, c).  
 
Figure 3.3. (a-c) TEM images of DMONs synthesized at (NaSal/CTAB) of (a) 0.5/1, (b) 
0.75/1 and (c) 1/1. Scale bar: 100 nm.  
The organic/inorganic silica molar ratio (BTEE/TEOS) is another important parameter for 
the structure of final products. When pure TEOS is used, monodispersed inorganic DMSNs 
with a uniform particle size of ~ 210 nm and ultra large pore size can be obtained as 
evidenced by SEM, TEM and ET (figure S3.4). Similar to the trend observed in organosilica 
system, the particle size and pore size can be increased from ~40 to ~210 nm and 2.1 to 
64.5 nm, respectively, by adjusting (NaSal/CTAB) from 0/1 to 1/1 (figure S3.5, S3.6). As 
the (BTEE/TEOS) increased from 0.05/1 to 0.15/1, a gradually decreasing pore size from 
29 to 22 nm was observed as shown in TEM and nitrogen adsorption-desorption (figure 
S3.7, S3.8), and eventually reaching 17.5 nm at (BTEE/TEOS) of 0.5/1 (figure 3.2c). These 
results imply that the anion assisted approach is versatile for preparing both inorganic and 
organic large pore silica materials with well-controlled structures.  
Conventional oil based synthetic systems of DMSNs use a large amount of oil to achieve an 
effective swelling effect.12, 14, 23 In our synthetic system, salicylate anion (Sal-) is used for the 
formation of large pores and the required amount is significantly reduced, indicating their 
superior micelle penetration effect compared to oils. It is proposed that the interaction 
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between Sal- and CTA+ micelles is energetically favored due to their high miscibility and 
strong electrostatic attraction, and eventually Sal- migrates into the micelles with its 
hydrophobic part embedded in the hydrophobic region of micelles. Therefore, our anion 
assisted approach is also highly reproducible as evidenced by the negligible influence of 
stirring rate on particle structure (Figure S3.9). In contrast, nonpolar oil molecules are 
expected to have an energy barrier associated with the micelle penetration because they 
"feel" no attraction towards the micelle hydrophobic core before passing through the polar 
head region. Moreover, oil molecules in oil/water suspension tend to form large oil clusters.  
Hence, large amount of oil and strong shear force is required to break oil clusters and to 
increase the probability of collision between oil and micelles to ensure sufficient micelle 
penetration.24  
The easy penetration of Sal- with a large hydrophobic portion into the micelles leads to an 
increase in packing parameter (g), which induces the micelles structural transition towards 
vesicular/lamellar structure and eventually form the central radial structure as monitored by 
time dependent study for DMONs (figure S3.10). At the reaction time of 20 min, the co-
existence of ~20 nm sized vesicles and their aggregates with diameters of ~40 nm was 
observed (Figure S3.10). The fusion of vesicles (indicated by white circles) and breakage of 
these vesicles (indicated by white arrows) can be seen. At the reaction time from 40 min to 
1 h, dendritic structures were formed and the size increased slightly from ~80-90 to ~100 
nm, which eventually enlarged to 200 nm in size (Figure 3.1a-c) at 12 h. No individual 
vesicular structures were observed after 40 min, suggesting that the composite vesicles are 
building blocks for the assembly of the final dendritic morphology. In the case of DMSNs, 
relatively large lamellar structures were observed prior to the formation of the final dendritic 
structure (Figure S3.11). The difference in intermediate structures observed in organic and 
inorganic systems is attributed to the distinct different nature of silica precursors that 
significantly affect the cooperative self-assembly of the final structure (See Supporting 
Information for more discussions).    
Since other hydrophobic additives will compete with Sal- for penetration into the micelle,25 
the hydrophobic organosilica precursor BTEE used in our synthesis may cause a 
compromised penetration behavior. Therefore, the pore sizes of nanoparticles are reduced 
with the increase of (BTEE/TEOS) (figure S3.7, S3.8). It is widely accepted that the number 
of nuclei formed at the initial reaction stage can significantly affect the final particle size.26 
Since the initial nucleation process involves the assembly between CTA+ and silica species 
through electrostatic interaction, increased concentration of Sal- would cause reduced 
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surface charge of Sal-/CTA+ complex, resulting in delayed assembly kinetics. Hence, fewer 
nuclei are formed with increased concentration of Sal-, leading to larger particle sizes as 
demonstrated in figure 3.3a-c and figure S3.5.   
To demonstrate the advantages of DHMONs, protein loading and release experiments were 
conducted using bovine serum albumin (BSA) with dimensions of 4×4×14 nm as a model. 
The BSA loading capacities of the DMONs and DHMONs were evaluated at pH 7.4 in 
phosphate buffered saline (PBS) solution. DHMONs exhibit a loading capacity of 481.1±15 
μg mg-1, which is more than six times of DMONs (75.3±2.5 μg mg-1). The release of BSA 
loaded in two MONs was further tested in PBS solution at 37 °C. A burst release is observed 
in the first 4 h for both MONs (figure S3.12), where around 90% and 50% of proteins have 
been released from DMONs and DHMONs, respectively. Afterwards, DHMONs show a 
sustained release profile till 48 h, releasing an additional 37% (accumulative release of 87%) 
of BSA. Compared with DMONs, the enhanced loading capacity and extended release 
profile of DHMONs should be attributed to the increased surface area, pore volume and 
organic content. 
Next, the hemocompatibility of DMONs and DHMONs was assessed because the hemolysis 
of red blood cells (RBC) influenced by silica based nanomaterials is critical for their clinical 
applications. As shown in figure S3.13, a hemolytic activity of 3.9%±0.4 at a DMONs 
concentration of 2 mg/ml was observed. At the same concentration, DHMONs showed a 
lower hemolytic activity of 2.6%±0.3 (p<0.05). The hemolytic activities of both DMONs and 
DHMONs are significantly lower than that of pure silica nanoparticles7, 27 due to the 
existence of organosilica in the framework.27 The relatively higher hemolytic activity of 
DMONs over DHMONs (50%) indicates the importance of DHMONs with an organosilica 
rich composition.  
3.3 Conclusion 
In summary, DHMONs with a unique dendritic shell/hollow morphology, large pore size (29.5 
nm) and high pore volume (1.88 cm3 g−1) have been synthesized through an anion assisted 
approach and a new understanding on the composition gradient in DMONs. The successful 
synthesis of hybrid dendritic silica based nanoparticles with controllable pore structures, 
composition and morphology is a substantial advance over traditional MSNs/MONs, and is 
expected to find promising applications in drug delivery, especially for large-sized 
biomacromolecules. 
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3.5 Supporting Information 
Experimental Section  
Chemicals: Cetyltrimethylammonium bromide (CTAB), Tetraethyl orthosilicate (TEOS), 
1,2-Bis(triethoxysilyl)ethane (BTEE), triethanolamine (TEA), sodium salicylate (NaSal) and 
bovine serum albumin (BSA) were purchased from Sigma-Aldrich. Hydrochloric acid (HCl), 
ethanol, methanol were received from ChemSupply Pty Ltd. All chemicals were used as 
received without purification. 
Synthesis of dendritic mesoporous organosilica nanoparticles (DMOSNs): DMONs 
were achieved via a one-pot synthesis using cationic surfactant CTAB and NaSal as a 
structure directing agent, TEOS and BTEE as a silica source and TEA as a catalyst. A 
typical synthesis of DMONs was performed as follows. At first, 0.068 g of TEA were added 
to 25 ml of water and stirred gently at 80 °C in an oil bath under a magnetic stirring for 0.5 
h. Afterwards, 380mg CTAB and 168mg NaSal was added to the above solution and keep 
stirring for another 1h. Then, a mixture of  2 ml TEOS and 1.6 ml BTEE was added to the 
water-CTAB-NaSal-TEA solution with gentle stirring (~ 300 rpm) for 12 h. The products 
were collected by high speed centrifugation and washed several times with ethanol to 
remove the residual reactants. Then, the collected products were extracted with HCl and 
methanol solution at 60.0 °C for 6 h for three times to remove the template, followed by 
drying in vacuum at room temperature overnight.  
For the synthesis of DMSNs, the procedures are similar to that of DMONs, with the only 
difference that 4ml TEOS was added the water-CTAB-NaSal-TEA solution and the final 
product was  obtained after 2 h reaction.  
Synthesis of dendritic hollow mesoporous organosilica nanoparticles (DHMOSNs): 
DHMONs were prepared through selective etching at alkaline condition. In a typical 
synthesis, 40 mg of as–synthesized DMONs were dispersed in 80 ml of 0.6 M Na2CO3 
solution and stirred at 60˚C for 4h. The product was recovered by centrifugation at 14000 
RCF (g) for 10min. Sufactant was removed by HCl/methanol extraction. 
Characterizations: The morphologies of the samples were observed using and JEOL 
JSM 7800 field emission scanning electron microscope (FE-SEM). Transmission electron 
microscopy (TEM) images were obtained with a JEOL 1010 operated at 100 kV. For TEM 
measurements, the samples were prepared by dispersing the powder samples in ethanol, 
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after which they were dispersed and dried on carbon film on a Cu grid. Electron 
tomography was conducted under Tecnai G2 F30 (FEI) operated at 300 kV. The ET 
specimens were prepared by dispersion of the samples in ethanol by ultrasonication, and 
then deposition directly onto a formvar film supported by a copper grid (3×1 mm slot, 
Electron Microscopy Science). Colloidal gold particles (10 nm) were deposited on both 
surfaces of the grid as fiducial markers for the subsequent image alignment procedures. 
Two tilting series were recorded in the range of +70° to -70° with increments of 1°/tilt in two 
perpendicular axes. Low dose mode was used to prevent radiation damage on the elegant 
nanostructures, and the tomograms were created using the IMOD software. Nitrogen 
adsorption–desorption isotherms were measured at 77 K using a Micromeritics ASAP 
Tristar II 3020 system. The samples were degassed at 393 K overnight on a vacuum line. 
The pore size distribution curve was derived from the adsorption branch of the isotherms 
using the Barrett–Joyner–Halanda (BJH) method. The Brunauer–Emmett–Teller (BET) 
method was utilized to calculate the specific surface areas. The total pore volume was 
calculated from the amount adsorbed at a maximum relative pressure (P/P0) of 0.99. 13C 
CPMAS NMR spectra were measured by solid state Bruker Avance III spectrometer with 
7T (300 MHz for 1 h) magnet, Zirconia rotor, 4 mm, rotated at 7 kHz. 
BSA loading and release: For the protein loading, BSA was first dissolved in PBS (0.1 M, 
pH 7.4) to obtain a protein stock solution with a concentration of 2 mg ml-1. PBS buffer 
solution (0.75 ml) was added to 1.5 mg of the nanoparticles in 2 ml capped vials. After the 
mixture was sonicated for 10 min, 0.75 ml of protein stock solution was added. The total 
volume and concentration of protein solution were 1.5 ml and 1 mg ml-1, respectively. The 
resulting mixture was shaking at 200 rpm at room tempearature for 6 h followed by 
centrifugation. The amount of protein adsorbed to nanoparticles was further quantified by 
measuring the absorbance of the supernatant at 280 nm. The amount of protein adsorbed 
was calculated by the concentration difference between before and after adsorption. 
For the protein release test, nanoparticles after BSA loading were immersed in 2 ml of 
PBS solution and gently shaken at 100 rpm at 37°C. At a predetermined time point, the 
solution was centrifuged and the supernatant was removed and replaced by the same 
amount of fresh PBS solution. The release amount of protein was quantified by UV-vis 
measurement. 
Hemolytic evaluation: Mice blood anticoagulated with citric acid-dextrose anticoagulant 
was kindly provided by Australian Institute for Bioengineering and Nanotechnology. 
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Typically, the red blood cells (RBCs) were obtained by centrifugation (400 RCF (g), 5 min) 
and suctioned to remove the upper clear solution, and the RBCs were obtained at the 
bottom of centrifugal tubes. The RBCs were washed for six times by PBS solution, and 
then 200μL of RBCs was diluted to 4ml with PBS for further use. the diluted RBCs 
suspernsion (0.2ml) was then mixed with nanoparticle suspensions in PBS (0.8ml) at 
various concentrations. The mixture was gently vortexed and incubated at room 
temperature for 2 h.  The mixture was then centrifuged at 400 RCF (g) for 5 min and the 
absorbance of the supernatants 541 nm was meausured by a plate reader. The hemolysis 
percentages of DMONs and DHOMONs were calculated the following equation: 
Hemolysis% = (Asample-A(-)control)/(A(+)control- A(-)control). A is the absorbance 
intensity of UV-Vis spectra.  
 
 
Figure S3.1 13C CP/MAS NMR spectra of DMONs. 
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Figure S3.2 TEM image of MONs prepared at CTAB/NaSal molar ration of 1/0. 
 
 
Figure S3.3 N2 adsorption-desorption isotherm (a) and pore size distribution (b) of 
MONs/DMONs prepared at various CTAB/NaSal molar ratio. 
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Figure S3.4 SEM images (a, b), TEM image(c) and ET slice (d) of DMSNs synthesized 
using pure TEOS at CTAB/NaSal molar ratio of 1 to 1. 
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Figure S3.5 TEM images of DMSNs synthesized at various CTAB/NaSal molar ratio: (a) 
1/0, (b) 1/0.25, (c) 1/0.5 and (d)1/1. Scale bar: 100 nm. 
 
 
 
 
 
 
Figure S3.6 N2 adsorption-desorption isotherm (a) and pore size distribution (b) of 
MSNs/DMSNs prepared at various CTAB/NaSal molar ratio. 
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Figure S3.7 TEM images of DMONs synthesized at organosilica (OSi)/inorganic silica (Si) 
molar ration of (a) 0.1/1 and (b) 0.3/1. 
 
 
 
 
 
Figure S3.8 N2 adsorption-desorption isotherm (a) and pore size distribution (b) of DMONs 
prepared at various OSi/Si molar ratio. 
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Figure S3.9 TEM image of DMONs synthesized at low stirring speed of ~ 100rpm 
(NaSal/CTAB =1 and OSi/Si= 1). No obvious difference can be observed compared to 
DMONs at ~300 rpm (figure 3.1b, main text), indicating that the penetration process of Sal- 
into micelle is a thermodynamically controlled process. 
 
 
  
 
 
Fig S3.10. Time dependant study of DMONs synthesized at CTAB/NaSal ratio of 1/1. 
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Fig S3.11. Time dependant study of DMSNs synthesized at CTAB/NaSal ratio of 1/1. The 
temperature was decreased to 65°C to slow down the reaction rate. Scale bar: 100 nm. 
A time dependant study of the dendritic mesoporous silica nanoparticles (DMSNs, 
inorganic silica system) was performed to understand the effect of silica precursor on the 
formation mechanism. In order to slow down the reaction rate to have a wider time window 
to capture the intermediate structures, we reduced the reaction temperature from 80 to 65 
°C. This is because (1) the TEOS system reacts faster than the organosilica synthesis 
system under alkaline conditions and (2) the final structures of DMSNs obtained at both 
temperatures are similar. As shown in Figure S11, at the time point of 20 min after the 
addition of TEOS, the formation of lamellar structures with wrinkles can be observed. 
However, vesicular structures similar to that obtained in DMONs synthesis at 20 min 
(Figure S10) were not found. After 1 h, the structure of DMSNs is roughly shaped. The 
particle size increases with time (2 h), eventually the dendritic nanoparticles are formed at 
6 h.  
Our results indicate that the surfactant templates, the addition of NaSal, and the nature of 
silica sources are all responsible for the cooperative self-assembly of the final structure. It 
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is noted that in the absence of Sal-, the dendritic mesostructure cannot be formed while 
only mesostructures with small pore sizes (~2-3 nm) and mostly closed-pores are 
observed as evidenced from Figures S3.2, indicating the use of Sal- induces micellar to 
vesicular/lamellar structure transformation in the surfactant/silica /organosilica composites. 
As explained in our main text, the use of Sal- partially neutralizes the positive charge of 
CTA+ headgroups, leading to increase in packing parameter and the observed structural 
transition. In addition to the anion, the choice of silica source is also important on the self-
assembly process. When we compare the BTEE/TEOS system in the synthesis of DMONs 
(Figure S3.10) to the pure TEOS system in the synthesis of DMSNs (control group, Figure 
S3.11), it is suggested that the addition of BTEE could suppress the hydrolysis and 
condensation of TEOS, leading to silica oligomers with higher hydrophobicity compared to 
the pure TEOS system. Eventually in the BTEE/TEOS system, the formed composite 
vesicular/lamellar structures are less condensed and easier to enclose to smaller and 
partially enclosed vesicular structures, compared to the relatively large lamellar structures 
observed in the pure TEOS system. In the BTEE/TEOS system, we speculate the 
vesicular/lamellar structures formed at early reaction stage (< 1 h) is primarily comprised of 
silica due to the faster hydrolysis/condensation of TEOS compared to BTEE under basic 
conditions (evidenced from the etching results). The collapse of these small vesicular 
aggregates and subsequent deposition of silica oligomers is possibly associated with the 
formation of the final relatively dense and inorganic silica rich core. The final structure is 
formed by the further co-deposition of organosilica-rich shell. 
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Figure S3.12 BSA release profile of DMONs and DHMONs as a function of time. 
 
 
 
 
Figure S3.13 Percentage of RBCs hemolysis after co-incubation with DMONs and 
DHMONs at different concentrations ranging from 25 – 2000 μg/mL. Inset: Digital photos 
showing the hemolytic effects after 2 h co-incubation with DMONs and DHMONs. Water 
was used as the positive control and PBS as the negative control. (* p < 0.05 based on t-
test)  
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Chapter 4 
 
Structure-Dependent and Glutathione-
Responsive Biodegradable Dendritic 
Mesoporous Organosilica Nanoparticles 
for Safe Protein Delivery 
The chapter has been published on Chemistry of Materials, 2016, 28, 9008. 
 
ABSTRACT The design of smart nano-carriers that could recognize and differentiate cancer 
cells and normal cells is of great importance in drug delivery. Here we report the first 
example of cancer cell-specific degradable dendritic mesoporous organosilica nanoparticles 
(DDMONs). A unique pore structure-dependent glutathione (GSH)-responsive degradation 
behaviour is revealed: the degradation rates of two nanoparticles with different pore sizes 
are similar in normal cells (“levelling effect”), while large-pore DDMONs show a faster 
degradation rate than small-pore nanoparticles in cancer cells with relatively high 
intracellular GSH levels (“differentiating effect”). The cancer cell-specific degradability and 
concomitant cargo release lead to efficient protein delivery towards cancer cells, but reduced 
cytotoxicity towards normal cells. 
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4.1 Introduction 
Intracellular delivery of therapeutic proteins has been regarded as a safe and direct 
approach to manipulate cell function and treat human disease.1 This is because only 
transient actions of proteins are needed in protein therapy, thus nether permanent genetic 
alterations nor significant systematic toxicity as well as drug resistance are induced 
compared to conventional gene therapy and chemotherapy. Nevertheless, due to the fragile 
nature of proteins, their practical applications are limited. In this context, the development of 
effective protein delivery systems has become a multidisciplinary hot topic and attracted 
tremendous attention.  
As an interesting family of porous nanomaterials, mesoporous silica nanoparticles (MSNs) 
have been developed as one promising protein delivery system.2 However, unwanted side 
effects to healthy cells, premature release and uncontrollable degradability of Si-O-Si 
framework have potential risks, making their practical use problematic.3-5 Precise control 
over the nanoparticle degradation, on demand cargo release and cancer cell specific 
inhibition remains a bottle-neck.6 Recently, tremendous efforts have been devoted to the 
development of stimuli-responsive degradable therapeutic delivery systems that are capable 
of recognizing and responding to cell-specific microenvironmental changes.7-11 For instance, 
the huge difference of glutathione (GSH) concentration between extracellular (2~10 µM) and 
intracellular (2~10 mM) conditions has been widely utilized as a stimuli to trigger the 
disintegration of disulfide bond (-S-S-) incorporated structures (Scheme 4.1A).7, 11-12 
Importantly, the GSH concentration in cancer cells was found several times higher than that 
in normal cells,13 which could be recognized by rationally designed polymeric nanoparticle 
and micelle based drug delivery systems for selective cancer treatment.14-15 However, 
differentiating such a small variation of GSH levels (in contrast to the ~ 1000 fold difference 
of GSH levels between extracellular and intracellular conditions) by conventional silica 
based systems is extremely challenging. In addition, in previous reports, dense or small pore 
(< 3 nm) structures question their suitability in protein delivery. To date, there is no report 
on biodegradable MSNs that degrade preferentially in cancer cells in response to the higher 
GSH level than in normal cells, which calls for new concepts and understanding of structure-
degradation relationship in the design of GSH-responsive materials for cancer specific 
protein delivery. 
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Scheme 4.1. Pore structure dependent degradability of nanoparticles within normal cells 
and cancer cells. A) The redox reaction of disulfide bond and GSH. B) Schematic illustration 
for (I) the organic–inorganic hybrid composition of DDMONs, (II) small pore MONs, (III) large 
pore DDMONs, (IV) normal cells, (V) MONs and (VI) DDMONs degradation in normal cells, 
(VII) cancer cells, (VIII) MONs and (IX) DDMONs degradation in cancer cells. 
Herein, we report the first example of cell-type specific degradable dendritic mesoporous 
organosilica nanoparticles (DDMONs) preferentially in cancer cells than in normal cells 
(Scheme 4.1B). The disulfide groups (I) is homogeneously distributed in the hybrid 
framework of nanoparticles with controllable small and large pores (II, III). A unique pore 
structure-dependent GSH-responsive degradation behavior is observed. For normal cells 
with relatively low intracellular GSH levels (IV), the degradation rates (V and VI) of two 
nanoparticles are similar (“levelling effect”). On the other hand, for cancer cells with relatively 
high intracellular GSH concentrations (VII), large-pore DDMONs show a much faster 
degradation rate than small-pore MONs (IX and VIII). The “differentiating effect” makes it 
possible to use large-pore DDMONs as proteins carriers with cancer cell specific 
degradation and concomitant cargo release, showing excellent cancer cell inhibition 
efficiency but reduced cytotoxicity towards normal cells. 
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Figure 4.1. TEM (a) and SEM images (b) of DDMONs synthesized at NaSal/CTAB molar 
ratio of 0.5/1. (c) EDS mapping of DDMONs. (d, e) Solid state 29Si NMR (d) and 13C NMR 
(e) spectra of DDMONs. 
4.2 Results and dicussion 
The DDMONs were prepared in an aqueous solution using tetraethylorthosilicate (TEOS) 
and 1,4-bis(triethoxysilyl)-propane tetrasulfide (BTES) as precursors, triethanolamine as a 
catalyst, cetyltrimethylammonium bromide (CTAB) and sodium salicylate (NaSal)16 as 
structure-directing agents (see Experimental Section). Monodispersed DDMONs with a 
uniform particle size of ~200 nm and well-defined central-radial pore structure are observed 
in transmission electron microscopy (TEM) and scanning electron microscopy (SEM) 
images (Figure 4.1a and 4.1b). Dynamic light scattering (DLS) analysis shows an average 
particle size of ~220 nm with a polydispersity index (PDI) of 0.10 in phosphate buffered 
saline (PBS) solution (Figure S4.1 a). The slightly larger than the size observed in TEM 
images due to the surface hydration.17 When mixing DDMONs with PBS supplemented with 
10 mM GSH and 10% serum for 10 min, a certain degree of aggregation was observed 
(Figure S4.1 b), as evidenced by the increased hydrodynamic size (388 nm) and PDI (0.34) 
compared to that obtained in pure PBS solution. The increased aggregation of nanoparticles 
is due to the surface coating of serum proteins.18 
Energy-dispersive X-ray (EDX) elemental mapping shows that the Si, O, C and S elements 
are uniformly distributed in the hybrid frameworks of DDMONs (Figure 4.1c). The Si/S 
atomic ratio was measured to be ~ 4.2/1. 29Si solid-state NMR spectrum of DDMONs exhibits 
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two peaks at -102 and -111 ppm, corresponding to Q3 [Si(OSi)3(OH)] and Q4 [Si(OSi)4] 
species generated from TEOS, respectively (Figure 4.1d).19 The other two at -59 and -67 
ppm are attributed to T2 [C–Si(OSi)2(OH)] and T3 [C–Si(OSi)3] species originated from 
BTES, respectively. The 13C NMR spectrum of DDMONs (Figure 4.1e) shows the 
characteristic peaks at 11, 22, and 41 ppm, corresponding to the 1C, 2C, and 3C in –Si–
1CH2–2CH2–3CH2–S–S–S–S–3CH2–2CH2–1CH2–Si–, respectively.20 The other peaks at 16 
and 57 ppm are associated with the presence of unhydrolyzed Si-OC2H5 groups of BTES.21 
Compared to DDMONs after CTAB removal (Figure 4.1e), the 13C NMR spectrum of the as-
synthesized DDMONs shows two additional peaks at 54 and 30 ppm (Figure S4.2), which 
is attributed to the C4-C13 and CN of CTAB molecules, indicating the presence of CTAB. The 
disappearance of these peaks after three times extraction (Figure 4.1e) confirms that CTAB 
had been completely removed, which is crucial for the biocompatibility. The complete 
removal of CTAB was further confirmed by analysing the wash solutions using liquid 
chromatography–mass spectrometry (LC-MS) (Figure S4.3). Raman spectrum of DDMONs 
confirms the presence of stretching vibrations of S-S and S-C bonds located at 440, 490, 
and 634 cm−1 (Figure S4.4).22 The digital images show that the as-synthesized nanoparticles 
have a yellowish color due to the presence of sulfur (Figure S4.5). The above results 
collectively support the conclusion that the disulfide moieties are incorporated in the hybrid 
framework of DDMONs. The N2 adsorption-desorption isotherm (Figure S4.6) reveals a 
steep capillary condensation step at relative pressure (P/P0) of ~0.9, corresponding to a 
large pore size with a broad distribution centered at ~14 nm (inset of Figure S4.6). The pore 
volume and the Brunauer-Emmett-Teller (BET) surface area are calculated to be ~0.98 
cm3g-1 and 405 m2g-1, respectively. Notably, both the particle size and pore size of the hybrid 
nanoparticles can be easily tuned up to ~500 nm and ~ 40 nm, respectively, by adjusting 
the  CTAB/NaSal molar ratio or concentrations (Figure S4.7, S4.8).  
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Figure 4.2. Degradation test of DDMONs (a1-a4) and MONs (b1-b4) tested at 1 mM (a1-a2, 
b1-b2) and (a3-a4, b3-b4)10 mM GSH solution for 24 h (a1, a3, b1, b3), and 48 h (a2, a4, b2. b4) 
in the presence of serum. GSH oxidation percentage (black columns) and relative quantity 
of –SH groups (OD 412 nm, red columns) after incubation of DDMONs or MONs in 1 mM 
(c) and 10 mM (d) GSH solution for 48 h in the presence of serum. 
In order to study the structure-degradation relationship, another two particles were prepared 
as control groups: one is disulfide bond bridged (MONs) with a small pore size of ~ 4.6 nm 
(Figure S4.9), which possess a similar Si/S atomic ratio of ~ 3.9/1 to DDMONs as measured 
by EDX; the other is ethyl bridged dendritic mesoporous organosilica nanoparticles 
(DMONs, Figure S4.10). All of the three particles (DDMONs, DMONs and MONs) were 
synthesised following the anion assisted approach we reported recently,16 which is highly 
reproducible. The GSH responsive degradability of DDMONs, MONs and DMONS was 
tested at 1 mM, 10 mM and 10 µM GSH concentrations in the presence of serum, 
corresponding to the intracellular conditions of normal cells, cancer cells and extracellular 
environments, respectively. The relative amount of reacted GSH and the generated 
reduction product –SH (Scheme 4.1A) at different GSH concentrations in the presence of 
DDMONs or MONs were measured using high performance liquid chromatography (HPLC) 
and Ellman test, respectively.  
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As shown in Figure 4.2a1-a2, after incubation of DDMONs in serum-containing 1 mM GSH 
solution, partially collapsed structures can be observed at 24 and 48 h whereas the spherical 
morphologies are mostly maintained. However, upon incubation in serum-containing 10 mM 
GSH solution, the initial structure is seriously destructed at 24 h (Figure 4.2a3). After 48 h, 
the nanoparticles were completely disintegrated into small debris with sizes of ~ 35 nm 
(Figure 4.2a4), which was further supported by DLS measurement (Figure S4.11). For 
MONs, compared to their initial structure (Figure S4.9 a), the degradation at 24 h and 48 h 
in both GSH concentrations (Figure 4.2b1-b4) are limited, as only partially damaged 
structures are observed. The degradation behaviour of nanoparticles was quantified by 
HPLC and Ellman test at various GSH concentration in the presence of serum. As shown in 
Figure 4.2c, after 48 h incubation of nanoparticles at a GSH concentration of 1 mM, the 
oxidized GSH percentages of DDMONs (85%) was slightly higher than that of MONs (~ 
76%). The OD value corresponding to the generated –SH amount in the DDMONs (0.20) 
was also slightly higher than that in MONs (0.17). The small difference of oxidized GSH and 
generated –SH for two nanoparticles suggest a “leveling effect” at a GSH level of 1 mM. In 
contrast, at a higher GSH concentration of 10 mM (Figure 4.2d), the oxidized GSH 
percentage in DDMONs was ~32%, which is almost three times higher than that of MONs 
(11%). The Ellman test also exhibited a significantly increased –SH amount of DDMONs 
than that of MONs, suggesting a “differentiating effect” at high GSH level. These results 
indicate that the nanoporous structure has significant influence on the nanoparticle 
degradation: large pore DDMONs exhibit a faster degradation than small pore MONs with a 
similar composition in 10 mM GSH, but in 1 mM GSH the degradation of two particles is 
both slow and the difference is not significant. Notably, the incubation of DDMONs in 10 µM 
GSH solution did not result in obvious structural alteration, implying their good stability at 
extracellular conditions (Figure S4.12). The pore structure of DMONs (incorporated with 
ethyl groups) was well-preserved after incubation in 10 mM GSH solution for 48 h (Figure 
S4.13), confirming that the GSH triggered degradability is attributed to the cleavage of –S–
S– bonds, while the –C–C– groups are quite stable.23 Our results indicate that both the 
composition and pore structure are important parameters to adjust the GSH-responsive 
degradation behavior. This new understanding of structure-degradation relationship leads 
to the development of large-pore DDMONs with cancer-specific degradation and protein 
delivery performance.  
Considering that our nanoparticles are designed for cellular delivery of proteins, efficient 
cellular uptake and endo/lysosomal escape to deliver proteins to the cytosolic region are 
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important prerequisites.24 To this goal, the nanoparticles were functionalized with cationic 
polymer, polyethylenimine (PEI), which contains abundant secondary and/or tertiary amine 
groups for protons adsorption, resulting in swelling from an influx of water into the 
endosomal compartment and eventually causing rupture, a process also known as the 
“proton sponge effect”.25 Epoxysilane was firstly grafted onto DDMONs to produce 
DDMONs-epoxy via alcoholysis reaction. Then, PEI was covalently linked to DDMONs-
epoxy to yield DDMONs-PEI through nucleophilic reaction between the nitrogen in the amine 
group of PEI and the carbon atom of the epoxy ring.26 We choose a low molecular weight 
PEI (MW = ~1800) to ensure a relatively low cytotoxicity. The successful modification of 
epoxy and PEI are confirmed by solid state 13C NMR spectrum (Figure S4.14), 
thermogravimetric analysis (TGA) (Figure S4.15), zeta-potential (Table S4.1) and N2 
adsorption-desorption (Figure S4.16 a, b, Table S4.1). The pore structure and dispersity of 
DDMONs-PEI are well maintained after the step-by-step modifications (Figure S4.17). The 
in vitro cell viability test of DDMONs-PEI and DMONs-PEI show that more than 80% cell 
survival of both cancer cell (B16F0) and HEK293t cell can be maintained after 24 h and 48 
h incubation when the particle concentration is below 40 µg/ml (Figure S4.18), indicative of 
their good biocompatibility.  
 
Figure 4.3. In vitro degradability of DDMONs-PEI after incubation with B16F0 cancer cell 
for 4 h (a1), 24 h (a2) and 48 h (a3) and HEK293t cells for 24h (b1) and 48h (b2). In vitro 
degradability of MONs-PEI after incubation with B16F0 cancer cell for 4 h (c1), 24 h (c2) and 
48 h (c3) and HEK293t cells for 24h (d1) and 48h (d2). 
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We further studied the intracellular degradability of DDMONs-PEI, DMONs-PEI and MONs-
PEI after incubation with HEK293t normal cells and B16 melanoma cancer cells (B16F0). It 
was reported that the intracellular GSH levels in B16 melanoma could reach 30 – 40 
nmol/106 cells,27-28 while the intracellular GSH levels in HEK293 cells was only around 12.4 
± 0.39 nmol/106 cells.29 These data suggest that the B16 cancer cells have ~3-fold higher 
GSH than HEK293 normal cells.  As indicated by TEM images, DDMONs-PEI can be rapidly 
internalized by B16F0 cells within 4 h (Figure 4.3a1). Moreover, the structure gradually 
collapse with prolonged time (Figure 4.3a2), and completely dissembled into aggregated 
debris after 48 h (Figure 4.3a3). In contrast, the degradation of DDMONs-PEI after incubation 
with HEK293t cells is significantly suppressed (Figure 4.3b1, b2) due to lower GSH 
concentration in normal human cells. Unlike DDMONs-PEI, the degradation of MONs-PEI 
in both cell lines (Figure 4.3c1-c3, d1-d2) was not significant even after 48 h incubation. For 
DMONs-PEI, no evident degradation was observed as indicated by the well-maintained 
intact structure in both cancer and normal cells (Figure S4.19). These results are consistent 
with previous observations conducted in simulated GSH solutions, showing that the PEI 
functionalization did not influence the degradation behaviour of nanoparticles and the pore 
structure-degradation relationship is retained in cell tests. In order to demonstrate the 
generality of the cancer cell-specific degradability of DDMONs-PEI, we further compared 
the intracellular degradability in MCF-7 breast cancer cell line, Chinese hamster ovary 
(CHO) normal cell line and RAW264.7 macrophage cell line. As shown in Figure S4.20, the 
incubation of DDMONs-PEI with MCF-7 cancer cells resulted in partially collapsed pore 
structure at 24 h and further disintegrated small fragments at 48 h. In contrast, the 
degradation of DDMONs-PEI in both CHO normal cells and RAW264.7 immune cells was 
significantly slower than that in cancer cells, as indicated by the partially degraded pore 
structures at 48 h. These results further suggest the cancer cell specific degradability of the 
nanoparticles, which is of great importance for reduced cytotoxicity to normal cells.    
It would be very interesting to explore the mechanism of the pore structure-dependent 
degradability (Scheme 4.1B). We speculate that effective contact between disulfide groups 
in the nanoparticle matrix and the GSH molecules in the solution has impact on the reaction 
kinetics. As illustrated in Figure 4.4a, in the case of MONs, the small mesopores can be 
easily blocked by the coating of serum protein in the cell culture media,30 which, to a certain 
extent, inhibit the diffusion of GSH molecules into the nanoparticle matrix and hinder the 
redox reaction. This trend is reduced for DDMONs as the serum proteins can hardly block 
the large pores, making the disulfide groups more accessible to GSH. However, the 
74 
 
difference between two materials is not significant (“leveling effect”) at a low GSH 
concentration because most of the GSH are consumed (Figure 4.2a), but amplified at a 
higher GSH concentration as the serum protein coated small pore MONs separate the 
excessive GSH outside the particles from the disulfide groups located inside the particles 
(differentiating effect). The proposed mechanism is evidenced by the degradation of 
DDMONs and MONs in the absence of serum. As shown in Figure 4.4 b-c, the degradation 
rate was much faster than that in the presence of serum for MONs (compared to Figure 4.2 
b3, b4), whereas for DDMONs the difference was no obvious compared to Figure 4.2 a3, a4. 
The significant influence of serum on the degradation of small pore nanoparticles was further 
confirmed by monitoring the hydrodynamic sizes of MONs after incubation with serum-free 
or serum-containing GSH solution (10 mM) after 24 and 48 h using DLS. As shown in Figure 
S4.21, MONs showed very large hydrodynamic sizes of ~ 459 nm at 0 h due to severe 
particle aggregation. In the absence of serum, a significant size reduction from 459 to 255 
nm after 48 h incubation was observed (Figure S4.21 a), suggesting the partially 
disintegrated structures. In contrast, after incubation with serum-containing GSH solution for 
48 h, the hydrodynamic size was almost kept at ~ 460 nm (Figure S4.21 b). These results 
are consistent with the observation from TEM images in the absence or presence of serum, 
respectively (Figure 4.4 b-c; Figure 4.2 b3-b4), further suggesting that serum proteins would 
significantly retard the degradation rate of small pore MONs. Previously, the degradation of 
disulfide incorporated hybrid silica was studied generally in serum free medium7, 31 and thus 
the influence of serum on the degradation was not revealed.  
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Figure 4.4. a) Schematic illustration of the role of serum protein in the pore structure-
dependent degradability. TEM images of MONs (b-c) and DDMONs (d-e) incubated in 10 
mM GSH solution for 24 h (b, d) and 48 h (c, e) in the absence of serum. 
It is expected that the preferential degradation within cancer cells is beneficial for cancer-
specific protein delivery. As a demonstration, a cheap and potent cytotoxic enzyme, 
ribonuclease A (RNase A, 13.7 kD, pI = 9.6) with hydrophobic nature and dimensions of 2.2 
nm × 2.8 nm × 3.8 nm was chosen as a model therapeutic protein.32 RNase A is positively 
charged at physiological condition, thus their binding with the cationic polymer modified 
nanoparticles would be relatively weak due to the electrostatic repulsion. To solve this 
problem, RNase A was modified with cis-aconitic anhydride (RNase A-Aco) according to the 
procedures described in a previous report to alter its surface charge.33 The successful 
modification is evidenced by the change of Zeta potential from + 10 mV to -7 mV in PBS 
solution (pH = 7.4). DDMONs-PEI shows a loading capacity toward RNase A-Aco as high 
as 426.2 ± 15 μg/mg, which is more than two times higher than that of DMONs-PEI (199.8 
± 8 μg/mg). The loading of RNase A-Aco on MONs-PEI is negligible and can only be loaded 
onto external surface due to their limited pore size, thus will not be included in the following 
biological test. 
 
Figure 4.5. (a-b) Cumulative release of RNase A-Aco from DDMONs-PEI (a) and DMONs-
PEI (b) in various concentration of GSH solution for 48 h. (c) Confocal images of cell uptake 
of DDMONs-PEI/RNase A-Aco-FITC complex by B16F0 cells at 10 h. (d) Confocal images 
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of DDMONs-PEI/RNase A-Aco-FITC complex incubated with B16F0 cells for 24 h. The 
endo/lysosome was stained with Lysotracker Red. While arrow indicates separated red dots 
from green florescence, suggesting proteins were escaped from endo/lysosomal 
entrapment with assistance of nanoparticles. (e-f) Cell viability test of DDMONs-PEI delivery 
systems by delivering cytotoxic RNase A-Aco against B16F0 cancer cell (e) and Hek293t 
normal cell (f) 48 h (** P < 0.01). 
The release profile of both RNase A-Aco loaded DDMONs-PEI and DMONs-PEI was then 
tested at various GSH concentration (10 µM, 1 mM and 10 mM) in PBS. As shown in Figure 
4.5a, DDMONs-PEI showed zero premature release within 2 h, and less than 30% release 
after 48 h incubation in 10 µM GSH contained PBS. Such a sustained release profile is 
attributed to the electrostatic and strong hydrophobic interaction between protein and long 
carbon/sulfur chain (–Si–(CH2)3–S4–(CH2)3–Si–) incorporated hybrid organosilica 
framework. At GSH concentration of 1 mM, an increased protein release was observed, 
reaching ~57% at 48 h owning to the partial degradation. When the GSH concentration 
further increased to 10 mM, a rapid release was observed, reaching ~97% at 48 h due to 
the sever rupture of the pore structure. In contrast, non-degradable DMONs-PEI showed a 
fast protein release profile independent of GSH levels (Figure 4.5b). This is mainly attributed 
to the much smaller hydrophobic organo-bridge group (–(CH2)2–) of DMONs than that of 
DDMONs (–(CH2)3–S4–(CH2)3–), resulting in a weaker hydrophobic interaction with protein 
molecules and thus a rapid cargo release at both low and high GSH concentrations.   
To confirm the successful cellular uptake and endo/lysosomal escape, we labelled RNase 
A-Aco with fluorescent fluorescein isothiocyanate (RNase A-Aco-FITC) (Figure S4.22) to 
track their intracellular distribution. As shown in confocal microscopy image, pure RNase A-
Aco-FITC possess negligible uptake due to cell membrane impermeability (Figure S4.23). 
When incubating DDMONs-PEI/RNase A-Aco-FITC complex with B16F0 cells for 10 h 
(Figure 4.5c), strong FITC signals (green fluorescence) can be observed within cell 
membrane, confirming that the complex has been internalized into cells. Moreover, the 
complex was able to escape from the endo/lysosomal entrapment after 24 h incubation, as 
demonstrated by the separation of green (protein) and red fluorescence (Lysotracker Red 
stained endo/lysosome) (white arrows) in the cytoplasm (Figure 4.5d inset). 
We further evaluated the cell inhibition of degradable and non-degradable complex in cancer 
cells and normal cells. After 24 and 48 h incubation, pure protein can only induce very limited 
cell inhibition in both cell lines (Figure S4.24 a, b; Figure 4.5e, f). For the nanoparticle/protein 
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complex, it is noted that DDMONs-PEI/RNase A-Aco showed higher cytotoxicity than that 
of DMONs-PEI/RNase A-Aco at all concentrations towards B16F0 cancer cells (Figure 
S4.24 a; Figure 4.5e), which should be primarily attributed to the minimized protein leaking 
before cell internalization and rapid GSH triggered intracellular release of DDMONs-
PEI/RNase A-Aco. In contrast, the viability of HEK293t cells treated with DDMONs-
PEI/RNase A-Aco is significantly higher than that of DMONs-PEI/RNase A-Aco, owning to 
the lower intracellular GSH concentration (FigureS4.24 b; Figure 4.5f). These results 
strongly suggest the superior therapeutic efficiency and safety profile of the GSH-responsive 
degradable nanoparticle based protein delivery system.  
4.3 Conclusions 
Disulfide bond incorporated hybrid dendritic mesoporous organosilica nanoparticles have 
been synthesized as the first example of cell-type specific biodegradable silica 
nanoparticles. A pore structure dependent degradation understanding has been revealed: 
large pore DDMONs show similarly slow degradation compared to small pore MONs in 
normal cells, but much faster degradation rate in cancer cells. Our findings contribute to 
developing smart nano-carriers with cancer cell-specific degradability as a safe and efficient 
delivery platform for therapeutic biomacromolecules in cancer treatment applications. Given 
that whether there is GSH level difference between tumor tissue and normal tissue is still 
under debate, the possibility of extending this concept from the cellular level to tissue level, 
that is, from “cancer cell-specific” to “tumor tissue-specific”, is questionable and should be 
studied further at the in vivo level. 
4.4 Experimental Section  
Chemicals: Cetyltrimethylammonium bromide (CTAB), tetraethyl orthosilicate (TEOS), 1,2-
bis(triethoxysilyl)ethane (BTEE), bis[3-(triethoxysilyl)propyl] tetrasulfide (BTES) 
triethanolamine (TEA, > 99%), sodium salicylate (NaSal) and Ribonuclease A (RNase A) 
were purchased from Sigma-Aldrich. Hydrochloric acid (HCl), ethanol, methanol were 
received from ChemSupply Pty Ltd. All chemicals were used as received without purification. 
For biology experiments: Dulbecco’s Modified Eagle Medium (DMEM) and trypsin-EDTA 
(0.25%) were purchased from GIBCO or Invitrogen, Life Sciences, Life Technologies. Fetal 
bovine serum (FBS) and trypan blue solution (0.4%) were purchased from Sigma-Aldrich. 
Ribonuclease A (RNase A) from bovine pancreas was purchased from ROCHE (Germany). 
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B16F0 skin cancer cells and HEK293t (Human Embryonic Kidney 293) were purchased from 
ATCC (American Type Culture Collection).  
Synthesis of degradable dendritic mesoporous organosilica nanoparticles 
(DDMONs): DDMONs were synthesized via a one-pot synthesis using NaSal and cationic 
surfactant CTAB as structure directing agents, TEOS and BTES as a silica source and TEA 
as a catalyst. The synthesis was conducted in a 50 ml flat bottom glass bottle with a stirring 
bar of 3 cm. In a typical synthesis of DDMONs, 0.034 g of TEA were added to 12.5 ml of 
water and stirred gently (~ 700 rpm) at 80 °C in an oil bath under a magnetic stirrer for 0.5 
h. Afterwards, 190 mg of CTAB and 42 mg of NaSal was added to the above solution and 
kept stirring for another 1h. After CTAB and NaSal are completely dissolved, a mixture of 1 
ml of TEOS and 0.8 ml of BTES was added to the water-CTAB-NaSal-TEA solution with 
vigorous stirring for 12 h. The products was recovered by centrifugation of 14,000 RCF (g) 
for 5 min and washed with ethanol three times to remove the residual reactants. Finally, the 
yellow powder was dried in vacuum oven at 40 °C for 6h.  Then, the collected products were 
extracted with HCl and methanol solution at 60 °C for 6 h for three times to remove the 
template, followed by drying in vacuum at room temperature overnight.  
Synthesis of degradable mesoporous organosilica nanoparticles (MONs) with small 
pores: MONs were synthesized via a one-pot synthesis using NaSal and cationic surfactant 
CTAB as structure directing agents, TEOS and BTES as a silica source and TEA as a 
catalyst. The synthesis was conducted in a 50 ml flat bottom glass bottle with a stirring bar 
of 3 cm. In a typical synthesis of DDMONs, 0.034 g of TEA were added to 12.5 ml of water 
and stirred gently (~ 700 rpm) at 80 °C in an oil bath under a magnetic stirrer for 0.5 h. 
Afterwards, 190 mg of CTAB and 5 mg of NaSal was added to the above solution and kept 
stirring for another 1h. After CTAB and NaSal are completely dissolved, a mixture of 1 ml of 
TEOS and 0.8 ml of BTES was added to the water-CTAB-NaSal-TEA solution with vigorous 
stirring for 12 h. The products was recovered by centrifugation of 14,000 RCF (g) for 5 min 
and washed with ethanol three times to remove the residual reactants. Finally, the yellow 
powder was dried in vacuum oven at 40 °C for 6h.  Then, the collected products were 
extracted with HCl and methanol solution at 60 °C for 6 h for three times to remove the 
template, followed by drying in vacuum at room temperature overnight.  
Synthesis of non-degradable dendritic mesoporous organosilica nanoparticles 
(DMONs):  DMONs were synthesized according to the procedure in our previous work (Yu, 
et al., Chem Mater 2016, 28, 704-707) with minor modifications. In a typical synthesis of 
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DDMONs, 0.034 g of TEA were added to 12.5 ml of water and stirred gently (~ 700 rpm) at 
80 °C in an oil bath under a magnetic stirrer for 0.5 h. Afterwards, 190 mg of CTAB and 84 
mg of NaSal was added to the above solution and kept stirring for another 1h. After CTAB 
and NaSal are completely dissolved, a mixture of 1.35 ml of TEOS and 0.55 ml of BTEE 
was added to the water-CTAB-NaSal-TEA solution with vigorous stirring for 12 h. The 
products was recovered by centrifugation of 14,000 RCF (g) for 5 min and washed with 
ethanol three times to remove the residual reactants. Finally, the yellow powder was dried 
in vacuum oven at 40 °C for 6h.  Then, the collected products were extracted with HCl and 
methanol solution at 60 °C for 6 h for three times to remove the template, followed by drying 
in vacuum at room temperature overnight. 
Surface modification: In order to achieve endosomal escape for successful protein 
delivery, 1.8 kDa polymer of PEI (Alfa Aesar) was attached to DMONs or DDMONs through 
a linker of 3-glycidoxypropyl trimethoxysilane (3-GPS, Sigma-Aldrich). First, epoxysilane 
was grafted onto the surfaces nanoparticles (100 mg) in toluene (30 ml) and stirring for 15 
minutes at 343 K. Then, 3-GPS (1.5 ml) was added into the solution, which was further 
stirred for 24 hours at the same temperature in a nitrogen atmosphere. The solid products 
were centrifuged, washed three times with toluene and methanol and dried. Solid products 
(50 mg) were mixed with PEI (250 mg) in carbonate buffer (100 ml, 50 mM, pH 9.5) for 24 
hours at 298 K. In this step, PEI is attached to the nanoparticles via epoxy-groups. The 
products were washed with NaCl solution (20 ml, 1.0 M), followed by three washes with 
deionized water, and were then recovered by centrifugation. At the final stage, the solid 
products were re-suspended in ethanolamine (20 ml, 1.0 M, pH 9) and stirred at 298 K for 6 
hours to block free epoxy groups. The solids were then washed again with NaCl solution (20 
ml, 1.0 M) and deionized water (20 ml). 
 
Characterizations: The morphologies of the samples were observed using and JEOL JSM 
7800 field emission scanning electron microscope (FE-SEM). Transmission electron 
microscopy (TEM) images were obtained with a JEOL 1010 operated at 100 kV. For TEM 
measurements, the samples were prepared by dispersing the powder samples in ethanol, 
after which they were dispersed and dried on carbon film on a Cu grid. Nitrogen adsorption–
desorption isotherms were measured at 77 K using a Micromeritics ASAP Tristar II 3020 
system. The samples were degassed at 393 K overnight on a vacuum line. The pore size 
distribution curve was derived from the adsorption branch of the isotherms using the Barrett–
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Joyner–Halanda (BJH) method. The Brunauer–Emmett–Teller (BET) method was utilized to 
calculate the specific surface areas. The total pore volume was calculated from the amount 
adsorbed at a maximum relative pressure (P/P0) of 0.99. 13C CPMAS NMR spectra were 
measured by solid state Bruker Avance III spectrometer with 7T (300MHz for 1H) magnet, 
Zirconia rotor, 4mm, rotated at 7 kHz. Hydrodynamic size and zeta (z)-potential (ZP) 
Dynamic light scattering (DLS) size and ZP values were collected at 25 1C using a Zetasizer 
Nano-ZS from Malvern Instruments. 
LC-MS measurement: The three wash solutions were diluted with water by 50-fold. The 
CTAB standard was dissolved in 1:9 (v/v) ethanol-water with a concentration of 0.2 mg/mL. 
The HPLC solvents are as follows: solvent A was 0.5% formic acid in Millipore water, solvent 
B was 0.5% formic acid in acetonitrile. The LC-MS was performed on Agilent 1100 series 
LC/MSD using an Agilent column Zorbax SB-C8 (150 * 4.6 mm) with a 2 uL sample injection 
volume. The LC gradient in 30 min: 10-100% solvent B in 15 min, hold for 10 min at 100% 
solvent B, change to 10% solvent B in 1 min, hold for 4 min.   
Degradation test at simulated condition: A mixture of 1.5 mg nanoparticles (DDMONs, 
DMONs or MONs) and PBS buffer (1ml) containing 10% FBS and various concentrations of 
GSH (10μM, 1mM and 10mM) was stirred at 37°C in an 2 ml eppendorf tube. At 
predetermined time point, aliquots were taken and washed with PBS before performing the 
TEM and DLS analyses. 
GSH oxidation test: The disulfide-bridged dendritic mesoporous organosilica nanoparticles 
(1.5 mg) were mixed with 1 mM or 10 mM GSH in 1 mL PBS buffer supplemented with 10% 
FBS. The control samples were prepared at the same condition but without nanoparticles 
for comparison. After 48 h stirring at room temperature the suspension was centrifuged and 
the supernatant was collected. The levels of GSH in the supernatant were then measured 
quantitatively by HPLC via the integration of the GSH peak areas. The values obtained from 
control groups are subtracted. Each experiment was repeated twice. 
Ellman’s test: The nanoparticle precipitates from the GSH oxidation test were washed with 
potassium phosphate buffer (pH = 8) for 3 times and then suspend in 1 mL of potassium 
phosphate buffer (pH = 8). A standard Ellman’s assay was used to measure the accessible 
thiol functionalities of the dendritic mesoporous organosilica nanoparticles. Specifically, 1 
mL of 10 mM 5, 5'-dithiobis-(2-nitrobenzoic acid) solution (in potassium phosphate buffer, 
pH= 8) was added to the 1mL nanoparticles suspension. After 10 min stirring at room 
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temperature the suspension was centrifuged and the colored supernatant solution was 
collected and diluted with 1 ml buffer to 3 mL, followed by the UV/VIS measurements at 412 
nm (NOVASPEC® III+ SPECTROPHOTOMETER). 
In vitro bio-TEM: Different cell lines (B16F0, HEK293t, MCF-7, CHO and RAW264.7) were 
seeded in 3 cm petri-dishes at a cell number of 300,000 for 24 h, and they were incubated 
with a suspension of nanoparticles (DDMONs-PEI or DMONs-PEI) at a concentration of 40 
mg ml-1 for another 4, 24 or 48 h. Then cells were first fixed with 2.5% glutaraldehyde at 
room temperature for 30 min, and post-fixed in 1% osmium tetraoxide in microwave 
conditions. After that, cells were embedded into a 2% agarose gel cube, followed by 
dehydration in acetone of increasing concentration (50%, 70%, 90%, 100% and 100%) 
under microwave conditions. The dehydrated cell cubes were embedded in Epon resin, and 
solidified at 60 °C for 2 days. Microtome (Leica, EM UC6) was then used to cut the 
embedded cell-resin cube into ultra-thin slices (70–90 nm in thickness). Samples were 
mounted on form-bar coated copper grids and double stained with 2% aqueous uranyl 
acetate and commercial lead citrate aqueous solution. TEM images were taken using a 
JEOL 1010 microscope operated at 80 kV. 
Protein modification with cis-aconitic anhydride: RNase A-Aco were prepared 
according to the procedures described in previous reports with slight modification (Y. Lee, 
et al., Angew Chem Int Ed 2009, 48, 5309-5312). Briefly, RNase A (5 mg) was dissolved in 
0.1 M NaHCO3 buffer solution (pH = 9.5), 25 mg cisaconitic anhydride was added to the 
protein solutions, followed by additional 2 hours of stirring at room temperature. The 
mixtures were dialyzed against a 0.5% NaCl solution for 24 hours to remove excess salt in 
the dialysis cassette (Slide-A-Lyzer, MWCO = 3500, Pierce, IL). The RNase A-Aco was 
obtained after lyophilization. 
Fluorescein labeling of RNase A-Aco: RNase A-Aco (8 mg) was dissolved in 3 mL of 
sodium bicarbonate solution (0.1 M, pH = 9.5), and mixed with 1 ml freshly prepared FITC 
solution (4 mg/mL in DMSO). The reaction mixture was protected from light and stirred at 
room temperature for 2 hours. The resulting FITC labelled RNase A-Aco was purified by 
Agilent Zorbax C18 column (300 Å, 10 μm, 250mm×10 mm). The purification was carried out 
by preparative RP-HPLC using a Shimadzu LC-8A solvent delivery system. The absorbance 
was monitored at 214 nm and 230 nm with a Shimadzu SPD-10AV UV/Vis detector. For 
MALDI-TOF MS, the product was analyzed on an Applied Biosystems 4700 proteomics 
analyzer using CHCA as the matrix that was made as follows: 10 mg/mL CHCA in ACN/H2O 
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(v/v: 50/50) with 0.5% TFA. All mass spectra were obtained in the positive ion linear mode 
with an accumulation of 2000 laser shots under a laser intensity of 4000 instrument units, 
where 20 different sites in each spots were detected and each site proceeded 100 times of 
laser shots. 
RNase A-Aco loading and release: For the protein loading, RNase A-Aco was first 
dissolved in PBS (0.1 M, pH 7.4) to obtain a protein stock solution with a concentration of 2 
mg ml-1. PBS buffer solution (0.75 ml) was added to 1.5 mg of the nanoparticles in 2 ml 
capped vials. After the mixture was sonicated for 10 min, 0.75 ml of protein stock solution 
was added. The total volume and concentration of protein solution were 1.5 ml and 1 mg ml-
1, respectively. The resulting mixture was shaking at 200 rpm at  4°C for 6 h followed by 
centrifugation. The amount of protein adsorbed to nanoparticles was further quantified by 
measuring the absorbance of the supernatant at 280 nm. The amount of protein adsorbed 
was calculated by the concentration difference between before and after adsorption. 
For the protein release test, nanoparticles after RNase A-Aco loading were immersed in 2 
ml of PBS solution and gently shaken at 100 rpm at 37°C. At a predetermined time point, 
the solution was centrifuged and the supernatant was removed and replaced by the same 
amount of fresh PBS solution. The release amount of protein was quantified by UV-vis 
measurement. 
Cellular uptake: For Confocal imaging of the cellular uptake of nanoparitlce/protein 
complex, B16F0 cells were seeded in a 6-well culture slide at a density of 100, 000 cells per 
well. After 24 h, cells were treated with RNase A-Aco-FITC, DDMONs-PEI/ RNase A-Aco-
FITC or DMONs-PEI/ RNase A-Aco-FITC at 40 μg/ml concentration in serum-contained 
DMEM medium. Before imaging, the endosome/lysosome was labelled with 
LysoTracker@Red (Invitrogen) according to the manufacturer’s instructions. At the end of 
staining process, the cells were washed twice with PBS and fixed with 10% formaldehyde. 
The cell nuclei were then stained with DAPI, and the uptake performance of nanoparticles 
was assessed using a confocal microscopy (LSM710, Zeiss). 
In Vitro protein delivery: Briefly, B16F0 cancer cells or HEK293t normal cells were seeded 
in 96-well plates at a density of 8,000 cells per well over night. Next day, cells were treated 
with protein, protein/nanoparticle or blank nanoparticles at various concentrations in DMEM 
media. Control experiments were performed by adding the same volume of phosphate buffer 
without nanoparticle or protein. The cell viability was determined by MTT assay after 24 h 
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and 48 h of incubation. All protein delivery and control experiments were performed in 
triplicate. 
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4.6 Supporting Information 
 
 
 
Figure S4.1. Hydrodynamic diameter of DDMONs in PBS buffer solution (a) and PBS 
solution supplemented with 10 mM GSH and 10% FBS (b) measure by DLS. 
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Figure S4.2. Solid state 13C NMR spectra of as-synthesized DDMONs. 
Compared to DDMONs after CTAB removal (Figure 4.1e), the as-synthesized DDMONs 
showed two additional peaks at 54 ppm and 30 ppm, which is attributed to the C4-C13 and 
CN of CTAB molecules, indicating the presence of CTAB. The disappearance of these 
peaks after three times extraction (Figure 4.1e) confirms that CTAB had been completely 
removed, which is crucial for the biocompatibility. 
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Figure S4.3. The total ion current (TIC) chromatograms of a) blank, b) 0.2 mg/mL CTAB 
standard, c) wash solution 1, d) wash solution 2 and e) wash solution 3. The insets in b) 
and c) are the mass signal of the peaks in the two TIC, while f) is the enlarged version of 
the inset.  
The total ion current (TIC) chromatogram in LC-MS was applied to monitor the CTAB in 
the wash solutions. The wash solutions obtained from first-, second- and third-time 
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extractions were label as wash solution 1, wash solution 2 and wash solution 3, 
respectively. No peak related to CTAB was observed in the blank (Figure S4.3a), while a 
strong peak corresponding to CTAB was detected in the CTAB standard (Figure S4.3b). 
For the three wash solutions, CTAB peak was only observed in the wash solution 1 while 
absent in the wash solution 2 and 3 (Figure S4.3 c-e). The composition of the peak was 
identified by MS (Figure S4.3 b-c inset and f), the mass-to-charge ratio of 284.2 agreed 
well with that of CTA+. These results further confirm the complete removal of CTAB in 
DDMONs. 
 
 
Figure S4.4. Raman spectrum of DDMONs. 
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Figure S4.5. Digital image of as-synthesised DDMONs. The yellowish colour indicates the 
presence of sulfur content. 
 
 
 
 
 
 
 
Figure S4.6. N2 sorption isotherm and pore size distribution (inset) of DDMONs. 
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Figure S4.7. TEM (a-b, d-e) and SEM (c, f) images of disulfide incorporated dendritic 
mesoporous organosilica nanoparticles synthesized at various NaSal/CTAB concentration 
and molar ratio: (a-c) NaSal/CTAB = 2.09 mmol L-1/4.17 mmol L-1 ; (d-f) NaSal/CTAB = 
4.17 mmol L-1/4.17 mmol L-1. 
For drug delivery application, it is generally accepted that sub-100 nm nanoparticles would 
have better performance compared to larger ones, because nanoparticles with relatively 
small sizes favoured blood vessel extravasation, tumour tissue penetration and cellular 
internalization under in vivo conditions.1 In this sense, the sizes of DDMONs in the range 
of 200-500 nm prepared in the current work are not ideal for animal studies. While 
reducing the amount of sodium salicylate in materials synthesis led to nanoparticles with 
size of ~ 50 nm (Figure S4.9a), the resultant nanoparticles unfortunately do not have 
dendritic structures and suffer from small pores and severe aggregation. We speculate 
that in the current synthesis system, both the particle size and pore size change 
simultaneously by adjusting the sodium salicylate/surfactant ratio, thus it is difficult to 
synthesize monodispersed DDMONs with large pores but reduced particle sizes. In our 
future work, new synthesis systems should be explored to prepare monodispersed 
DDMONs with sub-100 nm sizes for in vivo drug delivery applications.  
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Figure S4.8. N2 sorption isotherms and pore size distributions of disulfide incorporated 
dendritic mesoporous organosilica nanoparticles synthesized at NaSal/CTAB = 2.09 mmol 
L-1/4.17 mmol L-1 (a) and NaSal/CTAB = 4.17 mmol L-1/4.17 mmol L-1 (b).  
The particle size and pore size of DDMONs can be tuned by controlling the synthetic 
conditions, including NaSal/CTAB concentration and their molar ratio. When using a low 
concentration of NaSal/CTAB  = 2.09 mmol L-1/4.17 mmol L-1 (0.5/1 molar ratio), the size 
of the hybrid nanoparticles can be increased from ~ 200 nm (Figure 4.1a-c) to ~530 nm 
(Figure S4.5 a-c), which can be explained by the less number of nucleus formed during 
nucleation step owning to the lowered SDA concentration. The accompanied enlargement 
in pore size (~ 22 nm, Figure S4.6 a) is likely as result of the central-radial pore structure. 
When increase the NaSal/CTAB molar ratio from 0.5/1 to 1/1, it can be clearly observed 
that the particle diameter remains similar (~ 530 nm) but the pore size was significantly 
enlarged (Figure 4.2d-f), which is measured to be ~ 42 nm by N2 sorption analysis (Figure 
S4.6 b). This increased pore size is believed as a consequence of the enhanced micelle 
penetration of salicylate anion (Sal-).  
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Figure S4.9. TEM image (a), nitrogen adsorption-desorption isotherm (b) and pore size 
distribution (c) of small pore disulfide bridged MONs. 
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Figure S4.10. TEM image (a) and N2 sorption results (b) of ethyl incorporated non-
degradable DMONs.  
Similar to DDMONs, the monodispersed DMONs also possess a central-radial pore 
structure and uniform particle size of ~ 200 nm (Figure S4.7 a). Their structural properties, 
including pore size (~17.5 nm), mesopore volume (0.95 cm3 g-1) and BET surface area 
(436.7 m2 g-1) determined by N2 sorption (Figure S4.7 b) are quite close to those of 
DDMONs, thus they are chosen as a control group for the following experiments. 
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Figure S4.11. DLS results of DDMONs incubated with serum-containing 10 mM GSH 
solution for 48 h. 
 
 
 
 
Figure S4.12. TEM images of DDMONs incubated with 10 µM GSH for 48 h. 
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Figure S4.13. TEM images of DMONs incubated at 10 mM GSH for 48 h. 
 
 
Figure S4.14. Solid state 13C NMR spectrum of DDMONs-Epoxy and DDMONs-PEI. The 
peaks of C1 (12 ppm), C2 (22 ppm) and C6 (44 ppm) are overlapped with the carbon 
signals from organosilane. 
 
Epoxysilane was firstly grafted onto particles via alcoholysis reaction. Then, PEI was 
covalently linked to epoxy functionalized particles through nucleophilic reaction between 
the nitrogen in the amine group of PEI and the carbon atom of the epoxy ring. We choose 
a low molecular weight PEI (MW = ~1800) to ensure a relatively low cytotoxicity.   
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Figure S4.15. TGA curves of DDMONs, DDMONs-epoxy and DDMONs-PEI under oxygen 
flow. The weight loss from 200 to 900 °C were 2.1 and 7.6% for DDMONs-epoxy and 
DDMONs-PEI, respectively, compared to the unmodified DDMONs. The surface 
conjugated quantity of epoxy group and PEI is calculated to be 0.18 and 0.08 mmol/g, 
respectively.   
 
 
 
 
Figure S4.16. N2 sorption isotherm (a) and pore size distributions (b) of DDMON-PEI and 
DMONs-PEI.  
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Figure S4.17. TEM images of DDMONs-epoxy (a) and DDMONs-PEI (b).  
 
The positively charged nanoparticles are not favoured for in vivo applications, since they 
are more cytotoxic and immunogenic compared to their neutral and anionic counterparts, 
and tend to accumulate in liver and excreted in feces, or to be eliminated by 
reticuloendothelial system after opsonisation.2 Generally, a neutral charged surface is 
considered optimal due to the reduced accumulation in major organs and lower interaction 
with plasma proteins compared to both positively or negatively charged particles, which 
result in a smaller hydrodynamic size and favourably long circulation lifetime and interstitial 
transport in tumours. Therefore, in order to improve the drug delivery efficiency under in 
vivo condition, in our future work, it would be important to further modify the DDMONs-PEI 
with polyethylene glycol (PEG) or bovine serum albumin to endow the materials with 
stealth property for prolonged circulation lifetime.3-4 
  
100 
 
 
 
Figure S4.18. Cytotoxicity of DDMONs-PEI and DMONs-PEI for B16F0 cancer cell (a, b) 
and HEK293t normal cell (c, d) at 24 h (a, c) and 48 h (b, d).    
 
Figure S4.19. TEM images of DMONs-PEI incubated with (a) B16F0 cancer cells and (b) 
HEK293t normal cells for 48 h.  
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Figure S4.20. Intracellular degradability of DDMONs-PEI after incubation with MCF-7 
breast cancer cells, CHO normal cells and RAW264.7 macrophage cells for 24 h and 48 h. 
Scale bar: 500 nm. 
 
 
 
Figure S4.21. DLS analysis of MONs incubated with serum-free (a) and serum-containing 
(b) PBS buffer solution at 10 mM GSH for 0, 24 and 48 h. 
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Figure S4.22. a) A semi-preparative RP-HPLC trace of the final products obtained from 
RNase A-Aco labelling reaction. LC method: 1%/min linear gradient of 10-60 % solvent B 
at a flow rate of 7 mL/min. b) MALDI-MS result of the purified RNase A-Aco-FITC. 
 
 
Figure S4.23. Confocal image of B16F0 cells incubated with RNase A-Aco-FITC for 10h. 
No green florescence can be observed, indicating the negligible cellular uptake of proteins.  
 
 
Figure S4.24. Cell viability test of DDMONs-PEI delivery systems by delivering cytotoxic 
RNase A-Aco against B16F0 cancer cell (a) and Hek293t normal cell (b) at 24 h. 
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Table S4.1. Structural properties of DDMONs after stepwise 
surface functionalization.  
Sample Pore size 
(nm) 
Vp (cm3 
g−1) [a] 
SBET (m2 g-
1)[b] 
Zeta 
potential 
DDMONs 14.1 nm 0.98 404.6 -15.6 ± 0.4 
mV 
DDMONs-
epoxy 
13.6 nm 0.87 366.0 -7.2 ± 0.4 
mV 
DDMONs-
PEI 
12.6 nm 0.70 246.0 +38.3 ± 0.8 
mV 
[a] Total pore volume calculated at relative pressure (P/P0) of 
0.99. [b] BET surface area. 
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Chapter 5 
 
Stepwise Degradable Nanocarriers Enabled 
Cascade Delivery for Synergistic Cancer 
Therapy 
The chapter has been published on Advanced Functional Materials, 2018, 1800706 
 
Abstract. Hypoxia-activated prodrugs have brought new opportunities for safe and effective 
tumor ablation, but their therapeutic efficacy is limited by insufficient activation in tumor 
microenvironments. Herein, a novel cascade delivery system with tandem functions by 
integrating a hypoxia-activated prodrug (AQ4N) and glucose oxidase (GOx) is designed to 
improve its efficacy. Innovative yolk-shell organosilica nanoparticles with a tetra-sulfide 
bridged composition, a small-pore yolk and a large-pore shell featuring a shell-to-yolk 
stepwise degradability are constructed as a carrier for AQ4N and GOx, one enzyme that 
catalyzes the oxidation of glucose to produce hydrogen peroxide. The glutathione (GSH) is 
depleted by tetra-sulfide bond in the framework and induces shell degradation for fast 
release of GOx, which in turn induces starvation (glucose removal), oxidative cytotoxicity 
(H2O2 production and GSH depletion) and hypoxia (oxygen consumption). Finally, the 
hypoxia activates the liberated prodrug AQ4N for chemo-therapy. The cascading and 
synergistic functions including GSH depletion, starvation, oxidative cytotoxicity and 
chemotherapy lead to improved performance in tumor inhibition and anti-metastasis. 
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5.1 Introduction 
Tumor hypoxia is one of the key factors for the poor prognosis and efficacy of cancer 
therapy.1-3 Recent progress in developing hypoxia-activated prodrugs that can be converted 
from a non-toxic to cytotoxic form via tumor hypoxia induced reduction has provided new 
possibilities to selectively kill cancer cells.4-7 Unfortunately, their therapeutic efficacy has 
been limited, which is affected by the heterogeneous distribution of oxygen within a solid 
tumor and consequently insufficient prodrug activation.8, 9 One widely used strategy to 
address this issue is to synergize with photodynamic therapy (PDT), which induces hypoxia 
by converting molecular oxygen into free radicals and simultaneously activate the 
prodrugs.10-13 Nevertheless, its efficacy is limited by the light penetration and self-catalysis 
of photosensitizers. It is therefore highly desirable to develop new strategies for effective 
delivery of the hypoxia activated prodrugs with enhanced performance.  
Cancer starvation therapy is an emerging strategy for inhibiting tumor cell proliferation by 
blocking the nutrient supply.14-17 Given the crucial role of glucose in providing energy for 
tumor growth and metabolism, its strategical depletion in tumors catalyzed by glucose 
oxidase (GOx) and concomitant generation of hydrogen peroxide (H2O2) causing oxidative 
damage to cells was reported for tumor ablation very recently.15 Notably, the GOx catalyzed 
glucose oxidation creates hypoxia, but its further application to activate hypoxia-responsive 
prodrugs has not been reported. Moreover, considering the abundant intracellular 
glutathione (GSH) that is capable of removing excessive H2O2 and reducing the oxidative 
damage,18 developing functional nanosystems that can deplete the intracellular GSH level 
is highly beneficial for further improving the therapeutic efficiency of oxidative therapy. 
Recently, molecularly dispersed hybrid mesoporous organosilica nanoparticles (MONs) 
have become an emerging drug delivery platform.19-21 In particular, disulfide bond bridged 
MONs have attracted tremendous attention due to their intriguing inherent properties such 
as GSH triggered biodegradability and hydrophobic framework enabled high cargo 
payload.22-28 The GSH-responsive degradability is dependent on structural parameters such 
as pore sizes.25 However, constructing disulfide bond bridged MONs with stepwise GSH-
responsive degradability is challenging and has not been reported to our knowledge. 
Moreover, previous reports on disulfide bond bridged organosilica nanoparticles focus 
mainly on the GSH-responsive framework degradation and drug release,22, 28-31 while the 
function of GSH depletion in applications has been rarely utilized.  
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Herein, we report an innovative cascade delivery system integrating hypoxia-activated 
prodrug (AQ4N) and enzyme (GOx) with tandem functions and improved performance in 
cancer therapy. Stepwise degradable yolk-shell tetrasulfide bond bridged dendritic MONs 
(YS-DMONs) with a small-pore yolk and a large-pore dendritic shell have been constructed 
(Scheme 5.1a) for cascade delivery of AQ4N and GOx. Our designed nanosystem 
integrated tandem functions in sequence, and each reaction has a unique function beneficial 
for the next step (Scheme 5.1b). First, the dual-pore yolk-shell structure enables a high co-
loading efficiency and a preferential degradation of the large-pore shell, causing depletion 
of GSH and release of GOx (Scheme 5.1b, i). Second, the released GOx catalyzes the 
reaction between oxygen and glucose, which reduces the glucose supply, produces H2O2 
to induce oxidative damage to GSH-depleted tumor cells and concomitantly consumes 
oxygen resulting in a hypoxic microenvironment (Scheme 5.1b, ii). Third, hypoxia activates 
the AQ4N that released with yolk degradation to a cytotoxic form (AQ4) for chemotherapy 
(Scheme 5.1b, iii). Taken together, our rationally designed cascade delivery system 
integrates the three cascading and cooperative functions, i.e., (1) GSH-depletion and fast 
release of GOx; (2) GOx catalyzed starvation, oxidative cytotoxicity and hypoxia; and (3) 
hypoxia induced chemo-therapy. The synergistic functions (GSH 
depletion/starvation/oxidative cytotoxicity/chemo-therapy) lead to improved efficacy in tumor 
and metastasis inhibition with reduced biological risks and side effects. 
Scheme 5.1. A schematic illustration of the cascade delivery system. YS-DMONs were 
firstly fabricated to form a small-pore yolk and large-pore shell together with a tetrasulfide 
incorporated framework (a). A small molecule prodrug AQ4N and an enzyme GOx were 
encapsulated in the YS-DMONs with cascading functions (b). Intracellular GSH causes the 
cleavage of tetrasulfide bond through the redox chemistry, leading to the fast degradation 
of the large pore shell and concomitant GSH depletion as well as release of the GOx (i). The 
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released GOx oxidizes glucose, which (1) reduce the energy supply of tumor, (2) induce 
oxidative damage through generated cytotoxic H2O2 and depleted antioxidant (GSH), and 
(3) consume molecular oxygen to create a hypoxic microenvironment (ii). The hypoxia 
activates the prodrug AQ4N, which is liberated with the inner yolk degradation, creating AQ4 
and eliciting potent cytotoxicity for tumor inhibition (iii). 
5.2 Results and discussion 
The synthetic procedure for YS-DMONs is schematically illustrated in Figure 5.1a. The 
small pore mesoporous organosilica nanoparticles (MONs) were synthesized using 
cetyltrimethylammonium bromide (CTAB) and sodium trifluoroacetate (NaTFA) as 
structural-directing agents, triethanolamine as a catalyst, tetraethylorthosilicate (TEOS) and 
Bis[3-(triethoxysilyl)propyl] tetrasulfide (BTES) as silica precursors. The choice of NaTFA is 
due to the short carbon chain with limited micelle penetration capability,32 which ensures the 
formation of small mesopores as evidenced by transmission electron microscopy (TEM) 
image (Figure 5.1b). A dendritic organosilica shell with a radial large pore structure formed 
with the assistance of sodium salicylate (NaSal), an anion with strong micelle penetration 
property,33 was then coated onto MONs, leading to a core-shell structure (CS-DMONs) with 
increased particle size from ~140 to ~190 nm (Figure 5.1c). After hydrofluoric acid (HF) 
etching to remove the silica at the core/shell interface with lower condensation degree 
(evidenced by the disappearance of Q2 [Si(OSi)2(OH)2] peak in Figure 5.1h as compared to 
those before etching in Figure S5.1), a yolk-shell structure with particle size of 204 ± 15 nm 
was obtained (Figure 5.1d).  
The large open pores of YS-DMONs were further evidenced by scanning electron 
microscope (SEM) as shown in Figure 1e. Dark field scanning transmission electron 
microscope (DF-STEM) image (Figure 5.1f) and the corresponding energy-dispersive X-ray 
spectroscopy (EDS) elemental mapping (Figure 5.1g) of the YS-DMONs indicate the uniform 
distribution of C, O, Si and S elements in the nanostructures. 29Si solid-state NMR spectrum 
of YS-DMONs exhibits two peaks at -103 and -112 ppm, corresponding to Q3 [Si(OSi)3(OH)] 
and Q4 [Si(OSi)4] species generated from TEOS, respectively (Figure 5.1h). The other two 
peaks at -59 and -67 ppm are attributed respectively to T2 [C–Si(OSi)2(OH)] and T3 [C–
Si(OSi)3] species originated from BTES. The 13C NMR spectrum of YS-DMONs (Figure 5.1i) 
shows the characteristic peaks at 11, 22, and 41 ppm, corresponding to the C1, C2, and C3 
in –Si–1CH2–2CH2–3CH2–S–S–S–S–3CH2–2CH2–1CH2–Si–, respectively.34 The peaks at 
16and 57 ppm are associated with the presence of unhydrolyzed Si-OC2H5 groups of 
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BTES.34 The N2 adsorption-desorption isotherm and pore size distribution (Figure 5.1 j, k) 
confirm the small pores of MONs (~ 4.2 nm) and bimodal pores of YS-DMONs (4.2 and 11.7 
nm). Notably, CS-DMONs prior to HF etching (Figure 5.1c) show only a single pore size 
distribution (Figure S5.2) due to blockage of the small pores as a result of the growth of the 
outer shell, implying the importance of HF treatment to enable the access of the inner 
mesoporous yolk. The zeta-potential of YS-DMONs was 28.2 ±0.3 mV in PBS. Dynamic light 
scattering (DLS) results show that YS-DMONs possess a hydrodynamic size centered at 
396 nm (Figure S5.3), which is almost two-fold larger than the size observed in TEM. These 
results indicate that these nanoparticles with hydrophobic nature has a certain degree of 
aggregation in aqueous solutions. 
 
Figure 5.1. Characterization and intracellular stepwise degradability of YS-DMONs. (a) 
Schematic illustration of the synthesis process of YS-DMONs. TEM images of MONs (b), 
CS-DMONs (c) and YS-DMONs (d). SEM image of YS-DMONs (e). Dark-field STEM image 
(f) and corresponding EDS mapping (g) of YS-DMONs. Solid state 29Si NMR (h) and 13C 
NMR (i) spectra of YS-DMONs. Nitrogen adsorption-desorption isotherm (j) and pore size 
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distribution (k) of MONs and YS-DMONs. (l) Bio-TEM images of YS-DMONs after incubation 
with 4T1 cells for different days, illustrating a shell-to-yolk stepwise degradability of the 
nanoparticles. Scale bar: 200 nm 
 
Figure 5.2. YS-DMONs-GOx mediated generation of H2O2 and hypoxic environment in 4T1 
cells. a) CLSM images of 4T1 cells with oxidative stress/hypoxia detection probes in different 
treatments. Quantitative analysis of fluorescent intensity of H2O2 production (b) and hypoxia 
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environment (c) in 4T1 cells with different treatments (n = 3, mean ± SD).  (d) CLSM images 
of 4T1 cells exposed to YS-DMONs mediated intracellular delivery of AQ4N and GOx for 4 
h. GOx-FITC was used for generating green fluorescence.   
The intracellular shell-to-yolk stepwise degradability of YS-DMONs was tested by incubating 
the nanoparticles with 4T1 breast cancer cells for various times and visualized by bio-TEM. 
As shown in Figure 5.1l, after one day incubation, the yolk-shell structure was still observed, 
although the outer dendritic shell was partially collapsed.  On day 2 and day 3, the dendritic 
pore structure of the outer shell was almost completely degraded, while the yolk structure 
with small pores was maintained. On day 5, the entire pore structure of nanoparticles was 
almost completely destructed, giving rise to the formation of aggregated debris. These 
observations suggest that the large-pore shell degrades relatively faster (~1 day) than the 
small-pore yolk, showing potential applications for sequential therapeutic delivery. 
Moreover, YS-DMONs showed more than 80% cell viability (4T1 cells) at particle 
concentration up to 200 µg/ml by (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) (MTT) assay (Figure S5.4), indicative of the good biocompatibility of the 
nanoparticles. To demonstrate the GSH-depleting capacity of YS-DMONs, their inorganic 
counterpart, yolk-shell dendritic mesoporous silica nanoparticles (YS-DMSNs) without 
organic contents prepared by calcination of YS-DMONs in air were used for comparison. 
YS-DMSNs show similar structure and texture properties compared to YS-DMONs (Figure 
S5.5a, c, d, Table S5.1), with the only difference that the organic content was removed 
(Figure S5.5 b). As expected, the tetrasulfide bond incorporated YS-DMONs were able to 
effectively deplete intracellular GSH level in a concentration-dependent manner in 4T1 cells, 
showing an almost 50% GSH reduction at concentration of 200 µg/ml (Figure S5.6). 
However, YS-DMSNs without tetrasulfide bond could not significantly alter the GSH level, 
confirming the -S-S-/GSH redox reaction induced GSH deletion mechanism (Scheme 1b, i).    
We then attempt to encapsulate AQ4N and GOx into YS-DMONs. As shown in Figure S5.7, 
GOx molecules in aqueous solution show a hydrodynamic diameter of 5.5 nm, suggesting 
that they can only be encapsulated into large pore shell (pore size of ~11.7 nm) rather than 
the small pore yolk (pore size of ~4.2 nm). The loading capacity of AQ4N and GOx in YS-
DMONs was evaluated as shown in Figure S8 a-b. In comparison to YS-DMSNs, the intrinsic 
hydrophobic property of YS-DMONs significantly improved the loading capacity towards 
AQ4N and GOx, exhibiting a co-loading amount of 200.6 mg/g of AQ4N and 20.1mg/g of 
GOx. The fluorescence spectrum of YS-DMONs after co-loading of AQ4N and GOx (YS-
111 
 
DMONs-AQ4N-GOx) are shown in Figure S5.9 (excitation 570 nm). The maximum emission 
wavelength is at 710 nm. The release profile of two cargos was monitored in 2 uM and 5 
mM GSH concentrations, which simulate the extracellular and intracellular GSH levels, 
respectively (Figure S5.10). At 2 µM GSH condition, since the intact pore structure was well-
maintained even after 5 days (Figure S5.11), the small amount of AQ4N and GOx released 
(<10% in 2 days) is attributed to the leakage of the cargos. In contrast, at 5 mM GSH 
condition both the release of GOx and AQ4N was significantly increased. For GOx, a burst 
release (39%) was observed in the first 8 h. For AQ4N, a two-step release was recorded 
with 15% release in the first step (till 8 h) followed by a second step release of 44% till 4 
days. These observations suggest that the GSH depletion triggers the degradation of the 
large-pore shell and the fast release of GOx, which is preferentially loaded inside the large-
pore shells. AQ4N with a much smaller molecular weight than GOx is possibly located in 
both the yolk and the shell, and the two-step release is a consequence of the shell-to-yolk 
stepwise framework degradation of YS-DMONs. This is supported by the observation that 
GOx and AQ4N loaded YS-DMONs showed a fast disintegration of the large-pore shell 
within 1 day. After 3 days, the shell is significantly degraded, while the degradation of the 
small-pore yolk is not evident. The degradation of the yolk was observed after 5 days 
incubation (Figure S5.12).  The trend observed in TEM images agreed well with the DLS 
analysis (Figure S5.13), which shows a gradual reduction in particle size from day 0 to day 
3 and steep decrease on day 5. Moreover, additional peaks centered at ~ 51 nm on day 3 
and ~43 nm on day 5 attributed to the debris were observed. These results collectively 
suggest that the GSH induced degradation of YS-DMONs follows a yolk-to-shell stepwise 
manner, rather the disintegration of one nanoparticle as a whole. 
To understand the role of the stepwise degradation in the sequential release, we prepared 
CS-DMONs without the yolk-shell structure as the control sample and investigated their 
AQ4N release profile. Since the inner small pores are blocked by the shell (evidenced by 
the nitrogen sorption results), the AQ4N can only be loaded in the outer large pore shell. As 
revealed in Figure S5.14, AQ4N showed a burst release profile with more than 50% released 
within 12 h at 5 mM GSH, although no significant release occurred at low GSH 
concentration. The significantly faster release of AQ4N from CS-DMONs than that of YS-
DMONs at 5 mM GSH condition (Figure S5.10) suggest that the yolk-shell structure with 
accessible small pores inside is crucial to slow down the leaching of prodrugs and enable a 
sequential release behaviour at intracellular environment. This is further confirmed by a 
relatively long term release study of AQ4N from YS-DMONs. As shown in Figure S5.14, a 
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clear three step release behaviour was observed. In step (i) (< 12 h), a burst release of 
~32% is attributed to the AQ4N molecules adsorbed on the shell, either on the external 
surface or on the pore wall. Step (ii) (12 h – 4 days) exhibited a sustained release profile 
(20% release), which is mainly attributed to two contributions: One is the leaching of the 
residue AQ4N molecules adsorbed on the shell as a result of the shell degradation, and the 
other is the release of AQ4N from the yolk with smaller pores than the yell. A rapid release 
of AQ4N (48%) occurred after 4 days (step iii), which is attributed to a yolk degradation 
induced drug release. Based on this release study, it is can be estimated that over 48% 
AQ4N was loaded within the small-pore yolk compartment while less than 52% AQ4N was 
encapsulated in the shell. 
Next, we investigated the nanoparticles/GOx-mediated intracellular H2O2 generation and the 
concomitant induction of local hypoxic microenvironment. 4T1 breast cancer cells were 
incubated with phosphate-buffered saline (PBS), YS-DMONs, GOx and YS-DMONs-GOx 
and the intracellular environment was detected using oxidative stress/hypoxia probes. As 
shown in the confocal laser scanning microscopy (CLSM) image (Figure 5.2a), YS-DMONs 
alone induced a certain degree of enhancement of intracellular oxidative stress compared 
to control group as indicated by the increased green fluorescence generated by the oxidative 
stress probe, which can be attributed to their GSH-depleting capability. Pure GOx also 
moderately increased oxidative stress due to the production of H2O2. Cells treated with YS-
DMONs-GOx exhibited the strongest green fluorescence. It was also noted that cells treated 
with YS-DMONs-GOx showed the strongest red fluorescence intensity (hypoxia probe), 
indicative of a highly hypoxic intracellular environment. The fluorescent intensities of 
oxidative stress and hypoxia detection probes were further quantitatively measured and 
plotted in Figures 5.2b and 5.2c, respectively, which agreed well with the observations in 
CLSM images. The above results suggest that the combination of GSH-depleting (the 
composition of nanoparticles) and intracellularly delivered GOx (Scheme 5.1b, ii) enhances 
the oxidative stress/hypoxia in cells.  
We then evaluated the intracellular co-delivery of the hypoxia-activated prodrug (AQ4N) and 
GOx. AQ4N is able to generate red florescence upon laser irradiation, while GOx was 
conjugated with fluorescein isothiocyanate (GOx-FITC) to generate green fluorescence. 
CLSM was used to visualize the cellular distributions after 4 h incubation (Figure 5.2d). Only 
red fluorescence was observed in cells that treated with the mixture of AQ4N and GOx-
FITC, indicating that the GOx molecules alone cannot be internalized by cells due to their 
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large molecular size and electrostatic repulsion (isoelectric point = 4.2) with negatively 
charged cell membranes. However, with the assistance of nanocarriers, GOx could be 
effectively delivered intracellularly as evidenced by the strong green fluorescence observed 
in cells incubated with YS-DMONs-GOx.  In the case of YS-DMONs-AQ4N-GOx, both strong 
red and green fluorescence were observed, suggesting AQ4N and GOx had been 
successfully co-delivered into cells. The mostly overlapped red and green fluorescence 
indicates that the majority of drug and enzyme were still entrapped in nanoparticles (after 
4h). However, after 12 h incubation, a large amount of GOx was released as evidenced by 
the spread of green fluorescence and its separation from the aggregated red dots, 
suggesting a preferential intracellular release of GOx (Figure S5.16). Notably, the cell 
nucleus after YS-DMONs-AQ4N-GOx treatment became condensed and irregular, implying 
the occurrence of cell apoptosis.35 
 
Figure 5.3. Effect of the cascade delivery system on the cell viability and apoptosis in 4T1 
cells. a-b) Cell viability of 4T1 cells subject to different treatment at normoxic (a) and hypoxic 
(b) conditions for 48 h (n = 3, mean ± SD). The corresponding concentration of YS-DMONs 
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from low to high concentration is 0.781, 3.125, 12.5, 50 µg/ml. (c) Comparison of the 
inhibition of cell viability by YS-DMONs-AQ4N-GOx at normoxic and hypoxic conditions 
obtained from (a) and (b). d) IC50 values YS-DMONs-AQ4N-GOx against 4T1 cells in 
normoxic and hypoxic conditions. (e) Analysis of the glucose-responsive cell viability 
inhibition activities of different formulations after 48 h incubation (n = 3, mean ± SD) The 
corresponding concentration of YS-DMONs is 6.25 µg/ml. (f) Flow cytometry analysis of 4T1 
cell apoptosis induced by various formulations for 4 h using the Annexin V-FITC/PI staining. 
Next, the in vitro therapeutic efficacy of the cascade delivery system was studied. The 4T1 
cell viability was quantitatively measured using MTT assay at simulated normoxic (20% 
oxygen, Figure 5.3a) or hypoxic (2% oxygen, Figure 5.3b) conditions. YS-DMONs-AQ4N-
GOx exhibited significantly enhanced efficacy compared to other formulations as 
demonstrated by extremely low cell viability of 9.2% under normoxia and 5.0% under 
hypoxia (AQ4N concentration: 10 µg/ml, GOx concentration: 1µg/ml), which is attributed to 
the synergistic effects between the hybrid nanoparticles and co-delivered enzyme and 
prodrug.  The IC50 of AQ4N in YS-DMONs-AQ4N-GOx formulation was calculated (Figure 
5.3c, d), further confirming its high potency at hypoxic environment (IC50 of 0.59 µg/ml) 
compared to normoxic environment (IC50 of 0.96 µg/ml). It is noted that YS-DMONs-AQ4N 
show a lower cell inhibition activity than YS-DMONs-GOx even at hypoxic condition, which 
could be interpreted from two aspects. First of all, AQ4N is not a highly potent anticancer 
drug compared to most first-line chemo-drugs even after activation, thus it generally requires 
a very high dosage to accomplish effective tumour inhibition.36 The highest concentration of 
AQ4N (10 µg/ml) used for in vitro study is not sufficient to completely inhibit the growth of 
cancer cells. Secondly, the oxidative damage caused by the generation of H2O2 in 
conjunction with the starvation due to glucose consumption through GOx mediated catalytic 
reaction is highly potent for in vitro cell inhibition37-38 even at simulated hypoxic condition 
since the exposure of samples to normoxic oxygen during processing is inevitable. 
Therefore, although AQ4N can be activated in hypoxic condition, the cell inhibition activity 
is still weaker than that of GOx. Moreover, the cell growth and the potency of the combined 
formulation is glucose-dependent as evidenced by the cell viability measured at varied 
concentrations of glucose in the media (Figure S5.17, Figure 5.3e), suggesting that the 
formulation was able to consume glucose to starve cancer cells and induce oxidative 
damage to achieve a high cell inhibition potency. The addition of antioxidant (GSH) into the 
media significantly abolished the inhibition efficacy of YS-DMONs-AQ4N-GOx (Figure 5.3e), 
further confirming that the cell death was partially due to oxidative damaged caused by H2O2, 
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and highlighting the great importance of GSH depletion in achieving a superior therapeutic 
performance.  
The apoptosis-inducing capabilities of different formulations were further studied by using 
the Annexin V-FITC/PI apoptosis detection assay and quantified by flow cytometry.  YS-
DMONs-AQ4N-GOx exhibited the highest late apoptotic ratio of 16.3% compared with other 
formulations (Figure 5.3f). The results in Figure 5.3 collectively support our proposed 
cascade delivery concept that integrates the 1) GSH-depletion and GOx release, 2) glucose 
starvation, H2O2 caused oxidative damage and hypoxia and 3) release and activation of 
prodrug, making it promising for a new paradigm of glucose responsive, hypoxia-activated 
cancer therapy. 
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Figure 5.4. YS-DMONs mediated sequential delivery system inhibits 4T1 tumors and 
reduces lung metastasis. (a) Tumor volume over 12 days (n = 5, mean ± SD). (b) Tumor 
weights at the end point (day 12) (n = 5, mean ± SD). (c) H&E staining images of tumor 
sections at the end point. 1: Control; 2: YS-DMONs-AQ4N; 3: YS-DMONs-GOx; 4:AQ4N + 
GOx; 5: YS-DMONs-AQ4N-GOx. Scale bar: 100 µm (d) Representative digital images 
showing the formation of tumor nodules in the lungs. (e) The numbers of tumor nodules 
present in the lungs (n = 5, mean ± SD). 
The biodistribution of YS-DMONs-AQ4N-GOx was evaluated in 4T1 tumor-bearing mice. 
After 24 h intratumoral injection, most of the nanoparticles remained in tumor tissues, and 
certain amount was found in reticuloendothelial systems, such as spleen and liver (Figure 
S5.18).  The in vivo anti-tumor efficacy was then assessed upon treatment of different 
formulations, including the PBS, YS-DMONs-AQ4N, YS-DMONs-GOx, AQ4N + GOx or YS-
DMONs-AQ4N-GOx. As shown in Figure 5.4 a-b, YS-DMONs-AQ4N and AQ4N + GOx 
showed moderate tumor inhibition capabilities compared to control group due to the limited 
activation of AQ4N in solid tumor. No significant tumor inhibition was observed in the mice 
treated with YS-DMONs-GOx, possibly because 1) the relatively low dosage of GOx (500 
µg kg-1) administrated is insufficient to starve cancer cells and induce high level of H2O2 and 
2) the low oxygen intratumoral microenvironment would reduce the efficacy of GOx. It is 
notable that YS-DMONs-AQ4N-GOx resulted in the strongest tumor inhibition efficiency, 
suggesting the great contribution of GSH-depleting nanocarriers (as compared with AQ4N 
+ GOx group) as well as the cascade delivery of GOx and AQ4N (as compared with YS-
DMONs-AQ4N group) induced tumor inhibition. Indeed, the cascade delivery system 
significantly improved the conversion rate of AQ4N due to the GOx induced hypoxia as 
detected by liquid chromatography–mass spectrometry (LC-MS) both in vitro (~98.3%) and 
in vivo (~92.2%) (Figure S5.19), which largely contributes to the excellent anticancer 
performance. 
Hematoxylin and eosin (H&E) staining results further showed the strong necrosis of tumor 
cells after the treatment of YS-DMONs-AQ4N-GOx compared to other formulations (Figure 
5.4c). We further studied the tumor microenvironment alteration induced by the YS-DMONs-
AQ4N-GOx treatment. As shown in Figure S5.20, after 24 h injection of YS-DMONs-AQ4N-
GOx, the GSH was significantly reduced while the ROS level and hypoxic condition were 
greatly elevated compared to control group, implying the synergistic effects of the 
nanoparticles and the therapeutics.  It is also noted that, compared to the control group, YS-
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DMONs-AQ4N, YS-DMONs-GOx and AQ4N + GOx showed little effect on inhibiting lung 
metastasis, while the YS-DMONs-AQ4N-GOx significantly reduced tumor nodules (Figure 
5.4d, e): only an average of 4.6 nodules were found in those treated with the nanoparticles 
enabled combined therapy, compared to an average of 18.5 tumor nodules observed in the 
control group. These results clearly validate that the GSH-depleting YS-DMONs mediated 
cascade delivery system enabled the reinforcement on the anti-tumor and anti-metastasis 
performance. Moreover, compared to the control group, YS-DMONs-AQ4N-GOx did not 
induce any acute toxicity to major organs, including heart, liver, spleen, lung and kidney as 
revealed by H&E staining (Figure S5.21), suggesting the good biosafety of this cascade 
delivery system. 
5.3 Conclusion 
We have developed an innovative shell-to-yolk stepwise degradable YS-DMONs enabled 
cascade delivery system, which integrates the cooperative functions of (1) GSH-depletion 
and preferential release of GOx, (2) GOx catalyzed starvation, oxidative cytotoxicity and 
hypoxia, and (3) hypoxia induced chemo-therapy for enhanced anti-tumor and anti-
metastasis efficacy. To the best of our knowledge, this is the first study to demonstrate an 
unprecedented concept of cascading starvation/oxidative/chemotherapy. Our proof of 
concept study is expected to provide new possibilities in developing effective yet green 
cancer treatment paradigm. 
5.4 Experimental section 
Chemicals: Cetyltrimethylammonium bromide (CTAB), tetraethyl orthosilicate (TEOS), 
bis[3-(triethoxysilyl)propyl] tetrasulfide (BTES), triethanolamine (TEA, > 99%), sodium 
salicylate (NaSal) and sodium trifluoroacetate (NaTFA)were purchased from Sigma-Aldrich. 
Hydrochloric acid (HCl), ethanol, methanol were received from ChemSupply Pty Ltd. All 
chemicals were used as received without purification. 
For biology experiments: Roswell Park Memorial Institute medium (RPMI 1640) and 
trypsin-EDTA (0.25%) were purchased from Life Technologies. Fetal bovine serum (FBS) 
and trypan blue solution (0.4%) were purchased from Sigma-Aldrich. 4T1 breast cancer cells 
were purchased from American Type Culture Collection (ATCC). 
Synthesis of tetra-sulfide bond bridged mesoporous organosilica nanoparticles 
(MONs) with small pores: MONs were synthesized via a one-pot synthesis using NaTFA 
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and cationic surfactant CTAB as structure directing agents, TEOS and BTES as a silica 
source and TEA as a catalyst. In a typical synthesis of MONs, 0.068 g of TEA, 75 mg of 
NaTFA and 380 mg of CTAB were added to 25 ml of water and stirred gently (~ 700 rpm) at 
80 °C in an oil bath under a magnetic stirrer for 1 h. Afterwards, a mixture of 2 ml of TEOS 
and 1.6 ml of BTES was added to the water-CTAB-NaSal-TEA solution with vigorous stirring 
for 8 h. The products was recovered by centrifugation of 14,000 RCF (g) for 5 min and 
washed with ethanol three times to remove the residual reactants. Finally, the yellow powder 
was dried in vacuum oven at 40 °C for 6h.  
Synthesis of core-shell dendritic mesoporous organosilica nanoparticles (CS-
DMONs): 
CS-DMONs were synthesized via a surface coating of dendritic shell on MONs. The 
synthesis was conducted in a 25 ml flat bottom glass bottle. In a typical synthesis, 0.027 g 
of TEA, 200 mg of MONs, 152 mg of CTAB and 33.6 mg of NaSal were added to 10 ml of 
water and sonicated for 30 mins before stirred gently (~ 700 rpm) at 80 °C in an oil bath for 
1 h. Afterwards, a mixture of 0.5 ml of TEOS and 0.4 ml of BTES was added to the solution 
with vigorous stirring for 8 h. The products was recovered by centrifugation of 14,000 RCF 
(g) for 5 min and washed with ethanol three times and dried in vacuum oven at 40 °C for 6h.  
Synthesis of yolk-shell dendritic mesoporous organosilica nanoparticles (YS-
DMONs): 
YS-DMONs were synthesize by selective etching of CS-DMONs in hydrofluoric acid (HF). 
In a typical synthesis, 100 mg of CS-DMONs were dispersed in 50 ml of water. Next, 84 µL 
of HF (50%) was added. The above solution was stirred at 60 °C in a water bath for 1h. The 
products were then collected and thoroughly washed with water and ethanol. Extraction was 
conducted using HCl/ethanol at 60 °C for 6 h for three times to remove the template.  
Characterizations: The morphologies of the samples were observed using and JEOL JSM 
7800 field emission scanning electron microscope (FE-SEM). Transmission electron 
microscopy (TEM) images and EDS mapping were obtained with a JEOL 2100 operated at 
200 kV. For TEM measurements, the samples were prepared by dispersing the powder 
samples in ethanol, after which they were dispersed and dried on carbon film on a Cu grid. 
Nitrogen adsorption–desorption isotherms were measured at 77 K using a Micromeritics 
ASAP Tristar II 3020 system. The samples were degassed at 393 K overnight on a vacuum 
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line. The pore size distribution curve was derived from the adsorption branch of the 
isotherms using the Barrett–Joyner–Halanda (BJH) method. The Brunauer–Emmett–Teller 
(BET) method was utilized to calculate the specific surface areas. The total pore volume 
was calculated from the amount adsorbed at a maximum relative pressure (P/P0) of 0.99. 
13C CPMAS and 29Si CPMAS NMR spectra were measured by solid state Bruker Avance III 
spectrometer.  
In vitro bio-TEM: 4T1 cells were seeded in six-well plate at cell densities of 2×105/well (for 
1 day test), 1×105/well (for 2 days test), 5×104/well (for 3 days test) and 2×104 (for 5 days 
test) for 24 h.  Afterwards, the medium was removed and replaced with fresh medium 
containing 40 mg ml-1 of YS-DMONs and incubated for another 1 day, 2 days, 3 days or 5 
days. Then cells were collected, washed and fixed with 2.5% glutaraldehyde at room 
temperature for 30 min, and post-fixed in 1% osmium tetraoxide in microwave conditions. 
After that, cells were embedded into a 2% agarose gel cube, followed by dehydration in 
acetone of increasing concentration (50%, 70%, 90%, 100% and 100%) under microwave 
conditions. The dehydrated cell cubes were embedded in Epon resin, and solidified at 60 °C 
for 2 days. Microtome (Leica, EM UC6) was then used to cut the embedded cell-resin cube 
into ultra-thin slices (70–90 nm in thickness). Samples were mounted on form-bar coated 
copper grids and double stained with 2% aqueous uranyl acetate and commercial lead 
citrate aqueous solution. TEM images were taken at 80 kV to observe the intracellular 
degradation of nanoparticles. 
Cytotoxicity test: The cell viability was measured using MTT ((3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay. Briefly, 4T1 cancer cells were seeded in 96-well 
plates at a density of 3,000 cells per well. Next day, cells were treated with PBS or various 
concentration of YS-DMONs. After 48 h incubation, the cell viability was determined. All 
experiments were performed in triplicate. 
Measurement of cellular GSH:  4T1 cancer cells were seeded in black 96-well plates at a 
density of 8,000 cells per well. After 24h, various concentrations of YS-DMONs were added 
and incubated for 6 h. The cellular GSH probe (Cell Signaling Technology) was then added 
according to the manufacture’s protocol and the fluorescent intensity was measured using 
microplate reader. 
AQ4N and GOx loading:  For the drug loading, AQ4N was first dissolved in PBS (pH 7.4) 
to obtain a stock solution with a concentration of 2 mg ml-1. Then, 150 µL of AQ4N stock 
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solution were mix with 150 µL of YS-DMONs suspension (4 mg/ml) and incubated at 4°C 
overnight. After loading, the solution were centrifuged and washed with PBS three times to 
remove loosely adsorbed drugs. The supernatant and washing solution were used to 
measure the loading amount using UV-Vis at wavelength of 610 nm. The amount of drug 
adsorbed was calculated by the concentration difference between before and after 
adsorption. 
For GOx loading, 100 µL of GOx stock solution (1mg/ml) were mixed with 100 µL YS-
DMONs or YS-DMONs-AQ4N suspension (10 mg/ml) and incubated at 4°C overnight. The 
loading amount was measured using UV-Vis at wavelength of 280 nm. The amount of 
protein adsorbed was calculated by the concentration difference between before and after 
adsorption. 
Fluorescein labeling of GOx: GOx (8 mg) was dissolved in 3 mL of sodium bicarbonate 
solution (0.1 M, pH = 9.5), and mixed with 1 ml freshly prepared FITC solution (4 mg/mL in 
DMSO). The reaction mixture was protected from light and stirred at room temperature for 
2 hours. The resulting FITC labelled GOx (GOx-FITC) was further dialysed in PBS solution 
for three days to remove unreacted residues before freeze drying. 
 AQ4N and GOx release test: GOx were firstly labeled with FITC as aforementioned and 
the release profile of AQ4N and GOx were simultaneously monitored based on the 
fluorescent intensity in the supernatant. Briefly, 2 mg/ml of GOx and AQ4N co-loaded 
nanoparticles were dispersed in PBS containing different concentrations of GSH (2 µM and 
5mM). At pre-determined time intervals, 200 µl of supernatant were collected and replaced 
with equal volume of fresh solution. The amount of released AQ4N (ex 633, em 650) and 
GOx-FITC (ex 490, em 525) were measured using microplate reader.  
Degradation test at simulated condition: A mixture of AQ4N and GOx loaded YS-DMONs  
and PBS buffer (particle concentration = 0.5 mg/ml, total volume = 1ml) containing 5% FBS 
and various concentrations of GSH (2 μM or 5mM) was shaken at 37°C in an 2 ml eppendorf 
tube. At predetermined time point, aliquots were taken and washed with PBS before 
performing the TEM analyses. 
Intracellular oxidative stress/hypoxia detection: The delivery of GOx induced 
intracellular oxidative stress /hypoxia generation was detected using Hypoxia/Oxidative 
Stress Detection Kit (Enzo Life Sciences). Briefly, 4T1 cells were seeded on 6-well plates at 
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density of (1×105/well) and incubated in complete medium at 37 °C. The next day, the culture 
medium was removed and washed twice with PBS followed by incubation with fresh media 
containing YS-DMONs (5 µg/mL), GOx (0.1 µg/mL) or YS-DMONs-GOx (GOx = 0.1 µg/mL) 
for 4 h. Hypoxia/oxidative stress detection mix was added into cell culture media and 
measured using CLSM imaging or quantified by microplate reader according to the 
manufacturer’s instruction.  
Visualization of co-delivery of AQ4N and GOx: 4T1 cells were seeded in a 6-well plate at 
a density of 100, 000 cells per well. After 24 h, cells were treated with AQ4N + GOx-FITC, 
YS-DMONs-AQ4N, YS-DMONs-GOx-FITC or YS-DMONs-AQ4N-GOx-FITC at AQ4N and 
GOx concentrations of 1 µg/ml and 0.1 µg/ml for 4 h. Then, the cells were washed twice with 
PBS and fixed with 4% paraformaldehyde. The cell nuclei were then stained with DAPI, and 
the co-delivery performance was assessed using a confocal laser scanning microscopy 
(CLSM) (LSM710, Zeiss). 
Cell viability test: The cell viability was measured using MTT ((3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay. Briefly, 4T1 cancer cells were seeded in 96-well 
plates at a density of 3,000 cells per well over night in normoxia. Next day, cells were treated 
with PBS, AQ4N + GOx-FITC, YS-DMONs-AQ4N, YS-DMONs-GOx or YS-DMONs-AQ4N-
GOx at various concentrations incubated in normoxia (20% oxygen) or hypoxia (2% oxygen) 
conditions. After 48 h incubation, the cell viability was determined. All experiments were 
performed in triplicate. 
Apoptosis assay: Apoptosis of 4T1 cells was examined using the Annexin V-FITC/PI 
Apoptosis Detection Kit (BD Biosciences). Briefly, the cells were seeded in the 6-well plates 
at the density of 1 × 105 cells per well. After 24h, the cells were incubated with PBS, YS-
DMONs-AQ4N, YS-DMONs-GOx, AQ4N + GOx, or YS-DMONs-AQ4N-GOx for 4 h. The 
subsequent procedures were performed in accordance with the manufacturer’s protocol and 
determined using flow cytometry.  
Animals and tumor model: Animals: Female C57BL/6J (6~8 weeks of age) mice were 
purchased from the Biological Resource Facility, The University of Queensland. All 
experiments were approved by The University of Queensland, and were carried out in 
accordance with the institutional guidelines for animal experimentation. 4T1 tumor model 
was established by the subcutaneous injection of 4T1 cells (2.5 × 106) into the right flank of 
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the mice. The tumor size was monitored by a vernier caliper and the tumor volume (V) was 
calculated as V=L*W2/2, where L and W were the length and width of the tumor, respectively. 
In vivo antitumor efficacy: The tumor-bearing mice were weighed and randomly divided 
into five groups when the tumor volume reached to ~100 mm3 (day 0), and intratumorally 
injected with: 1. PBS; 2. YS-DMONs-AQ4N; 3. YS-DMONs-GOx; 4. AQ4N + GOx; 5.YS-
DMONs-AQ4N-GOx on day 0 and day 3. The dosages of AQ4N and GOx were 5 mg/kg and 
500 µg/kg, respectively. On Day 12, the mice were euthanized, and the tumors were 
collected, weighed, washed with PBS and fixed in the 10% formalin. The hematoxylin and 
eosin (HE) staining of the formalin-fixed tumors were prepared and observed by optical 
microscope. 
In vitro AQ4N conversion test: 3×105 4T1 cells were seeded in 6-well plate. After 
incubation for 24 h, YS-DMONs-AQ4N-GOx containing 5 µg/ml of AQ4N and 0.5 µg/ml of 
GOx were added and incubated for another 3 h before cell lysis. This was followed by mixing 
1 mL of the cell lysate contained solution with 3 mL of acetic acid/methanol (0.1%, v/v) for a 
liquid-liquid extraction and precipitation of serum proteins. After centrifugation, the 
supernatant were collected for LC/MS analysis. 
In vivo AQ4N conversion test: After 24 h intratumoral injection of PBS or YS-DMONs-
AQ4N-GOx, 100 mg of tumour samples were homogenized in PBS and subjected to liquid-
liquid extraction using acetic acid/methanol (0.1%, v/v). Following the centrifugation of tissue 
homogenates, the supernatants were collected and concentrated to a final volume of 0.5 
mL under vacuum before LC/MS analysis. 
Tumor microenvironment assessment: After 24 h intratumoral injection of PBS or YS-
DMONs-AQ4N-GOx, mice were sacrificed and tumors were collected and homogenized to 
produce single cell suspension. The red blood cells were removed using the RBC lysis 
buffer. Then, intracellular environments including GSH, ROS and hypoxia were measured 
using GSH Detection Kit and Hypoxia/Oxidative Stress Detection Kit as mentioned above.  
Biodistribution and in vivo toxicity test: YS-DMONs-AQ4N-GOx were intratumorally 
injected into 4T1 tumor-bearing mice. The dosages of YS-DMONs, AQ4N and GOx were 25 
mg/kg, 5 mg/kg and 500 µg/kg, respectively. 24 h later, the tumors and major organs, 
including heart, liver, spleen, lung, and kidney were collected, cut into small pieces and 
dissolved in concentration nitric acid. The silicon content in each tissue were quantified by 
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ICP-OES and calculated based on the injection dose and weight of tissues. The final values 
were obtained by subtracting the silicon content in control group. The rest part of tissues 
were used for H&E staining for evaluating the toxicity of the nanoformulation. 
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5.6 Supporting Information  
 
 
Figure S5.1 29Si solid-state NMR spectra of CS-DMONs. 
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Figure S5.2 Nitrogen adsorption-desorption isotherm (a) and pore size distribution (b) of 
CS-DMONs. 
 
 
 
Figure S5.3 DLS results of YS-DMONs in PBS.          
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Figure S5.4 Concentration dependent cytotoxicity of YS-DMONs against 4T1 cells after 48h 
incubation (n = 3, mean ± SD).  
 
 
Figure S5.5 TEM (a), 29Si solid state NMR (b), N2 adsorption-desorption isotherm (c) and 
pore size distribution of YS-DMSNs.  
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Figure S5.6 GSH-depleting capability of YS-DMONs and YS-DMSNs in 4T1 cells (n = 3, 
mean ± SD). The cellular GSH level was measured using Cellular Glutathione Detection 
Assay Kit.  
 
Figure S5.7. DLS results of GOx in PBS.  
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Figure S5.8 AQ4N (a) and GOx (b) loading capacities on different nanoparticles (n = 3, mean 
± SD). The loading of GOx was conducted after AQ4N adsorption and washing, leading to 
a reduced GOx loading capacity. This is explained by the inevitable adsorption of a certain 
amount of AQ4N even in the outer dendritic shell, which hinders the interaction between 
GOx molecules and the organosilica pore surface.   
 
Figure S5.9 fluorescence spectrum of YS-DMONs-AQ4N-GOx in water. 
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Figure S5.10 AQ4N and GOx-FITC release profile of YS-DMONs-AQ4N-GOx-FITC in PBS 
containing different concentrations of GSH. The released amount in the supernatant was 
measured based on fluorescent intensity using microplate reader (n = 3, mean ± SD). 
 
As shown in Figure S5.10, it is clear that the release of GOx is much faster than that of 
AQ4N particularly in the first 12 h, which is an important feature to accomplish the cascade 
delivery concept. It is very hard to achieve zero premature release of AQ4N since a certain 
proportion of the prodrugs would also adsorbed at the outer shell, thus will be released with 
the shell degradation (i.e. ~35% after 1 day). In addition, the intracellular sequential release 
profile was confirmed by the confocal image (Figure S5.16), showing a fast spread of green 
fluorescent (generated by GOx-FITC), while the red fluorescent (generation by AQ4N) were 
still in dot form due to entrapment in particles. 
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Figure S5.11 TEM image of YS-DMONs after incubation with 2 µM GSH for 5 days. 
 
 
 
Figure S5.12. DLS results in YS-DMONs after incubation with 5 mM GSH for a) 1 day, b) 3 
days and c) 5 days. 
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Figure S5.13 TEM images showing the stepwise degradation of the AQ4N and GOx co-
loaded YS-DMONs after incubation with 5 mM GSH for a) 1 day, b) 3 days and c) 5 days. 
Scale bar: 100 nm. 
 
 
 
Figure S5.14 AQ4N release profile of YS-DMONs-AQ4N in PBS containing 5 mM of GSH.  
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Figure S5.15 AQ4N release profile of CS-DMONs-AQ4N in PBS containing different 
concentrations of GSH (n = 3, mean ± SD). 
 
For comparison, we use CS-DMONs without the yolk-shell structure as the control sample 
and investigated their AQ4N release profile. Since the inner small pores are blocked by the 
shell (evidenced by the nitrogen sorption results), the AQ4N can only be loaded in the outer 
large pore shell. As revealed in Figure S5.15, AQ4N showed a burst release profile with 
more than 50% released within 12 h at 5 mM GSH, although no significant release occurred 
at low GSH concentration. Such significantly faster release of AQ4N from CS-DMONs than 
that of YS-DMONs at 5 mM GSH condition suggest that the yolk-shell structure with 
accessible small pores inside is crucial to slow down the leaching of prodrugs and enable a 
sequential release behaviour at intracellular environment. 
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Figure S5.16 CLSM image of 4T1 cells incubated with YS-DMONs-AQ4N-GOx-FITC for 
12h. AQ4N (red colour) showed several individual red dots, suggesting that the drug are still 
entrapped in nanoparticles. The green fluorescence generated from GOx-FITC exhibited 
partially overlapped dots with AQ4N as well as green colour that spread around cell nuclei 
and separated from red ones, confirming that GOx-FITC molecules had started to release. 
These results clearly demonstrate a sequential intracellular release pattern of GOx-FITC 
and AQ4N.  Scale bar: 10 µm  
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Figure S5.17 4T1 cell proliferation in RPMI1640 medium containing different concentrations 
of glucose. The results confirm the important role of glucose in providing nutrient and energy 
for cell growth (n = 3, mean ± SD).   
 
 
 
Figure S5.18 Biodistribution of YS-DMONs-AQ4N-GOx based on the silicon content in 
various organs and tissues of 4T1 tumour-bearing mice at 24 h post injection as determined 
by the ICP-OES. 
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Figure S5.19 The conversion rate of AQ4N in vitro (a) and in vivo (b). 
 
 
 
 
 
Figure S5.20  In vivo tumour microenvironment altered by administration of YS-DMONs-
AQ4N-GOx. (a) GSH level, (b) ROS level and (c) hypoxia environment in tumour tissues. 
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Figure S5.21 H&E staining of heart, liver, spleen, lung and kidney (Scale bar: 200 μm).    
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Table S5.1. Physical parameters of MONs, CS-DMONs and YS-DMONs. 
Sample   SBET 
[m2/g]  
Pore size 
[nm] 
Pore volume 
[cm3/g] 
MONs 336 4.2 0.43 
CS-
DMONs 
197 7.4 0.36 
YS-
DMONs 
325 4.2, 11.7 0.68 
YS-
DMSNs 
341 4.3, 11.7 0.68 
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Chapter 6 
 
Multi-shelled Dendritic Mesoporous 
Organosilica Hollow Spheres: Roles of 
Composition and Architecture in Cancer 
Immunotherapy 
 
The chapter has been published on Angewandte Chemie International Edition, 2017, 56, 
8446. 
 
 
Abstract: Developing potent adjuvants for the stimulation of robust immune response is 
central for effective cancer immunotherapy. Herein, we report for the first time double-
shelled dendritic mesoporous organosilica hollow spheres are an excellent adjuvant and 
provide superior immunity in cancer immunotherapy, better than their counterparts either 
with a pure silica composition or a single-walled architecture. Our study provides new 
insights in the rational design of effective nanostructured adjuvants for vaccine 
developments. 
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6.1 Introduction 
Cancer immunotherapy, a strategy that provokes the immune system to fight against 
tumours, has been regarded as an effective methodology for cancer treatment.[1] 
Development of potent and safe adjuvants for generating robust and long-lasting adaptive 
antitumor immunity remains challenging. Recent breakthroughs in fabrication of innovative 
nanomaterials have enabled emerging platforms for delivering cancer vaccines.[2] Among 
various nanostructured adjuvants under study,[3] mesoporous silica nanoparticles (MSNs) 
are promising[4] and their adjuvant property on stimulating anti-tumour immunity was 
reported only very recently.[5] Ideal nanomaterial-based adjuvants should possess several 
key features: 1) high payload;[6] 2) sustained release for prolonged exposure of antigens to 
the immune system;[7] 3) efficient cellular uptake,[8] endosomal escape capability[9] and 
hydrophobicity[10] for inducing potent cellular-mediated immunity. In this regard, MSNs with 
inorganic silica (-Si-O-Si-) framework could hardly meet any of the aforementioned 
requirements. An attractive strategy is introducing molecularly dispersed organic functional 
groups with intrinsic hydrophobicity in the framework of mesoporous organosilica 
nanoparticles (MONs), which have shown great promise in drug/gene delivery 
applications.[11] Inspired by these achievements, it is hypothesized that the incorporation of 
functional organic groups in rationally designed nanostructures will substantially extend the 
application of MONs from nanocarriers to immunoadjuvants. 
Multi-shelled hollow structures have attracted tremendous attention and offered advantages 
over single-shelled ones, especially in prolonged release.[11d, 12] Recently, mesoporous 
materials with radial dendritic pore structures have become a hot topic in bio-applications 
due to their highly accessible surface areas and high payload.[13] Constructing 
multigenerational dendritic MSNs has been reported by Zhao and co-workers.[13c] However, 
the synthesis of MONs with a multi-shelled hollow structure and hybrid dendritic framework 
has not been reported. It is expected that the combination of a functional organosilica 
framework and a tunable shell structure with dendritic large pores in one nanoparticle will 
provide novel materials with improved performance. 
Herein, for the first time, we report the synthesis of dendritic mesoporous organosilica hollow 
spheres (DMOHS) with controllable number (n) of shells (denoted S). When used as an 
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adjuvant in cancer immunotherapy, it is shown that (1) the hybrid organosilica framework 
(DMOHS-2S, Scheme 6.1) generates a higher level of immune response and better in vivo 
antitumor efficacy compared to a bare silica counterpart, i.e., double-shelled dendritic 
mesoporous silica hollow spheres (DMSHS-2S) when n is the same; (2) when the 
organosilica composition is the same, the double-shelled structure (DMSHS-2S) is 
advantageous over one-shelled (DMOHS-1S) and (3) the composition plays a more 
significant role than the architecture in modulating the immune response. Understanding the 
advantages of organosilica over silica and the contribution of nanostructure architecture 
(shell numbers of hollow spheres) in immunotherapy may pave the way for the next-
generation nanoadjuvants for effective cancer immunotherapy.  
Scheme 6.1. Schematic illustration of synthesis procedure of DMOHS-nS and DMSHS-2S.  
DMOHS-nS were prepared by coating a dendritic organosilica layer on preformed dendritic 
mesoporous organosilica nano-particles (DMONs) assembled using 
cetyltrimethylammonium bromide (CTAB) and sodium salicylate (NaSal)[14] as the structure 
directing agents (SDA), tetraethyl orthosilicate (TEOS) and 1,2-bis(triethoxysilyl)ethane 
(BTEE) as precursors, followed by selective etching and extraction (see Supporting 
Information for details). Particularly, DMOHS-1S were prepared by direct etching of DMONs 
without coating, while DMOHS-2S were obtained by one step coating (Figure S6.1 a-b, d-
e). Repeating the coating steps (e.g. 2 times) resulted in DMOHS-3S with multi-shells 
(Figure S6.1 c, f). To investigate the role of composition while keeping the shell number the 
same, DMSHS-2S with a pure silica composition was obtained by calcination of DMOHS-
2S. 
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Figure 6.1. TEM (a-b) and SEM images (c-d) of DMOHS-2S. Dark-field STEM image (e) 
and corresponding EDS mapping of DMOHS-2S (f-h). Solid state 29Si NMR (i) and 13C NMR 
(j) spectra of DMOHS-2S.  
The detailed characterization of DMOHS-2S is shown in Figure 6.1. Transmission electron 
microscopy (TEM) images show the double shelled dendritic structure with a particle size of 
~ 350 nm (Figure 6.1a, b). The monodispersity and large open pores are evidenced by 
scanning electron microscope (SEM) images (Figure 6.1c, d). Dark field scanning 
transmission electron microscope (DF-STEM) image (Figure 6.1e) and the corresponding 
energy-dispersive X-ray spectroscopy (EDS) elemental mapping of the DMOHS-2S indicate 
the uniformly distributed C, O, and Si elements in the double-shells (Figure 6.1f-h). 29Si MAS 
nuclear magnetic resonance (NMR) spectrum of the DMOHS-2S shows two main peaks at 
-66 and -111 ppm, corresponding to T3 (C-Si(OSi)3)and Q4 (Si(OSi)4) species (Figure 6.1i). 
Quantitative analysis based on relative peak areas indicates that 70.4% of the silicon atoms 
in the DMOHS-2S are located at the T sites, indicating a high organosilica content in the 
hybrid framework. The 13C NMR spectrum of the DMOHS-2S (Figure 6.1j) shows the 
characteristic peaks at 4 ppm, corresponding to the ethane moieties. No peaks of CTAB 
were observed, confirming that CTAB had been completely removed after ethanol 
extraction.[15] N2 adsorption-desorption analysis show that all three samples possess large 
mesopores of 14.4, 16.0, 17.7 nm, respectively (Figure S6.2a-b). In addition, the three 
nanoparticles exhibit similar pore volumes and Brunauer-Emmett-Teller (BET) surface areas 
(Table S6.1).  
The formation of DMOHS-1S can be explained by the composition gradient of DMONs due 
to the slower hydrolysis and condensation rate of organosilica precursor than that of silica 
precursor as reported recently.[14] With this finding, the preformed DMONs were coated 
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further by dendritic hybrid silica layers. It is postulated that the coated layer has similar 
composition gradient with the inner part rich in inorganosilica and the outer part rich in 
organosilica. HF etching removes most of the relatively unstable inorganosilica content (-O-
Si-O-),[11a] leading to the formation of void space between adjacent shells.  
Figure 6.2. OVA (a) and TF (b) release profile from various nanoparticles in PBS solution. 
c) Confocal images of OVA-FITC, DMSHS-2S/OVA-FITC and DMOHS-2S/OVA-FITC 
incubated with RAW264.7 for 10 h at OVA concentration of 10 μg/ml. White arrows indicates 
the presence of green fluorescence outside the red region, suggesting successful endo-
lysosomal escape. OVA-FITC positive cell population (d) and MFI (e) in different groups in 
triplicates measured by flow cytometry. **p < 0.01, ***p < 0.001. 
To highlight the importance of both architecture and composition of the DMOHS-2S, two 
control samples were prepared for comparison: 1) DMOHS-1S with the same composition 
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but single shell and 2) DMSHS-2S with the same shell number but a pure silica composition. 
The well maintained TEM image confirmed the double-shelled structure is well maintained 
in DMSHS-2S (Figure S6.3). Fourier transform infrared (FTIR) spectra show that the peaks 
at 2927, 2900, and 1411 cm−1 in DMOHS-2S (assigned to the vibration of C-H bond in 
ethane group) disappeared in DMSHS-2S (Figure S6.4), indicating the complete removal of 
organic content. [11d] 
We firstly tested the loading capacity of different biomolecules using our nanoparticles. As 
shown in Figure S6.5a, all nanoparticles exhibited almost complete adsorption of ovalbumin 
(OVA) at the particle/OVA mass ratio of 5/1. For B16F10 tumour cell fragments (TF), a 
tumour antigen for cancer immunotherapy,[5b, 16] more than 80% of TF was absorbed for the 
three particles at particle/TF mass ratio of 12/1 (Figure S6.5b). In addition, both DMOHS-2S 
and DMSHS-2S showed low cytotoxicity at concentrations below 80 µg/mL, suggesting their 
good biocompatibility (Figure S6.6). 
Subsequently, the release profiles of three nanoparticles were studied. As expected, the 
OVA or TF loaded DMOHS-2S showed the most sustained release profile compared to that 
of DMOHS-1S and DMSHS-2S, respectively (Figure 6.2 a, b). This is attributed to the strong 
hydrophobic interaction between DMOHS-2S and antigens and the presence of the double 
shelled structure that serves as an effective barrier to slow down the diffusion of protein 
molecules. These results suggest that both of the double shelled structure and the 
organosilica rich composition are essential factors for the long-term sustained cargo release. 
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Figure 6.3. The secretion level of IFN-γ (a), IL-12 (b), TNF-α (c) and IL-4 (d) by splenocytes 
obtained from immunized mice and restimulated with OVA. * p<0.05, ** p< 0.01, *** p< 
0.001. 
Next, the cellular uptake and intracellular distribution of nanoparticles in RAW264.7 
macrophage cell line were visualized using confocal microscopy (Figure 6.2c). Fluorescein 
isothio-cyanate (FITC) conjugated OVA (OVA-FITC) alone shows very weak green 
fluorescent signal, indicative of limited cellular uptake efficiency. Moderate green 
fluorescence is observed in the case of OVA-FITC loaded DMSHS-2S, suggesting slightly 
enhanced cellular uptake compared to protein alone. However, mostly overlapped green 
and red fluorescence (Lysotracker red) indicates the entrapment of the particle/protein 
complex in the endo-lysosome compartment. In contrast, strong FITC (green) fluorescence 
signal and the separation of green dots and red dots were observed in the cases of DMOHS-
1S and DMOHS-2S, suggesting efficient cellular uptake and a certain degree of 
endo/lysosome escape. The organosilica nanoparticle mediated endo/lysosome escape is 
very likely due to their intrinsic hydrophobicity,[17] which is important for the antigen 
presentation via major histocompatibility complex (MHC) class I and subsequent activation 
of cellular mediated immunity.[3b, 18] Quantitative measurements further confirms the superior 
cell uptake performance of  OVA-FITC loaded DMOHS-1S and DMOHS-2S, as evidenced 
by the significantly enhanced FITC positive cell population (Figure 6.2d) as well as mean 
fluorescent intensity (MFI) (Figure 6.2e) compared to other groups.  
To study the potential adjuvant performance, OVA was firstly used as a model antigen for T 
cell and cytokine measurement. The frequency of effector-memory T cells was evaluated 
using CD44highCD62Llow as the markers through flow cytometry. Mice immunized with the 
DMOHS-2S based vaccine formulation show the highest frequency of effector-memory 
CD4+ and CD8+ T cells compared to all of the other groups (Figure S6.7). The DMOHS-
2S/OVA can also induce enhanced CD8+ and CD4+ T cells proliferation than that of other 
formulations (Figure S6.8), suggesting its great potential in inducing both humoral and 
cellular immunity.  
Th1 immune response, characterized by the secretion of interleukin-12 (IL-12), interferon- γ 
(IFN-γ) and tumour necrosis factor-α, is essential for eliciting potent antitumor immunity. 
Mice immunized with OVA loaded DMOHS-2S exhibited significantly increased secretion 
level of IFN-γ, IL-12 and TNF-α (Figure 6.3 a-c) compared to other formulations, suggesting 
a potent cell-mediated immunity induced by DMOHS-2S. In addition, DMOHS-2S also 
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induced the strongest Th2 immune response, as evidenced by the highest secretion of 
interleukin-4 (IL-4) (Figure 6.3d).  
Figure 6.4. Antitumor performance of various vaccine formulations. a) Experimental 
procedure for the therapeutic immunization model. The tumor volume (b), survival rate (c), 
tumour free percentage (d) and body weight (e) of mice after immunization. * p<0.05, ** p< 
0.01. 
We then evaluated the in vivo antitumor performance of DMSHS-2S, DMOHS-1S and 
DMOHS-2S based vaccine formulation using TF as the tumour antigen in a therapeutic 
vaccination model (Figure 6.4a). Compared to the PBS groups, injections of TF, DMOHS-
2S alone or DMSHS-2S+TF only showed marginal effect on tumour inhibition (Figure 6.4b). 
The organosilica based vaccine formulations, however, exhibited significantly improved 
tumour inhibition. Particularly, mice immunized with DMOHS-2S+TF showed the best anti-
tumour performance with the smallest tumour volume at 20 days among all the groups. The 
survival rate of mice immunized with DMOHS-2S+TF was significantly prolonged compared 
to the other groups, showing a 50% survival after 35 days of tumour inoculation (Figure 
6.4c). Moreover, the DMOHS-2S+TF vaccine formulation effectively prolonged the tumour 
free rate of mice, showing a significantly delay of tumour growth up to 31 days, whereas all 
of the other groups have a 100% tumour occurrence within 25 days (Figure 6.4d). These 
results suggest both the organosilica rich composition and the double-shelled structure are 
favourable for the enhanced adjuvant effect in vivo. Meanwhile, we found that the body 
weights of mice were not significantly affected, indicating that there were no acute side 
effects in our nanoparticles based vaccine formulations (Figure 6.4e).  
It has been well-documented that the hydrophobicity of nanoparticles and the sustained 
release of antigens are the key parameters for stimulating the immune response, particularly 
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the cell-mediated immunity.[7b, 7c, 10, 19] Herein, we rationally designed DMOHS-2S with 
simultaneous control over composition, multi-shelled architecture and large-pore dendritic 
structures. Our preliminary results have demonstrated that the constructed hybrid 
nanoparticles offer several advantages: 1) The hybrid organosilica rich framework with 
intrinsic hydrophobicity improves the interaction of nanoparticles with antigen presenting 
cells (APCs) and induces endo-lysosomal escape; 2) The unique double shelled dendritic 
structure are beneficial for high payload and sustained release. These features eventually 
result in the strong antitumor immunity.[4c, 7b, 10]  
Interestingly, it is noted that DMOHS-1S exhibited a faster release than DMSHS-2S (Figure 
6.2a, b), but better adjuvant effects (Figures 6.3 and 6.4). These results suggest that the 
contributions from composition (organosilica over silica) such as endo/lysosome escape and 
antigen delivery efficacy are more important than sustained release in stimulating immune 
response. While the great potential of organosilica nanoparticles as vehicles for drug 
delivery has been extensively studied,[11b, 20] their immuno-adjuvant effect has not been 
reported. Our pioneer study clearly show that the DMOHS-2S are excellent adjuvants for 
effective cancer immunotherapy. Considering the enormous library of organosilica 
precursors available for adjusting the compositions,[21] understandings from this study may 
provide new opportunities for extending the applications of the large family of classical 
organosilica materials with rationally designed nanostructures for effective cancer 
immunotherapy. 
6.3 Conclusion 
In conclusion, organosilica hollow spheres with dendritic pore structure and tunable shell 
number has been successfully synthesized and applied as cancer immuno-adjuvant for the 
first time. The double-shelled structure and organic-inorganic hybrid framework are the key 
factors for the excellent tumour inhibition effect. The successful construction of the multi-
shelled DMOHS and the understandings drawn from this study is expected to open new 
doors in developing advanced vaccine delivery systems for cancer therapy.  
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6.5 Supporitng information 
Experimental Section  
Chemicals: Cetyltrimethylammonium bromide (CTAB), tetraethyl orthosilicate (TEOS), 
1,2-bis(triethoxysilyl)ethane (BTEE), triethanolamine (TEA), sodium salicylate (NaSal) and 
ovalbumin (OVA) were purchased from Sigma-Aldrich. Hydrochloric acid (HCl), 
hydrofluoric acid (HF), ethanol, methanol were received from ChemSupply Pty Ltd. All 
chemicals were used as received without purification. 
For biology experiments: Roswell Park Memorial Institute (RPMI)1640 Medium, 
Dulbecco’s Modified Eagle Medium (DMEM) and trypsin-EDTA (0.25%) were purchased 
from GIBCO or Invitrogen, Life Sciences, Life Technologies. Fetal bovine serum (FBS) and 
trypan blue solution (0.4%) were purchased from Sigma-Aldrich. B16F10 murine 
melanoma cell line and RAW264.7 cells were purchased from ATCC (American Type 
Culture Collection).  
 
Synthesis of ethane bridged multi-shelled dendritic mesoporous organosilica 
hollow spheres (DMOHS):  Multi-shelled DMONS were synthesized in aqueous solution 
through an anion assisted approach followed by selective etching of the dendritic 
mesoporous organosilica nanoparticles (DMONs).  In a typical synthesis, 0.068 g of TEA 
were added to 25 mL of water and stirred gently at 80 °C in an oil bath under a magnetic 
stirring for 0.5 h. Afterwards, 380 mg CTAB and 126 mg NaSal was added to the above 
solution with stirring for 1 h. Then, a mixture of 2 mL TEOS and 1.6 mL BTEE was added 
to the water-CTAB-NaSal-TEA solution with vigorous stirring for 12 h. The products were 
collected by high speed centrifugation (14,000 RCF (g), 5 mins) and washed three times 
with ethanol to remove the residual reactants, and dried in vacuum overnight.  For coating 
of the second organosilica shell, 100 mg of the dried DMONs were dispersed in 12.5 mL 
water containing 0.034g TEA. After sonication for 1 h, 190 mg CTAB and 63 mg NaSal 
were added and stirred at room temperature for 1h before the addition of premixed 1 mL 
TEOS and 0.8 mL BTEE. After 24 h reaction, the products were collected by centrifugation 
at 14,000 RCF (g) for 5 min, washed thoroughly with ethanol and dried in vacuum. In order 
to prepare DMOHS-2S, 50 mg of the dried products were etched in 50 ml water containing 
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174 µL concentrated HF (48%) for 1 h at 60 °C. After washing with water, the collected 
products were extracted with HCl and ethanol solution at 60 °C for 6 h three times to 
completely remove the template1, followed by drying in vacuum at room temperature 
overnight. DMOHS-1S were prepared by etching of DMONs at the same condition 
aforementioned, and DMOHS-3S were prepared via two coating steps before HF etching.  
Characterizations: The morphologies of the samples were observed using and JEOL 
JSM 7800 field emission scanning electron microscope (FE-SEM). Transmission electron 
microscopy (TEM) images were obtained with a JEOL 1010 operated at 100 kV. Energy-
didpersive X-ray spectroscopy (EDS) elemental mapping was from JEOL 2100 operated at 
200 kV. For TEM measurements, the samples were prepared by dispersing the powder 
samples in ethanol, after which they were dispersed and dried on carbon film on a copper 
grid. Nitrogen adsorption–desorption isotherms were measured at 77 K using a 
Micromeritics ASAP Tristar II 3020 system. The samples were degassed at 393 K 
overnight on a vacuum line. The pore size distribution curve was derived from the 
adsorption branch of the isotherms using the Barrett–Joyner–Halanda (BJH) method. The 
Brunauer–Emmett–Teller (BET) method was utilized to calculate the specific surface 
areas. The total pore volume was calculated from the amount adsorbed at a maximum 
relative pressure (P/P0) of 0.99. 29Si and 13C CP/MAS NMR spectra were measured by 
solid state Bruker Avance III spectrometer. The ATR-FTIR spectra were collected with 
ThermoNicolet Nexus 67000 FTIR spectrometer equipped with Diamond ATR Crystal. For 
each spectrum, 120 scans were collected at a resolution of 4 cm-1 over the range 500-
3400cm-1. 
Ovalbumin (OVA) loading and release: For the protein loading, 2 ml phosphate-buffered 
saline (PBS) containing 0.5 mg ml-1OVA and 2.5 mg ml-1 of the nanoparticles was shaking 
at 200 rpm at 4 °C for 6 h followed by centrifugation. The amount of protein adsorbed to 
nanoparticles was further quantified by measuring the absorbance of the supernatant at 
280 nm. The amount of protein adsorbed was calculated by the concentration difference 
between before and after adsorption. 
For the protein release test, nanoparticles after OVA loading were immersed in 2 ml of 
PBS solution and gently shaken at 100 rpm at 37 °C. At a predetermined time point, the 
solution was centrifuged and the supernatant was removed and replaced by the same 
amount of fresh PBS solution. The released amount of protein was quantified by the 
absorbance at 280 nm using UV-vis spectroscopy. 
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Tumor cell fragments (TF) adsorption and release: TF was used as the tumor antigen. 
B16F10 cells were dispersed in PBS (1×106 cells/mL), freezed at -80 °C, and lysed by a 
21G syringe for 20 times to get the TF.2 After centrifugation, the supernatant was collected 
and used for antigen adsorption test. Nanoparticles (6 mg) were mixed with 1 mL of TF 
solution at 4°C for 24 h. Then, the supernatant was used to test the tumor antigen content 
using bicinchoninic acid (BCA) assay kit (Thermo Fisher Scientific) according to the 
manufacturer’s protocol. The amount of tumor antigen adsorbed on nanoparticles was 
calculated from the decrease of tumor antigen concentration before and after adsorption, 
respectively. The nanoparticles adsorbed with TF (6 mg) was further dispersed in 1 mL 
PBS at 37°C with shaking. After different time points, 100 µL of the supernatant from each 
sample was taken to test the release and replace with 100 µL fresh PBS. 
Cytotoxicity: The RAW264.7 cell viability of the DMSHS-2S and DMOHS-2S were 
determined by the 3-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. Cells 
(6,000 per well) were seeded in a flat-bottomed 96-well plate and incubated at 37 °C and 
in 5% CO2. Cells were exposed to nanoparticles in a dose dependent manner for 48 h. 
Following treatment completion, cells were incubated with MTT reagent (10 μL/well volume 
from 5 mg/ml solution in PBS) for 4 h at 37 °C. Then 100 μL of dimethyl sulfoxide (DMSO) 
was added to each well and mixed to dissolve the formazan crystal. The optical density 
(OD) was recorded at 570 nm in a microplate reader and the percentage of residual cell 
viability was determined. All experiments were performed in triplicate. 
Cellular uptake using confocal microscopy: For confocal imaging of the cellular uptake 
of particle/OVA-FITC complex, RAW264.7 cells were seeded in a 6-well culture slide at a 
density of 3×105 cells per well. After 24 h, cells were treated with different 
nanoparticle/OVA-FITC complex at OVA-FITC concentration of 10 μg/mL in serum-
contained DMEM medium for 10 h. Before imaging, the endosome/lysosome was labelled 
with LysoTracker@Red (Invitrogen) according to the manufacturer’s instructions. At the 
end of staining process, the cells were washed twice with PBS and fixed with 10% 
formaldehyde. The cell nuclei were then stained with 4',6-diamidino-2-phenylindole (DAPI), 
and the uptake performance of nanoparticles was assessed using a confocal microscopy 
(LSM710, Zeiss). 
Cell uptake studies using flow cytometry: The cellular uptake was investigated using 
fluorescence activated cell sorting (FACS) analysis. RAW264.7 cells were seeded at 3.0× 
105 cells/mL in 6-well plate, and allowed to adhere overnight in a 37 °C, 5% CO2 
153 
 
incubator. Next day, the cells were treated with PBS, OVA alone, DMSHS-2S/OVA-FITC, 
DMOHS-1S/OVA-FITC, DMOHS-2S/OVA-FITC at OVA concentration of 10 μg/mL for 10 
h. Media was carefully removed and the dishes were gently washed three times with PBS. 
3 mL of PBS was added and the cells were collected in a 15 mL falcon tube. The cells 
were centrifuged at 1,000 g for 6 min at 4 °C. The supernatants were discarded and the 
pellets were resuspended in 4% paraformaldehyde and subsequently transferred into 
FACS tubes (Becton Dickinson, Franklin Lakes, NJ). BD LSRII analyser was used to 
determine the cell uptake. 
Animals: Female C57BL/6J (6~8 weeks of age) mice were purchased Biological 
Resource Facility, The University of Queensland (therapeutic model). All experiments were 
approved by The University of Queensland, and were carried out in accordance with the 
institutional guidelines for animal experimentation. 
Cytokine and effector memory T cell measurement: The mice were subcutaneously 
immunized with three injections of PBS, OVA (50 µg/mouse), OVA loaded DMSHS-2S (50 
µg OVA + 600 µg particle /mouse), OVA loaded DMOHS-1S (50 µg OVA + 600 µg particle 
/mouse) and OVA loaded DMOHS-2S (50 µg OVA + 600 µg particle /mouse) on day 0, 
day 3 and day 10. The mice were sacrificed on day 17 d. Spleens were collected and 
mechanically minced to make single cell suspensions. Splenocytes were cultured in RPMI 
1640+10% FBS, penicillin (100 U/mL) and streptomycin (100 μg/mL). The cells were 
stimulated with OVA (100 µg/ml) for 3 d. The amount of cytokines in the supernatant was 
tested using mouse interferon- γ (IFN-γ), interleukin-12 (IL-12), interferon- γ (IL-4) and 
tumour necrosis factor-α (TNF-α) enzyme-linked immunosorbent assay (ELISA) kits 
(Thermo Fisher Scientific) according to the manufacturer’s instructions. 
The percentage of CD4+ T cells, CD8+ T cells and memory T cells in the splenocytes was 
analysed using flow cytometer. Spleens were collected from immunized and control mice 7 
days after the third immunization. Spleens were mashed and passed through 70µm cell 
strainer to get the single cell suspension. The cells were washed twice in PBS plus 1 % 
bovine serum albumin (BSA) by centrifugation at 400 RCF (g) for 5 min. The resuspended 
cell pellet was treated with 1 mL of red blood cells (RBCs) lysis buffer for 5 min at 4 °C to 
lyse RBCs. The reaction was stopped by adding with the addition of RPMI 1640 
supplemented with 10% FBS, and the cells were washed twice. The isolated cells were 
stained with appropriate fluorochrome-conjugated anti-mouse antibodies: anti-mouse CD3, 
154 
 
anti-mouse CD4, anti-mouse CD8a, anti-mouse CD44, and anti-mouse CD62L 
(eBioscience), for cell surface markers and analysed by FACS.  
In vivo anti-tumor effect in a therapeutic immunization model: B16F10 cells (1×105 
cells/mouse) were injected subcutaneously into the right flank of mice (C57BL/6, female, 
6-8 weeks old) on day 0. Three vaccinisations of PBS, DMOHS-2S (600 µg/mouse), TF 
(1×105 cells/mouse), TF adsorbed DMSHS-2S (1×105 cells/mouse, 600 µg /mouse), TF 
adsorbed DMOHS-1S (1×105 cells/mouse, 600 µg /mouse) and TF adsorbed DMOHS-2S 
(1×105 cells/mouse, 600 µg /mouse) were performed on day 2, day 5 and day 9. Tumor 
growth was monitored for 35 days.  
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Figure S6.1. TEM images of ethane bridged DMONs (a), DMONs coated with a hybrid 
dendritic layer (b), DMONs coated with two hybrid dendritic layers (c), and the 
corresponding DMOHS-1S (d), DMOHS-2S (e) and DMOHS-3S (f) obtained via HF 
etching.  
TEM image reveals that the ethane bridged DMONs without coating have a uniform 
particle size of ~ 200 nm (Figure S1a). After one and two steps coating, the particle sizes 
of the organosilica nanoparticles increase to ~ 350 and then to ~ 530 nm (Figure S6.1b, c). 
After selective etching using hydrofluoric acid (HF) to remove the inorganic silica content, 
DMOHS-1S, DMOHS-2S and DMOHS-3S with sizes similar to their parent particles were 
obtained (Figure S1d-f). Notably, a certain degree of aggregation was observed in 
DMOHS-3S, which is likely due to the multiple coating steps. 
 
 
Figure S6.2. (a) N2 adsorption-desorption isotherm of DMOHS-1S, DMOHS-2S and 
DMOHS-3S and (b) their corresponding pore size distribution calculated from adsorption 
branch.  
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Figure S6.3. TEM image of DMSHS-2S obtained from calcination of DMOHS-2S.  
 
Figure S6.4. FTIR spectrums of DMOHS-2S and DMSHS-2S.  
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Fourier transform infrared (FTIR) spectra showed that the peaks at 2927, 2900, and 1411 
cm−1 in DMOHS-2S (assigned to the vibration of C-H bond in ethane group) disappeared 
in DMSHS-2S (Figure S6.4), indicating the complete removal of organic content. 
 
 
 
Figure S6.5. a) OVA adsorption capacity of different nanoparticles. The initial OVA 
concentration is 500 μg/mL, which is almost completely adsorbed by 2.5 mg/mL of 
nanoparticles. b) TF adsorption capacity of different nanoparticles. The initial TF is derived 
from 1×106/mL of B16F10 cells, equivalent to a protein concentration of 237 μg/mL as 
determined by BCA assay. More than 80% TF was absorbed by 6 mg/mL of nanoparticles. 
Release profile of OVA (c) and TF (d) from nanoparticles over 10 and 7 days, respectively. 
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Figure S6.6. Dose dependent cell viability of RAW264.7 cells after incubation with 
DMOHS-2S or DMSHS-2S for 48 h. 
 
 
 
Figure S6.7. FACS plots of the effector-memory T cells population in the splenocytes of 
mice immunized by various vaccine formulations. 
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Figure S6.8. FACS plots of the populations of CD4+ and CD8+ T cells in splenocytes of 
mice immunized by various vaccine formulations.  
 
 
Table S6.1. Structural parameters of nanoparticles measured by 
N2 adsorption-desorption.  
Sample Pore size 
(nm) 
Vp (cm3 
g−1) [a] 
SBET (m2 g-
1)[b] 
DMOHS-
1S 
14.4 nm 1.2 299 
DMOHS-
2S 
16.0 nm 1.1 360 
DMOHS-
3S 
17.7 nm 0.94 324 
[a] Total pore volume calculated at relative pressure (P/P0) of 
0.99. [b] BET surface area. 
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Chapter 7 
 
Hybrid Nanoreactors: Enabling an Off-the-
shelf Strategy for Concurrently Enhanced 
Chemo-immunotherapy 
The chapter has been published on Angewandte Chemie International Edition, 2018, 
doi:10.1002/anie.201807595 
 
Abstract: Immuno-suppressive tumours generally exhibit poor response to immune 
checkpoint blockade based cancer immunotherapy. In the present work, we report that 
rationally designed hybrid nanoreactors have integrated functions as Fenton catalysts and 
glutathione depletion agents for amplifying the immunogenic cell death and activating 
immune cells. A simple physical mixture of nanoreactors and chemodrugs in combination 
with immune checkpoint blockades show synergistically and concurrently enhanced chemo-
immunotherapy efficacy, inhibiting the growth of both treated primary immuno-suppressive 
tumours and untreated distant tumours. The “off-the-shelf” strategy uses in situ generated 
tumour antigens and avoids cargo loading, representing a substantial advance in 
personalized nanomedicine for clinical translation. 
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7.1 Introduction 
Blocking the programmed death-1/programmed death-ligand 1 pathway via immune 
checkpoint blockades (ICB) to recover the force of immune systems to eliminate tumour 
cells has gained remarkable success in treating various types of cancers, including 
melanoma and non–small cell lung cancer.[1] However, ICB exhibited disappointing clinical 
outcomes for immunosuppressive tumours, such as breast cancer, wherein the pre-
infiltrated immune cells and the exposure of damage-associated molecular patterns 
(DAMPs) on tumour cells are rather limited.[2] To reverse the immuno-suppressive tumour 
microenvironment, the induction of immunogenic cell death (ICD) through the treatment of 
chemodrugs is one promising solution.[3] The elevated intracellular reactive oxygen species 
(ROS) is one major cause of ICD, during which apoptotic cells release tumour associated 
antigens and expose DAMPs to activate an adaptive immune response.[4] Given the weak 
ICD induced by chemodrugs alone, many strategies have been developed to convert ICD 
into cancer immunotherapy with heavy reliance on photosensitisers and/or immune-
stimulatory reagents (e.g., toll-like receptor agonists).[5] These strategies, however, suffer 
from complicated manufacturing process, severe side effects and high-cost, thus hindering 
their clinical use. In this context, developing a simple strategy to promote the chemodrug 
induced immune response and simultaneously avoid the adverse effects caused by various 
therapeutic agents remain a central task in the field of cancer immunotherapy. 
Mesoporous silica based nanomaterials are excellent supports to enable highly dispersed 
reactive sites in the mesostructure for accomplishing superior reaction efficiency.[6] 
Particularly, dendritic mesoporous silica materials with a central-radial pore structure and 
highly accessible surface areas have exhibited appealing performance as supports of metal 
species for heterogeneous catalysis due to the unique architecture enabled free diffusion of 
reactants and/or products.[7] Inspired by the recent progress in silica-based catalytic 
systems,[8] we suspect that these nanoreactors with diverse functionalities would hold great 
potential in cancer immunotherapy, which, to our knowledge, remains largely unexplored.  
Herein, we have designed intelligent nanoreactors that are capable of triggering Fenton 
reaction and glutathione depletion for amplifying the immunogenic cell death and activating 
immune cells, leading to concurrently potentiated chemo/immunotherapy. These 
nanoreactors are constructed with a large pore dendritic structure and a hybrid silica 
framework incorporated with Fenton’s reagents (Cu2+) and tetrasulfide groups (Scheme 
7.1a), which respectively produce cytotoxic reactive oxygen species (ROS) and consume 
the antioxidant glutathione (GSH) in the doxorubicin (DOX) treated cancer cells, thus 
collectively result in elevated intracellular oxidative stress and remarkably improved ICD 
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(Scheme 7.1b i). Moreover, these nanoreactors with ROS-producing capability and 
hydrophobicity are intrinsically immunogenic, exhibiting excellent immune-adjuvant activity 
for stimulating the maturation of antigen presenting cells (APC) (Scheme 7.1b ii). As such, 
the nanoreactors/DOX formulation forms remarkable synergism with ICB (PD-L1 antibody), 
exhibiting excellent anticancer performance for both treated primary tumour and untreated 
distant tumours. Distinct from conventional drug delivery systems, this “off-the-shelf” 
strategy based on physical mixture of chemodrugs and nanoreactors dramatically simplifies 
the fabrication process by avoiding cargo loading, release control and surface 
functionalization, thus greatly merits their clinical translation.  
 
Scheme 7.1. (a) The nanostructure and composition of mesoporous organosilica 
nanoparticles. (b) After mixing with DOX for local administration, the nanoreactors are able 
to (i) amplify ICD, (ii) acting as immune-adjuvants to stimulate the maturation of immune 
cells, accomplishing synergistic effects with ICB (PD-L1 antibody) for effective inhibition of 
both treated primary tumours and non-treated distant tumours. 
7.2 Results and discussion 
We previously reported the synthesis of dendritic mesoporous organosilica nanoparticles 
(DMONs) with tunable organic groups.[9] Here, we attempt to move one step further to co-
incorporate tetrasulfide bond and metal species, i.e, copper ions, into the hybrid framework 
of DMONs to yield intelligent nanoreactors named as Cu-DMONs. To this end, we chose 
tosylate anions[10] without metal-coordinating capability as the structural-directing agents 
(SDA) to avoid their interference on the metal incorporation, resulting in a bluish product due 
to the presence of Cu2+ (Figure S7.1). Monodispersed Cu-DMONs with radial large pore 
structures can be clearly visualized by scanning electron microscope (SEM) and 
transmission electron microscope (TEM) (Figure 7.1 a-c). Energy-dispersive X-ray 
spectroscopy (EDS) mapping results showed the homogeneously distributed copper and 
sulfur in hybrid framework (Figure 7.1d). The copper content determined by inductively 
coupled plasma optical emission spectrometry (ICP-OES) was 7 µg/mg. As we expected, 
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the presence of Cu2+ in the framework significantly increased the ROS-generation property, 
exhibiting an approximately five-fold increase in the production of hydroxide radicals 
compared to that produced by Cu2+-free dendritic organosilica nanoparticles (DMONs) as 
measured by electron paramagnetic resonance (EPR) (Figure 7.1e).  
 
Figure 7.1 (a) SEM, (b) TEM, (c) dark-field scanning TEM and (d) EDS elemental mapping 
images of Cu-DMONs. (e) EPR spectra of DMONs and Cu-DMONs. (f) Time-dependant 
cellular uptake of silicon and copper by RAW264.7 macrophages and 4T1 cancer cells 
measured by inductively coupled plasma optical emission spectrometry (ICP-OES). 
The N2 adsorption-desorption isotherm and pore size distribution  indicates that the pore 
volume, Brunauer–Emmett–Teller (BET) surface areas and pore size slightly reduced after 
incorporating copper ions in the framework (Figure S7.2 a, b; Table S7.1). 29Si solid-state 
NMR spectrum of DMONs and Cu-DMONs exhibits two peaks at -103 and -112 ppm, 
corresponding to Q3 [Si(OSi)3(OH)] and Q4 [Si(OSi)4] species generated from TEOS, 
respectively (Figure S3). In addition, the two peaks at -59 and -67 ppm are attributed 
respectively to T2 [C–Si(OSi)2(OH)] and T3 [C–Si(OSi)3] species originated from BTES. 
Notably, the Cu incorporation led to slight shift of the T1 peak from -51 to -49 ppm, suggesting 
that the Cu2+ cations were mainly attached to the silanol groups of [C–Si(OSi)(OH)2].  
The leaching of Cu2+ is a major concern in biosafety. We thus studied the Cu2+ release profile 
at pH 7.4 + 2 µM GSH and pH 5 + 2 mM GSH to simulate the extracellular fluid and 
intracellular conditions, respectively (Figure S7.4). The leaching of copper ion was negligible 
at the former condition while reach approximately 44.3% under the latter condition after 3 
days incubation, which can be attributed to the weakened electrostatic interaction between 
Cu2+ and silanol groups under acidic environment, and can also be associated with the GSH 
induced disintegration of the nanostructure (see discussions for Figure S7.7 below). These 
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results suggest that the incorporation approach can minimize the leaching of copper ions at 
physiological condition and reduce their potential biological risks. Our nanoreactors showed 
very low cytotoxicity against RAW264.7 and 4T1 cells even at a high concentration of 160 
µg/ml (Figure S7.5), suggesting good biocompatibility. Moreover, after incubation of 
RAW264.7 or 4T1 cells with Cu-DMONs, the intracellular copper and silicon content were 
significantly elevated, suggesting the superior cellular uptake efficiency of the nanoparticles 
(Figure 7.1f). Owning to the -S-S-/GSH redox reaction, the intracellular GSH level was 
significantly reduced by tetrasulfide bond incorporated DMONs, and a further GSH-depleting 
effect was observed for Cu-DMONs in both 4T1 and RAW264.7 cell lines (Figure S7.6), 
which could be as a consequence of the Cu2+ mediated ROS production. We also utilized 
Bio-TEM to investigate the intracellular biodegradability of Cu-DMONs. As shown in Figure 
S7.7, Cu-DMONs can be broken into debris after incubating with 4T1 cells for 5 days due to 
the high GSH level of cancer cells, indicating their excellent biodegradability. We employed 
confocal laser scanning microscopy (CLSM) to directly visualize the intracellular oxidative 
stress using dichlorodihydrofluorescein diacetate (DCFH-DA) as the probe, which can be 
oxidized by ROS to generate green fluorescence.  While cells treated with Cu-DMONs, DOX 
or DMONs/DOX exhibited a certain degree of increased fluorescence intensity compared to 
control group, the Cu-DMONs/DOX mixture showed the brightest fluorescence (Figure 
7.2a), indicative of a significantly elevated oxidative stress. The intracellular oxidative stress 
were quantified in Figure 7.2c. 
Given the critical role of ICD of tumour cells in alerting the immune system, we sought to 
investigate whether the nanoreactors could facilitate such type of death.  Calreticulin (CRT) 
proteins have been widely recognized as the biomarker to characterize ICD.[11] Under a high 
oxidative stress microenvironment, CRT will translocate from endoplasmic reticulum lumen 
to the external membrane of dying cells where they act as an “eat me” signal to initiate the 
uptake and processing of tumour associated antigens upon cell apoptosis by antigen 
presenting cells (APCs).[3] CLSM images also showed that the stimulation of Cu-
DMONs/DOX induced the highest level of translocation of CRT on the cell membrane 
compared to other formulations (Figure 7.2b). Flow cytometry analysis showed that more 
than 90% cells treated with DOX or DOX/nanoparticles mixture were CRT-positive (Figure 
7.2d), which is consistent with previous reports that DOX are capable of inducing ICD. 
However, Cu-DMONs/DOX induced the highest amount of exposed CRT as indicated by 
the mean fluorescent intensity (MFI) (Figure 7.2e), implying a significantly amplified ICD. 
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We also found that taking the advantage of the Fenton’s reaction and GSH depletion, these 
nanoreactors can significantly improve the therapeutic efficacy of DOX. DOX has been 
known to be able to generate H2O2 intracellularly through the cascade reactions of 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and superoxide dismutase 
(SOD).[12] These nanoreactors are able to convert intracellular H2O2 to its downstream highly 
cytotoxic ROS through Cu2+ mediated Fenton’s reaction, which in conjunction with the GSH 
depletion would significantly improve the oxidative damage of DOX. As shown in Figure 7.2e 
and Figure 7.2f, the viability test of 4T1 breast cancer cell exposed to different formulations 
have clearly suggested the improved cell inhibition performance of DOX assisted by Cu-
DMONs in a drug dosage and particle dosage dependant manner. Moreover, the Annexin 
V/Propidium iodide (PI) staining assay indicates an enhanced apoptosis percentage of Cu-
DMONs/DOX compared to other groups (Figure S7.8). These results collectively suggest 
that our designed nanoreactors were capable of improving the efficacy of chemodrugs.  
 
Figure 7.2. (a) CLSM images for analysing the intracellular ROS level. The green 
fluorescence is generated by the oxidized ROS probe. (b) CLSM images for visualizing the 
CRT exposure on the surface of membrane upon treatment of different formulations for 6 h. 
(c) Quantitative measurement of intracellular ROS level using micro-plate reader. (d, e) 
Quantitative analysis of CRT exposure level using flow cytometry. (f) 4T1 cell viability after 
24 h treatment of different formulations. The weight ratio of DOX/nanoparticles is 1/10. (g) 
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4T1 cell viability after 24 h treatment of nanoparticles with various concentration. The DOX 
concentration is fixed at 2 µg/ml.   
We then evaluated the inherent immune-stimulatory activity of the nanoreactors. Extensive 
studies have shown that both of the ROS and hydrophobicity can act as a “danger signals” 
to cause inflammation and activate the maturation of immune cells.[13] We speculated that 
the nanoreactors integrates Fenton’s reagents, GSH-depleting capability and hydrophobic 
alkyl chain could possess potent adjuvanticity. After incubation of nanoparticles with 
splenocytes, Cu-DMONs induced the highest expression levels of CD80 and CD86 in APCs 
including macrophages and dendritic cells, suggesting these nanoreactors, in the absence 
of any antigens or immune-stimulatory reagents, can efficiently activate the maturation of 
macrophages and dendritic cells (Figure 7.3 a-d).  The secretion of significantly increased 
levels of pro-inflammatory cytokines including TNF-α, IL-12 and IL-1β, further leads us to 
conclude that Cu-DMONs are inherently immunogenic (Figure 7.3 e-g). 
 
Figure 7.3. Flow cytometry analysis of CD80 and CD86 expression on splenocytes treated 
with PBS or different nanoparticles. Macrophages were marked by F4/80 antibody (a, b) and 
DCs by CD11C antibody (c, d). (e-g) Secretion of cytokines from RAW264.7 macrophages 
treated with different nanoparticles. 
The encouraging in vitro results led us to investigate the in vivo antitumor performance. We 
firstly studied the anticancer activity in a unilateral tumour model. The nanoreactors were 
mixed with DOX and followed by intratumoural administration.   As shown in Figure 7.4a, 
mice treated with Cu-DMONs/DOX exhibited remarkably delayed tumour growth compared 
to those treated with DMONs/DOX, DOX or phosphate buffered saline (PBS), highlighting 
the critical roles of Fenton reagents and the tetrasulfide bonds in the nanoreactors in 
improving chemotherapy. Moreover, we found the concentrations of interferon (IFN)-γ in the 
serum of mice treated with Cu-DMONs/DOX were significantly increased compared to other 
groups (Figure 7.4b), suggesting the successful induction of cytotoxic T lymphocytes 
mediated cellular immunity. However, the tumours progression was observed 4 days post 
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administration of Cu-DMONs/DOX, indicating that breast cancer cells were able to evade 
the immune surveillance.   
It is expected that the nanoreactor based formulation can work synergistically with ICB to 
generate systemic immune response for supressing both treated primary tumours and 
distant tumours that did not receive any direct chemodrug treatment. To this goal, we 
established a bilateral tumour model, in which two tumours were simultaneously inoculated 
in the right and left flank of mice. The right ones were defined as primary tumours which 
were subject to treatment, while the left ones were defined as distant tumours that received 
no treatment. As shown in Figure 7.4c, the combination of DOX and PD-L1 antibody only 
showed limited inhibition activity for the primary tumour due to the immune-suppressive 
tumour microenvironment of breast cancer caused low response to ICB. While 
DMONs/DOX/PD-L1 and Cu-DMONs/DOX showed an enhanced primary tumour inhibition 
performance, the combination of Cu-DMONs/DOX/PD-L1 exhibited the most remarkable 
chemo/immunotherapy for the primary tumours, suggesting the synergism of PD-L1 
antibody with the Cu-DMONs/DOX to potentiate T cell immunity. Interestingly, Cu-
DMONs/DOX/PD-L1 elicited the strongest therapeutic response across all the treatment 
groups in delaying the growth of distant tumours (Figure 7.4d), indicative of a promoted 
abscopal effect. Furthermore, we found that the infiltration of cytotoxic T lymphocytes (CTLs) 
in the distant tumours increased remarkably by the Cu-DMONs based treatment (Figure 
7.4e). Meanwhile, the level of TNF-α, an important indicator of antitumour immunity, in the 
serum of mice treated with Cu-DMONs/DOX/PD-L1 was significantly higher than other 
groups (Figure 7.4f). 
To investigate the possible migration of the nanoparticles from the primary tumour to the 
distant tumour, both of the primary and distant tumors were collected 12 days post 
intratumoral injections. The intratumoural silicon and copper contents (injected dose per 
gram, ID/g) were measured via ICP-OES (Figure S7.9). Most of the nanoparticles were 
retained in the primary tumours (> ~50% ID/g), while the contents of silicon and copper 
detected in the distant tumours were negligible (~ 0.43% ID/g). Generally, the optimal size 
of nanoparticles to rapidly navigate between the tumor interstitium is less than 100 nm, while 
the movement of larger ones, e.g, ~210 nm sized nanoparticles in our case, is retarded in 
the extracellular matrix which impedes the intravasation.14 There could be a small portion of 
nanoparticles, either in intact or degraded forms, enters into the systemic circulation. 
However, given that neither passive (e.g polyethylene glycol) nor active targeting moieties 
(e.g. antibodies, aptamers) were functionalized on the nanoparticles, the accumulation of 
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the intravasated nanoparticles in the distant tumour was very limited. Noting that the copper 
distribution test were only carried out after day 10, further investigation at more time points 
as well as under different dosages would be valuable in the future to obtained a 
comprehensive understanding on the ion migration behaviour. These results strongly 
support that the inhibition of the distant tumour is not mainly contributed by the migration of 
nanoparticles. Instead, given the significantly increased CTL infiltration (Figure 7.4e) and 
TNF-α secretion level (Figure 7.4f), the systemic immune response is the major cause of 
such a superior abscopal effect. Taken together, our results indicate that Cu-DMONs can 
reverse the immunosuppressive tumour microenvironment and potentiate potent 
chemotherapy as well as systemic antitumour immunity.  
 
Figure 7.4. a) Tumour-growth curves of mice treated with chemo-therapy in a unilateral 
tumour model and b) the IFN-γ level in the serum. c-d) Tumour-growth curves of mice treated 
with chemo-immuno-therapy in a bilateral tumour model. The primary tumours were treated 
with different formulations while the distant tumours received no treatment. e) The infiltration 
of CTLs (defined as CD3+ CD8+) in the distant tumour tissue. f) The TNF-α level in the serum 
(n = 5). The black arrows indicate the injection of PBS, DOX or nanoparticle/DOX, while red 
ones indicate the injection of PD-L1 antibody.  
It is noted that the use of equivalent Cu2+ ions showed much weaker antitumour activity 
compared to the nanoreactors based formulation (Figure S7.9), indicative of the critical role 
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of nanoparticles in the therapeutic efficacy. These results can be interpreted from two 
aspects: Firstly, it is well known that excessive free Cu2+ can be readily pumped out from 
cells through the ATPase pathway,15 while their release in a sustained manner from 
nanoparticles can dramatically improve the intracellular accumulation efficiency and 
facilitate the Fenton reaction. Secondly, the nanoparticles with intrinsic immuno-adjuvant 
activity can effectively activate the immune cells for inhibition of both primary and distant 
tumours, which cannot be achieved by free copper ions.  
7.3 Conclusion 
In summary, we have constructed Cu-DMONs as intelligent nanoreactors to simultaneously 
trigger Fenton’s reaction and GSH depletion, thereby amplifying the ICD and activating the 
immune system for concurrently enhanced chemo-immunotherapy. We showed that, those 
nanoreactors with intrinsic hydrophobicity and oxidative stress-producing capacity not only 
dramatically improved the cell inhibition activity of DOX and promoted CRT exposure on 
cancer cells, but also act as potent immuno-adjuvants in stimulating the maturation of 
immune cells and the secretion of pro-inflammatory cytokines. As such, the nanoreactors 
based chemotherapy formulation is capable of reversing the immune-suppressive tumor 
microenvironment, resulting in robust anticancer activity in synergism with checkpoint 
blockades for both treated primary tumours and non-treated distant tumours, confirming a 
superior chemoimmunotherapy and promoted abscopal effect. In addition to the superior 
therapeutic efficacy, our strategy is promising in overcoming other two major obstacles in 
conventional nanomedicines. Firstly, our strategy replies on a simple physical mixture of 
nanoparticles and chemodrugs, which dramatically simplifies the manufacturing procedure 
due to the exemption of drug loading, release control and materials functionalization. 
Secondly, the immunotherapeutic outcome of traditional strategies is highly dependent on 
the choice of suitable antigens, which perhaps account for many failures in clinical trials 
since the tumour-cell diversity was hard to be taken into consideration. Our strategy 
successfully utilized the in situ dead cancer cells as the antigens to elicit robust antitumor 
immunity in a patient-specific manner, thus pave the way in developing precision medicine 
with personalized cancer therapy. 
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7.5 Supporting information 
Experimental Section  
Chemicals: Cetyltrimethylammonium p-toluenesulfonate (CTAT), tetraethyl orthosilicate 
(TEOS), Bis[3-(triethoxysilyl)propyl] tetrasulfide (BTES), triethanolamine (TEA), copper (II) 
nitrate trihydrate and doxorubicin (DOX) were purchased from Sigma-Aldrich. PD-L1 
antibody were purchased from Biolegend. All chemicals were used as received without 
purification. 
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For biology experiments: RPMI1640, Dulbecco’s Modified Eagle Medium (DMEM) and 
trypsin-EDTA (0.25%) were purchased from GIBCO. Fetal bovine serum (FBS) were 
purchased from Sigma-Aldrich. 4T1 breast cancer cells and RAW 264.7 macrophages were 
purchased from ATCC (American Type Culture Collection).  
Materials Synthesis:  Cu2+ and tetrasulfide bond co-incorporated dendritic mesoporous 
organosilica nanoparticles (Cu-DMONs) were synthesized as follows. In a typical synthesis, 
0.034 g of TEA and 240 mg CTAT were added to 11.5 mL of water and stirred gently at 80 
°C in an oil bath under a magnetic stirring for 0.5 h. Then, 1 mL of Cu(NO3)2 solution (10 
mg/mL), a mixed solution of 1 mL TEOS and 0.8 mL BTES were added to the water-CTAT-
TEA solution with vigorous stirring for 16 h. The products were collected by high speed 
centrifugation (14,000 RCF (g), 5 mins) and washed three times with ethanol and water to 
remove the residual reactants, and dried in vacuum overnight.  To remove the surfactants, 
50 mg products were added in 20 mL NaCl/MeOH solution (10 mg/mL) and stirred at 45 °C 
for 8 h and repeated three times before washed thoroughly with ethanol/water and dried. 
For the synthesis of tetrasulfide bond incorporated dendritic organosilica nanoparticles 
(DMONs), the procedure is similar to that of Cu-DMONs, the only difference was that 1 mL 
of water rather than 1 mL of Cu(NO3)2 solution was added at the second step. 
Characterizations: The morphologies of the samples were observed using a JEOL JSM 
7800 field emission scanning electron microscope (FE-SEM). Transmission electron 
microscopy (TEM) images were obtained with a JEOL 1010 operated at 100 kV. EDS 
mapping was conducted from JEOL 2100 operated at 200 kV. Nitrogen adsorption–
desorption isotherms were measured at 77 K using a Micromeritics ASAP Tristar II 3020 
system. The samples were degassed at 393 K overnight on a vacuum line. The pore size 
distribution curve was derived from the adsorption branch of the isotherms using the Barrett–
Joyner–Halanda (BJH) method. The Brunauer–Emmett–Teller (BET) method was utilized to 
calculate the specific surface areas. The total pore volume was calculated from the amount 
adsorbed at a maximum relative pressure (P/P0) of 0.99. 29Si CPMAS NMR spectra were 
measured by a solid state Bruker Advance III spectrometer.  
Extracellular ROS detection via Electron Paramagnetic Resonance (EPR): Free radicals 
generation was monitored by EPR (Elexsys E500 CW, Bruker) using 5, 5-dimethyl-pirroline-
N-oxide (DMPO) as a spin-trapping agent. The spectra were recorded at room temperature. 
Typically, fresh nanoparticles (DMONs, Cu-DMONs) at 1 mg·mL-1 were mixed with DMPO 
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(250 mM) and freshly diluted H2O2 (100 mM), after incubation at room temperature for 5 min 
under dark, the spectra were recorded.  
Cytotoxicity of nanomaterials: The 4T1 cell viability of the DMONs and Cu-DMONs were 
determined by the MTT colorimetric assay. Cells (8000 per well) were seeded in a flat-
bottomed 96-well plate and incubated at 37 °C and in 5% CO2. Cells were exposed to 
nanoparticles in a dose dependent manner for 24 h. Following treatment completion, cells 
were incubated with MTT reagent (10 μL/well volume from 5 mg/ml solution in PBS) for 4 h 
at 37 °C. Then 100 μL of dimethyl sulfoxide (DMSO) was added to each well and mixed to 
dissolve the formazan crystal. The optical density (OD) was recorded at 570 nm in a 
microplate reader and the percentage of residual cell viability was determined.  
Cell viability test: The cell viability was measured using MTT ((3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay. Briefly, 4T1 cancer cells were seeded in 96-well 
plates at a density of 8,000 cells per well over night in normoxia. Next day, cells were treated 
with PBS, DOX, DMONs/DOX, Cu-DMONs/DOX at various concentrations. After 24 h 
incubation, the cell viability was determined. All experiments were performed in triplicate. 
Cell uptake: To quantitatively compare cellular uptake of different silica nanoparticles, 3×105 
RAW264.7 cells per well were seeded in a 6-well plate and cultured for 24 h. Cells were 
incubated with Cu-DMONs (40 μg/ml) for 6 h followed by washing with PBS and harvested 
with trypsin. After centrifugation, the cell pellets were washed twice with PBS before cell 
number counting. The cells were then lysed by cell lysis buffer (Cell Signaling Technology) 
and the supernatants (containing cell components) were removed by centrifugation at 4,000 
RCF (g) for 10 minutes, followed by two washes with PBS. Aqueous NaOH solution (1 M) 
was then added to allow dissolution of the nanoparticles with ultrasound sonication. The 
silicon concentrations in the final solutions were measured by inductively coupled plasma 
optical emission spectrometer (ICP-OES) with a Vista-PRO instrument (Varian Inc, 
Australia). All experiments were performed in triplicate. 
Intracellular ROS measurement: Intracellular ROS level was investigated by using 2′,7′-
dichlorofluorescein diacetate (DCF-DA) as a fluorescent probe. Briefly, 4T1 cells were 
seeded on 6-well plates at a density of 1×105/well, then incubated in complete medium at 
37 °C. The next day, the culture medium was removed and washed twice with PBS followed 
by incubation with fresh media containing nanoparticles (20 µg mL-1) or DOX (2 µg mL-1) for 
6 h.  Then 10% v/v (100 μM) DCF-DA in PBS was added for 15 min at 37 °C. Samples were 
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washed with PBS and examined under a CLSM to observe green fluorescence with 
excitation and emission peak of 495 and 529 nm, respectively. The intensity of fluorescence 
was quantified by microplate reader using a 96 well black microplate following a similar 
protocol.  
Intracellular GSH measurement: 4T1 cancer cells were seeded in black 96-well plates at a 
density of 8,000 cells per well. After 24 h, various concentrations of Cu-DMONs were added 
and incubated for 12 h. The cellular GSH probe (Cell Signaling Technology) was then added 
according to the manufacture’s protocol and the fluorescent intensity was measured using 
the microplate reader. 
In vitro CRT detection: CRT exposure induced by Cu-DMONs was evaluated by flow 
cytometry and confocal laser scanning microscopy (CLSM). For flow cytometry analysis, 
4T1 cells were treated with nanoparticles (20 µg mL-1) or DOX (2 µg mL-1) for 6 h. Then the 
cells were washed and incubated with Alexa Fluor 488-CRT antibody for 0.5 h before 
analysed by flow cytometer. For CLSM analysis, cells were incubated with Alexa Fluor 488-
CRT antibody for 0.5 h, fixed with Paraformaldehyde (0.4%), stained with DAPI, and 
observed under CLSM using 405 nm and 488 nm lasers for visualizing nuclei and CRT 
exposure on the cell membrane, respectively. 
Apoptosis assay: Apoptosis of 4T1 cells was examined using the Annexin V-FITC/PI 
Apoptosis Detection Kit (BD Biosciences). Briefly, the cells were seeded in the 6-well plates 
at the density of 1 × 105 cells per well. After 24 h, the cells were incubated with PBS, DOX, 
DMONs/DOX, Cu-DMONs/DOX (nanoparticles: 20 µg mL-1; DOX: 2 µg mL-1) for 4 h. The 
subsequent procedures were performed in accordance with the manufacturer’s protocol and 
determined using flow cytometry.  
Ex vivo maturation of APCs:  Spleens from naïve mice were passed through a cell strainer 
to obtain single cell suspension, and red blood cells were lysed using erylysis buffer (Sigma–
Aldrich). The resulting cells were seeded in a 96-well plate at a density of 2×105 cells/well 
in DMEM media supplemented with 10% FBS, 100 U/ml penicillin, and 100 mg/ml 
streptomycin (Gibco®, Life technologies). PBS, DMONs or Cu-DMONs were added to the 
wells and incubated for 24 h. The adherent cells were scraped from the plate and incubated 
with Fc-block for 20 min at 4 °C, centrifuged and resuspended in a buffer containing CD11c, 
F4/80, CD80, CD86 (BioLegend) antibodies for 30 min at 4 °C. The cells were then 
176 
 
centrifuged and resuspended in 0.5 mL of FACS buffer (PBS, 0.02% sodium azide, 0.5% 
BSA) and analyzed using LSR II flow cytometer (BD Biosciences).  
In vitro cytokine secretion measurement: The RAW264.7 macrophages were seeded in 12 
well plate at a density of 2×105 cells/well. For measuring TNF-α, the cells were treated with 
nanoparticles are concentration of 100 µg mL-1 for 6 h and the supernatant were collected 
before analysed by ELISA. For measuring IL-1β and IL-12, the cells were pre-treated with 
lipopolysaccharide (LPS, 25 ng/ml) for 3 h before exposure to 100 µg mL-1 nanoparticles for 
6 h. 
Animals: Female BALB/c (6~8 weeks of age) mice were purchased Biological Resource 
Facility, The University of Queensland. All experiments were approved by The University of 
Queensland, and were carried out in accordance with the institutional guidelines for animal 
experimentation. 
In vivo anti-tumour studies:  For xenograft unilateral tumour model, 2×106 4T1 cells in 
phosphate-buffered saline (PBS) was subcutaneously injected in the right flank of the 
BALB/c mice on day -7. The mixtures of nanoparticles (25 mg/kg) and DOX (2.5 mg/kg) 
were intratumourally injected on days 0, 2 and 4. Eyebleed was conducted on day 5 to 
measure the IFN-γ in the serum using the enzyme-linked immunosorbent assay (ELISA). 
The tumour growth was monitored every other day and the tumour volume (V) was 
calculated based on V = 0.5 × Length × Width2.  
For xenograft bilateral tumour model, 2×106 4T1 cells were suspended in PBS and 
subcutaneously injected in the right flank of BALB/c mice on day -7 (primary tumours) and 
4×105 4T1 cells were subcutaneously injected in the left flank on day -5 (distant tumours). 
The right-flank tumours (primary tumours) were intratumourally injected with different 
formulations (25 mg/kg of nanoparticles, 2.5 mg/kg of DOX) on days 0, 2 and 4. The 
checkpoint blockade PD-L1 antibody (2.5 mg/kg) were intraperitoneally injected into the 
animals on days 1, 3 and 5.  Eyebleed was conducted on day 6 to test the level of TNF-α in 
the serum using ELISA. The mice in PBS group were euthanized on day 10 (Mice with the 
total volume of tumours more than 1000 mm3 need to be euthanized according to the 
institutional animal ethics) and the mice in other groups were euthanized on day 12. The 
distant tumours were collected to analyse the infiltration of T cells.      
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In vivo CTL infiltration test: Distant tumours were harvested on days 10–12 post-tumour 
inoculation for a flow cytometric analysis of the in vivo experiments. Single-cell suspensions 
were prepared via passing through a cell strainer. The cells were washed twice in PBS plus 
1 % BSA by centrifugation at 400 RCF (g) for 5 min. The resuspended cell pellet was treated 
with 1 mL of red blood cells (RBCs) lysis buffer for 5 min to lyse RBCs. The reaction was 
stopped by adding RPMI 1640 supplemented with 10% FBS, and the cells were washed 
twice in PBS plus 1 % BSA.  Trypan blue was applied for live/dead cell discrimination during 
cell counting. Before the surface staining, the samples were incubated with Fc Block for 10 
min on ice, followed by surface staining with anti-mouse CD3 CD8 and CD4 on ice for 20 
min. Wash again with PBS and analyse in flow cytometry.     
Intratumoral nanoparticle content: In a bilateral tumour model, PBS or Cu-DMONs/DOX 
were intratumorally injected into the primary tumour and PD-L1 antibody were injected 
intraperitoneally on days 0, 2, 4. The dose of Cu-DMONs, DOX and PD-L1 antibody were 
25 mg/kg, 2.5 mg/kg and 2.5 mg/kg, respectively. After 12 days, the primary and distant 
tumors were collected, cut into small pieces and dissolved in concentrated nitric acid and 
10% hydrofluoric acid. The silicon and copper contents in each tissue were quantified by 
ICP-OES and calculated based on the injection dose and weight of tissues. The final values 
were obtained by subtracting the silicon/copper contents in the control groups. 
Statistical analysis: Tumour growth over time was compared by two-way ANOVA. The P 
value for other data was calculated by t-test. n.s.= non-significant, *P < 0.05, **P < 0.01, 
***P<0.005, ****P<0.001. 
 
 
Figure S7.1. Digital image of Cu-DMONs post surfactants extraction. 
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Figure S7.2. The N2 adsorption-desorption isotherm and pore size distribution of DMONs 
and Cu-DMONs. 
 
 
Figure S7.3. 29Si solid-state NMR spectrum of DMONs and Cu-DMONs 
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Figure S7.4. Cu2+ leaching profile of Cu-DMONs at simulated extracellular (pH 7.4 + 2 µM 
GSH) and intracellular conditions (pH 5.0 + 2 mM GSH).  
 
 
Figure S7.5. Cell viability of RAW264.7 and 4T1 after incubation with various concentrations 
of Cu-DMONs for 48 h.  
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Figure S7.6. Intracellular GSH level of RAW264.7 (a) and 4T1 (b) cells after incubation with 
100 µg/ml of DMONs or Cu-DMONs for 12 h. 
 
 
 
Figure S7.7. Bio-TEM of Cu-DMONs after incubation with 4T1 cell for 1 day (a), 2 days (b), 
and 5 days (c). Scale bar: 200 nm. 
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Figure S7.8. Flow cytometry analysis of 4T1 cell apoptosis induced by various formulations 
for 4 h using the Annexin V-FITC/PI staining. 
 
 
Figure S7.9. The intratumoral Si (a) and Cu (b) content 12 days post injections.  
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Figure S7.10. Tumour-growth curves of mice treated with chemo-immuno-therapy in a 
bilateral tumour model. The primary tumours were treated with different formulations while 
the distant tumours received no treatment. 
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Chapter 8 
 
Conclusions and Outlook 
 
 
 
8.1 Conclusions 
Design of safe and efficient nanosystem for drug delivery is the central mission for scientists 
to develop the next generation of nanomedicines. In this thesis, we have rationally 
engineered the composition and the nanostructure of mesoporous silica based 
nanoparticles for impart interesting properties, such as biodegradability, glutathione 
depletion ability, immuno-adjuvant activity and catalytic activity for biomedical applications. 
This has been achieved via a universal anion assisted synthetic approach, which leads to 
the successful incorporation of diverse functional groups, including organic moieties and/or 
metal ions, into the hybrid silica framework and simultaneously create a large central-radial 
pore structure for high therapeutics encapsulating efficiency. We have demonstrated the 
superior delivery performance of these engineered nanoparticles with unique features for 
cancer therapy. The primary conclusions of this thesis can be summarized as below:  
1. An anion assisted synthetic approach has been developed for fabricating mesoporous 
hybrid organosilica nanoparticles with a unique dendritic large pore structure. Moreover, 
we found that these nanoparticles possess a composition gradient in the framework: the 
inner part is silica rich while the outer part is organosilica rich. By utilizing the relatively 
higher stability of organosilica, the inner part can be selectively etched to produce a 
hollow cavity. These organosilica nanoparticles exhibited low cytotoxicity and good 
hemocompatibility, thus highly promising for drug delivery applications. 
2.  To reduce the potential risks of nanoparticles on accumulating in major organs and the 
off-targeted delivery to damage normal cells, we developed a smart large pore 
organosilica nanoparticles by incorporating bio-active disulfide bonds into the framework. 
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Taking the advantage of the unique architecture and the composition, these smart 
nanocarriers are able to respond to the higher intracellular GSH level of cancer cells than 
that of normal cells and selectively degrade and release therapeutic protein in the former 
case, leading to targeted cancer therapy. This work for the first time demonstrated that 
silica based nanoparticles can differentiate the minor difference of intracellular 
environments of cancer cells and normal cells, thus providing a safe and efficient platform 
for drug delivery. 
3. Extended from the previous concept, we fabricated a disulfide incorporated yolk-shell 
structured mesoporous organosilica nanoparticles with a unique shell-to-yolk stepwide 
degradability. Based on this appealing property, we designed a cascade delivery system 
by integrating a hypoxia-activated prodrug and glucose oxidase. The shell with large 
pores was used to encapsulate the macromolecular enzymes which can be release as 
the consequence of the glutathione induced shell degradation. The release glucose 
oxidase were able to consume the glucose and oxygen to create a highly hypoxia 
condition for activating the subsequently released prodrug from the small pores of inner 
core. This nanosystem integrated multiple anti-cancer strategies, including glutathione 
depletion, glucose starvation, oxidative therapy and chemotherapy, thereby significantly 
inhibited the growth and metastasis of tumours in a breast cancer model.  
4. We speculate that the hybrid organosilica nanoparticles with intrinsic hydrophobicity can 
effectively stimulate systemic immune response for cancer immunotherapy. To 
investigate their immune-adjuvant property, we have prepared multi-shelled dendritic 
mesoporous organosilica nanoparticles via the anion assisted synthetic approach. These 
nanoparticles after encapsulating of tumour cell fragments induced robust immune 
response in mice, dramatically delayed the growth of melanoma tumours and improved 
the survival rate. We attributed the excellent anti-tumour vaccine performance to two 
aspects: i) at the molecular structure level, the incorporation of hydrophobic organic 
groups improved the cellular uptake and endosomal escape efficiency of nanoparticles, 
thus facilitating the cell mediated immunity; ii) at the nanostructure level, the multi-shelled 
structure slowed down the antigen release rate and therefore prolonged the interaction 
between antigens and immune cells.  Hence, by rational engineering of the nanoparticles 
based vaccine formulation at two levels, excellent antitumour immunity can be achieved.   
5. We moved one step further to construct intelligent nanoreactors by simultaneously 
incorporating disulfide groups and copper ions, a well-known Fenton’s reagent, into the 
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hybrid silica framework. These nanoreactors were capable of simultaneously triggering 
Fenton’s reaction and GSH depletion, thus effectively improved the cell inhibition activity 
of DOX and promoted calreticulin exposure on cancer cells, a widely used biomarker for 
characterizing the immunogenic cell death. In addition, these nanoreactors are potent 
immuno-adjuvants for activating immune cells. The combination of these diverse 
properties of these nanoreactors in conjunction with chemodrugs and immune 
checkpoint blockade were capable of reversing the immune-suppressive tumor 
microenvironment, resulting in a robust anticancer activity and abscopal effect for both 
treated primary tumours and non-treated distant tumours. 
8.2 Recommendations and outlook 
With central goals of improving the biosafety and delivery efficiency, great efforts have 
been devoted and significant progress has been achieved through rational design and 
engineering of the composition and architecture of nanoparticles to impart biodegradability, 
controlled release, immuno-adjuvanticity, etc. However, a number of challenges still 
remain, at levels of fundamental materials science and potential clinical translation. In this 
context, the following recommendations are made for future work: 
At fundamental materials science level: 
1. We have developed an anion assisted approach to fabricate hybrid organosilica 
nanoparticles. However, the maximum content of organic groups is generally less than 
20%. Therefore, more efforts need to be devoted to optimize the synthetic approach to 
increase the organic contents.  
2. The formation mechanism of these dendritic mesoporous silica nanoparticles is not 
clear so far. Although we have proposed a number of possible mechanisms, for instance, 
the penetration of anion induced micelle swelling, we still lack of direct evidence to support 
this mechanism. Cryo-TEM might be a useful tool for in situ characterisation and direct 
monitor the formation process.   
3. The size of the nanoparticles prepared in this thesis are above 200 nm, which is not 
optimal in terms of long-term blood circulation and cellular uptake. Further optimizing the 
particles size to below 50 nm is desired to improve their delivery performance. 
At clinical translation level: 
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1. While the incorporation of disulfide bond into the silica framework can impart glutathione 
responsive degradability, investigations on the in vivo bio-distribution and renal clearance 
behaviour of nanoparticles are needed to understand whether the biodegradability can 
reduce their accumulation in body. More importantly, the long term biosafety, for example, 
the damage to major organs and neural systems is critical to be studied.  
2. The targeted delivery of therapeutics specifically to tumour site is still a great challenge. 
While we have tried to utilize the intratumoral environment difference between normal cells 
and tumour cells to selectively release drug in the latter case, the efficiency of this 
targeting strategy remains to be demonstrated in vivo. A more ideal scenario is to 
conjugate conventional tumour targeting moieties on the surface of nanoparticles to 
accomplish combined cancer targeting therapy.   
3. The use of silica based materials for cancer immunotherapy is still in its infancy given 
the first report by Wang et al. in 2015. While we have demonstrate that the incorporation of 
hydrophobic organic groups or metal ions in the silica matric can dramatically improve the 
immune-stimulatory activity, there is plenty of room to further improve the adjuvanticity. For 
example, conjugating commercially available toll-like receptor agonists, to nanoparticles 
surface may lead to more potent nano-vaccine formulation.     
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